

11/13/02

130653 1131402

U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

RECEIVED

SEARCH REQUEST FORM

Requestor's

Name:

11/24/02

13110

69826

Serial

Number:

1051662

Date:

11/24/02

Phone:

20571

Art Unit:

1051662

Search Topic:

Please write a detailed statement of search topic. Describe specifically as possible the subject matter to be searched. Define any terms that may have a special meaning. Give examples or relevant citations, authors, keywords, etc., if known. For sequences, please attach a copy of the sequence. You may include a copy of the broadest and/or most relevant claim(s).

1. A compound of the structure CC1=CC=C(C=C1)C2=CC=CC=C2 or a pharmaceutically acceptable salt thereof, wherein the R group is defined as a phenyl ring substituted with a methyl group at the para position and a methyl group at the ortho position.

4. A method of treating a disease or condition by administering to a patient a compound of the structure CC1=CC=C(C=C1)C2=CC=CC=C2 or a pharmaceutically acceptable salt thereof, wherein the R group is defined as a phenyl ring substituted with a methyl group at the para position and a methyl group at the ortho position.

STAFF USE ONLY

Date completed: 8/21/04
Searcher: _____
Terminal time: _____
Elapsed time: _____
CPU time: _____
Total time: _____
Number of Searches: _____
Number of Databases: _____

Search Site
____ STIC
____ CM-1
____ Pre-S
Type of Search
____ N.A. Sequence
____ A.A. Sequence
____ Structure
____ Bibliographic

Vendors
____ IG
____ STN
____ Dialog
____ APS
____ Geninfo
____ SDC
____ DARC/Questel
____ Other

=> d his ful

FILE 'REGISTRY' ENTERED AT 14:43:02 ON 31 AUG 2004

E CNQX/CN
L1 1 SEA ABB=ON D
E S-AMOA/CN
E (S)-AMOA/CN
E AMOA/CN
L2 1 SEA ABB=ON D
E LY-293558/CN
E LY 293558/CN

FILE 'REGISTRY' ENTERED AT 14:55:21 ON 31 AUG 2004

E 17-ALPHA-HYDROXY-PROGESTERONE/CN
E PROGESTERONE/CN
E PROGESTERONE 17AHYDROXY-/CN
E PROGESTERONE 17A/CN
L3 1 SEA ABB=ON "PROGESTERONE 17A-HYDROPEROXIDE"/CN
E PROGESTERONE/CN
E PROGESTERONE/CN
L4 1 SEA ABB=ON PROGESTERONE/CN
L5 STRUCTURE
E 19-NORTESTOSTERONE/CN
L6 1 SEA ABB=ON 19-NORTESTOSTERONE/CN
L7 50 SEA SSS SAM L5
L8 4448 SEA SSS FUL L5
L9 1 SEA ABB=ON 19-NORTESTOSTERONE/CN
L10 4449 SEA ABB=ON L8 OR L9
E 1,25-DIHYDROXYVITAMIN D3/CN
L11 2 SEA ABB=ON "1,25-DIHYDROXYVITAMIN D3"/CN
L12 0 SEA ABB=ON L10 AND L11
E VITAMIN D
E VITAMIN D/CN
L13 1 SEA ABB=ON "VITAMIN D"/CN
L14 STRUCTURE
L15 47 SEA SSS SAM L14
L16 963 SEA SSS FUL L14
L17 0 SEA ABB=ON L10 AND L16

FILE 'HCAPLUS' ENTERED AT 15:04:04 ON 31 AUG 2004

L18 208802 SEA ABB=ON L10 OR PROGESTIN OR PROGESTERON? OR PREGNAN? OR
ESTRAN? OR GONAN? OR 17(W)A(W)?HYDROXY?(W)?PROGESTERON?
OR 19(W)?NORTESTOSTERON?
L19 34436 SEA ABB=ON L13 OR L16 OR ?VITAMIN?(W) (D OR D3)
L20 1440 SEA ABB=ON L18 AND L19
L21 10 SEA ABB=ON L20 AND (?OVAR? OR ?REPROD?) (W) (?CANCER? OR
?CARCIN? OR ?NEOPLASM? OR ?TUMOR? OR ?TUMOUR?)
SELECT RN L21 1-10

10 citi from CA Plus

FILE 'REGISTRY' ENTERED AT 15:08:13 ON 31 AUG 2004

L22 830 SEA ABB=ON (1406-16-2/BI OR 10540-29-1/BI OR 116057-75-1/BI
OR 13311-84-7/BI OR 50-28-2/BI OR 57-83-0/BI OR 63612-50-0/BI
OR 65807-02-5/BI OR 90357-06-5/BI OR 106096-93-9/BI OR
129453-61-8/BI OR 131384-38-8/BI OR 13598-36-2/BI OR 173937-91-
2/BI OR 177022-07-0/BI OR 209619-55-6/BI OR 2998-57-4/BI OR
33069-62-4/BI OR 427-51-0/BI OR 50-07-7/BI OR 50-23-7/BI OR
53-03-2/BI OR 53714-56-0/BI OR 55-86-7/BI OR 578-95-0/BI OR
65277-42-1/BI OR 68047-06-3/BI OR 74381-53-6/BI OR 7440-06-4/BI
OR 7585-39-9/BI OR 84449-90-1/BI OR 9003-99-0/BI OR 9013-20-1/
BI OR 9014-00-0/BI OR 9014-42-0/BI OR 9031-11-2/BI OR 94325-73-

2/BI OR 100-33-4/BI OR 10016-20-3/BI OR 100286-90-6/BI OR
 100324-81-0/BI OR 10043-49-9/BI OR 100817-46-7/BI OR 10087-89-5
 /BI OR 101-60-0/BI OR 10102-43-9/BI OR 10178-38-8/BI OR
 102396-24-7/BI OR 102676-31-3/BI OR 102676-47-1/BI OR 102822-56
 -0/BI OR 10318-26-0/BI OR 103222-11-3/BI OR 103612-80-2/BI OR
 10403-51-7/BI OR 104227-87-4/BI OR 104493-13-2/BI OR 10500-82-0
 /BI OR 105118-12-5/BI OR 105149-04-0/BI OR 10540-97-3/BI OR
 105615-58-5/BI OR 105844-41-5/BI OR 106-60-5/BI OR 106362-32-7/
 BI OR 106400-81-1/BI OR 106941-25-7/BI OR 107000-34-0/BI OR
 107256-99-5/BI OR 107868-30-4/BI OR 107910-75-8/BI OR 108736-35
 -2/BI OR 108852-90-0/BI OR 109837-67-4/BI OR 11002-22-5/BI OR
 110042-95-0/BI OR 11006-77-2/BI OR 110143-10-7/BI OR 110267-81-
 7/BI OR 11029-06-4/BI OR 110311-27-8/BI OR 110314-48-2/BI OR
 11043-98-4/BI OR 11043-99-5/BI OR 11056-06-7/BI OR 11056-12-5/B
 I OR 11056-14-7/BI OR 11056-15-8/BI OR 110690-43-2/BI OR
 110942-02-4/BI OR 110942-08-0/BI OR 11103-57-4/BI OR 111490-36-
 9/BI OR 111523-41-2/BI OR 112-14-1/BI OR 112515-43-2/BI OR
 112522-64-2/BI OR 112809-51-5/BI OR 112859-71-9/BI OR 112887-68
 -0/BI OR 112965-21-6/BI OR 113852-37-2/BI OR 114-70-5/BI OR
 114084-78-5/BI OR 114285-68-6/BI OR 114517-02-1/BI OR 114977-28
 -5/BI OR 115150-59-9/BI OR 115308-98-0/BI OR 115566-02-4/BI OR
 115575-11-6/BI OR 115956-12-2/BI OR 117048-59-6/BI OR 117091-64
 -2/BI OR 118292-40-3/BI OR 119169-78-7/BI OR 119413-54-6/BI OR
 119813-10-4/

FILE 'HCAPLUS' ENTERED AT 15:09:54 ON 31 AUG 2004

L23 10 SEA ABB=ON L21 AND L22

FILE 'MEDLINE, BIOSIS, EMBASE, JICST-EPLUS, JAPIO' ENTERED AT 15:15:35 ON
 31 AUG 2004

L24 1193867 SEA ABB=ON (PROGESTERON? OR PREGNAN? OR ESTRAN? OR GONAN? OR
 L3 OR L4 OR L6)

L25 108329 SEA ABB=ON VITAMIN? (W) (D OR D3) OR L11 OR L13

L26 4320 SEA ABB=ON L24 AND L25


L27 21 SEA ABB=ON L26 AND (?OVAR? OR ?REPROD?) (W) (?CANCER? OR
 ?CARCIN? OR ?NEOPLASM? OR ?TUMOR? OR ?TUMOUR?)

L28 17 DUP REMOV L27 (4 DUPLICATES REMOVED)

17 cuts from other

d.b.'s

=> d que stat 123
L5 STR




NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 24

STEREO ATTRIBUTES: NONE

L8 4448 SEA FILE=REGISTRY SSS FUL L5
L9 1 SEA FILE=REGISTRY ABB=ON 19-NORTESTOSTERONE/CN
L10 4449 SEA FILE=REGISTRY ABB=ON L8 OR L9
L13 1 SEA FILE=REGISTRY ABB=ON "VITAMIN D"/CN
L14 STR



NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 30

STEREO ATTRIBUTES: NONE

L16 963 SEA FILE=REGISTRY SSS FUL L14
 L18 208802 SEA FILE=HCAPLUS ABB=ON L10 OR PROGESTIN OR PROGESTERON? OR
 PREGNAN? OR ESTRAN? OR GONAN? OR 17(W)A(W)?HYDROXY?(W)?PR
 OGESTERON? OR 19(W)?NORTESTOSTERON?
 L19 34436 SEA FILE=HCAPLUS ABB=ON L13 OR L16 OR ?VITAMIN?(W) (D OR D3)
 L20 1440 SEA FILE=HCAPLUS ABB=ON L18 AND L19
 L21 10 SEA FILE=HCAPLUS ABB=ON L20 AND (?OVAR? OR ?REPROD?) (W) (?CANCE
 R? OR ?CARCIN? OR ?NEOPLASM? OR ?TUMOR? OR ?TUMOUR?)
 L22 830 SEA FILE=REGISTRY ABB=ON (1406-16-2/BI OR 10540-29-1/BI OR
 116057-75-1/BI OR 13311-84-7/BI OR 50-28-2/BI OR 57-83-0/BI OR
 63612-50-0/BI OR 65807-02-5/BI OR 90357-06-5/BI OR 106096-93-9/
 BI OR 129453-61-8/BI OR 131384-38-8/BI OR 13598-36-2/BI OR
 173937-91-2/BI OR 177022-07-0/BI OR 209619-55-6/BI OR 2998-57-4
 /BI OR 33069-62-4/BI OR 427-51-0/BI OR 50-07-7/BI OR 50-23-7/BI
 OR 53-03-2/BI OR 53714-56-0/BI OR 55-86-7/BI OR 578-95-0/BI
 OR 65277-42-1/BI OR 68047-06-3/BI OR 74381-53-6/BI OR 7440-06-4
 /BI OR 7585-39-9/BI OR 84449-90-1/BI OR 9003-99-0/BI OR
 9013-20-1/BI OR 9014-00-0/BI OR 9014-42-0/BI OR 9031-11-2/BI
 OR 94325-73-2/BI OR 100-33-4/BI OR 10016-20-3/BI OR 100286-90-6
 /BI OR 100324-81-0/BI OR 10043-49-9/BI OR 100817-46-7/BI OR
 10087-89-5/BI OR 101-60-0/BI OR 10102-43-9/BI OR 10178-38-8/BI
 OR 102396-24-7/BI OR 102676-31-3/BI OR 102676-47-1/BI OR
 102822-56-0/BI OR 10318-26-0/BI OR 103222-11-3/BI OR 103612-80-
 2/BI OR 10403-51-7/BI OR 104227-87-4/BI OR 104493-13-2/BI OR
 10500-82-0/BI OR 105118-12-5/BI OR 105149-04-0/BI OR 10540-97-3
 /BI OR 105615-58-5/BI OR 105844-41-5/BI OR 106-60-5/BI OR

106362-32-7/BI OR 106400-81-1/BI OR 106941-25-7/BI OR 107000-34-0/BI OR 107256-99-5/BI OR 107868-30-4/BI OR 107910-75-8/BI OR 108736-35-2/BI OR 108852-90-0/BI OR 109837-67-4/BI OR 11002-22-5/BI OR 110042-95-0/BI OR 11006-77-2/BI OR 110143-10-7/BI OR 110267-81-7/BI OR 11029-06-4/BI OR 110311-27-8/BI OR 110314-48-2/BI OR 11043-98-4/BI OR 11043-99-5/BI OR 11056-06-7/BI OR 11056-12-5/BI OR 11056-14-7/BI OR 11056-15-8/BI OR 110690-43-2/BI OR 110942-02-4/BI OR 110942-08-0/BI OR 11103-57-4/BI OR 111490-36-9/BI OR 111523-41-2/BI OR 112-14-1/BI OR 112515-43-2/BI OR 112522-64-2/BI OR 112809-51-5/BI OR 112859-71-9/BI OR 112887-68-0/BI OR 112965-21-6/BI OR 113852-37-2/BI OR 114-70-5/BI OR 114084-78-5/B

L23 10 SEA FILE=HCAPLUS ABB=ON L21 AND L22

=> d ibib abs hitstr l23 1-10

L23 ANSWER 1 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:513496 HCAPLUS

DOCUMENT NUMBER: 141:47278

TITLE: A method for creating nuclear receptor activity-modulating pharmaceuticals

INVENTOR(S): Fletterick, Robert J.; Borngraeber, Sabine; Baxter, John D.; Scanlan, Thomas S.; Chiellini, Grazia; Webb, Paul

PATENT ASSIGNEE(S): The Regents of the University of California, USA

SOURCE: PCT Int. Appl., 144 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004052303	A2	20040624	WO 2003-US39258	20031209
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

US 2004110154 A1 20040610 US 2002-317034 20021210

PRIORITY APPLN. INFO.:

US 2002-317034 A 20021210

US 2003-453608P P 20030310

US 2003-526931P P 20031203


AB Methods for screening, identifying and/or designing agents that modulate nuclear receptors are provided. These agents contact a site on a nuclear receptor involved in dimer/heterodimer formation, cofactor mol. interactions, and/or folding, which is termed the nuclear receptor dimer/heterodimer regulatory site (DHRS). Methods employing the DHRS are included, along with nuclear receptor:agent complexes and libraries of agents.

IT 656260-08-1, GC 24

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GC 24; method for creating nuclear receptor activity-modulating pharmaceuticals)

RN 656260-08-1 HCAPLUS

CN Acetic acid, [4-[[4-hydroxy-3-(phenylmethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)




IT 211110-63-3, GC-1

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(method for creating nuclear receptor activity-modulating pharmaceuticals)

RN 211110-63-3 HCAPLUS

CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



L23 ANSWER 2 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:220465 HCAPLUS

DOCUMENT NUMBER: 140:265659

TITLE: Human gene Edd and gene p53R2, their polynucleotide and polypeptide sequences, protein complexes, and diagnostic and therapeutic uses thereof for cancer
INVENTOR(S): Watts, Colin; Saunders, Darren; Henderson, Michelle; Clancy, Jennifer; Henshall, Susan; Sutherland, Robert; O'Brien, Philippa

PATENT ASSIGNEE(S): Garvan Institute of Medical Research, Australia

SOURCE: PCT Int. Appl., 331 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004022750	A1	20040318	WO 2003-AU1164	20030905
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
 PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
 TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
 NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
 GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

AU 2002-951346

A 20020905

US 2002-425218P

P 20021107

AB This invention provides methods of detecting or treating aberrant cell cycle regulation associated with expression of a nuclear protein encoded by a gene that is linked to map position 8q22.3 of the human genome, and to reagents that are useful therefor. More particularly, the invention provides nucleic acid probes and antibodies, for detecting a gene that is linked to map position 8q22.3 of the human genome or the expression products thereof, wherein expression or elevated expression of said gene is associated with the appearance or occurrence of tumors associated with cancer, DNA damage and **progesterone** receptor-mediated effects on cells. The invention also provides reagents and methods for detecting or modulating the expression products of the gene, such as, for example, in the diagnosis or treatment of cancer, cellular proliferation, DNA damage or **progesterone** receptor-mediated effects on cells. In addition, the invention claims cDNA and protein sequences for two human EDD protein isoforms that are splicing variants. The invention also provides sequences for EDD-interacting proteins, a human gene EDD microsatellite, nucleic acid primers, nucleic acid probes, and an anti-EDD target RNA sequence. The region of human chromosome 8 that is useful for cancer diagnosis also includes the p53R2 gene encoding a ribonucleotide reductase. The examples of the invention provide microsatellite markers that revealed allelic imbalance and abnormalities on human chromosome 8q22.3 in the Edd locus in tumor cell lines. The allelic imbalance is interpreted as gene amplification. The examples also describe overexpression of the Edd gene in various tumors, EDD protein interactions, including interaction with proteins involved in cell cycle regulation and response to DNA damage, targeted disruption of the Edd gene in mice, transcription co-activation by EDD protein and **progesterone** receptor B, and changes in gene expression in HMEC 184 and MCF-7 cells after EDD depletion by siRNA.

IT 150428-23-2P, Cyclin-dependent kinase 205265-40-3P, CDS1 protein kinase

RL: ANT (Analyte); BPN (Biosynthetic preparation); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)

(EDD protein complexes; human gene Edd and gene p53R2, their polynucleotide and polypeptide sequences, protein complexes, and diagnostic and therapeutic uses thereof for cancer)

RN 150428-23-2 HCAPLUS

CN Kinase (phosphorylating), protein (cyclin-dependent) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 205265-40-3 HCAPLUS

CN Kinase (phosphorylating), protein, Cds1 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 672548-33-3P 672548-34-4P 672548-58-2P,
 Karyopherin α -2 (human) 672548-60-6P, Karyopherin

α -4 (human) 672548-61-7P 672548-62-8P
672548-63-9P, Transcription factor BRCA2 (human)
672548-64-0P, Karyopherin α -1 (human) 672548-65-1P
, Progesterone receptor (human) 672548-66-2P
RL: ANT (Analyte); BPN (Biosynthetic preparation); DGN (Diagnostic use);
PRP (Properties); ANST (Analytical study); BIOL (Biological study); PREP
(Preparation); USES (Uses)
(amino acid sequence; human gene Edd and gene p53R2, their
polynucleotide and polypeptide sequences, protein complexes, and
diagnostic and therapeutic uses thereof for cancer)

RN 672548-33-3 HCAPLUS
CN Protein (human gene EDD 2799-amino acid isoform) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 672548-34-4 HCAPLUS
CN Protein (human gene EDD 2793-amino acid isoform) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 672548-58-2 HCAPLUS
CN Karyopherin α -2 (human) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 672548-60-6 HCAPLUS
CN Karyopherin α -4 (human) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 672548-61-7 HCAPLUS
CN Kinase (phosphorylating), gene chk2 protein (human gene CHK2 isoenzyme 1)
(9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 672548-62-8 HCAPLUS
CN Kinase (phosphorylating), gene chk2 protein (human gene CHK2 isoenzyme 2)
(9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 672548-63-9 HCAPLUS
CN Transcription factor BRCA2 (human) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 672548-64-0 HCAPLUS
CN Karyopherin α -1 (human) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 672548-65-1 HCAPLUS
CN Progesterone receptor (human) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 672548-66-2 HCAPLUS
CN Protein CIB (calcium and integrin-binding) (human) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 9047-64-7P, Ribonucleotide reductase
RL: ANT (Analyte); BPN (Biosynthetic preparation); DGN (Diagnostic use);
ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(gene p53R2; human gene Edd and gene p53R2, their polynucleotide and
polypeptide sequences, protein complexes, and diagnostic and
therapeutic uses thereof for cancer)
RN 9047-64-7 HCAPLUS

CN Reductase, ribonucleoside diphosphate (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 672548-39-9 672548-40-2

RL: ARG (Analytical reagent use); DGN (Diagnostic use); PRP (Properties);
ANST (Analytical study); BIOL (Biological study); USES (Uses)
(human gene EDD microsatellite 586F18b specific PCR primer; human gene
Edd and gene p53R2, their polynucleotide and polypeptide sequences,
protein complexes, and diagnostic and therapeutic uses thereof for
cancer)

RN 672548-39-9 HCAPLUS

CN DNA, d(G-C-T-A-G-G-G-A-A-C-C-A-A-A-C-T-G-C-C-A-G) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 672548-40-2 HCAPLUS

CN DNA, d(T-G-C-A-A-A-A-T-A-A-C-A-A-T-A-G-C-T-T-T-G-C-T-T-A-G) (9CI) (CA
INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 672548-35-5 672548-36-6

RL: ARG (Analytical reagent use); DGN (Diagnostic use); PRP (Properties);
ANST (Analytical study); BIOL (Biological study); USES (Uses)
(human gene EDD microsatellite CEDD specific PCR primer; human gene Edd
and gene p53R2, their polynucleotide and polypeptide sequences, protein
complexes, and diagnostic and therapeutic uses thereof for cancer)

RN 672548-35-5 HCAPLUS

CN DNA, d(T-A-C-C-C-T-G-C-A-G-T-A-A-A-T-C-T-C-A-C-A-T-G-T-A-C-T-C-C-C) (9CI)
(CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 672548-36-6 HCAPLUS

CN DNA, d(A-G-A-A-T-C-G-C-T-T-G-A-A-C-C-T-A-G-T-A-G-G-T-G-A-A-G-G-T-G) (9CI)
(CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 672548-57-1

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)

(human gene EDD siRNA target sequence; human gene Edd and gene p53R2,
their polynucleotide and polypeptide sequences, protein complexes, and
diagnostic and therapeutic uses thereof for cancer)

RN 672548-57-1 HCAPLUS

CN DNA, d(G-C-A-G-U-G-U-U-C-C-U-G-C-C-U-U-C-U-U-T-T) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 672548-46-8

RL: ARG (Analytical reagent use); DGN (Diagnostic use); PRP (Properties);
ANST (Analytical study); BIOL (Biological study); USES (Uses)
(human gene EDD specific PCR primer EDD-407F; human gene Edd and gene
p53R2, their polynucleotide and polypeptide sequences, protein
complexes, and diagnostic and therapeutic uses thereof for cancer)

RN 672548-46-8 HCAPLUS

CN DNA, d(G-C-T-A-G-T-C-A-C-C-A-A-C-T-T-C-T-G-G-G-T-C-T-A-A) (9CI) (CA INDEX
NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 672548-45-7

RL: ARG (Analytical reagent use); DGN (Diagnostic use); PRP (Properties);
ANST (Analytical study); BIOL (Biological study); USES (Uses)
(human gene EDD specific PCR primer EDD-409R; human gene Edd and gene

p53R2, their polynucleotide and polypeptide sequences, protein complexes, and diagnostic and therapeutic uses thereof for cancer)

RN 672548-45-7 HCAPLUS

CN DNA, d(C-A-G-C-A-A-A-A-G-A-T-A-A-A-T-C-A-C-A-G-T-G-T-A-A-A-T-T) (9CI)
(CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 672548-49-1 672548-50-4 672548-51-5
672548-52-6

RL: ARG (Analytical reagent use); DGN (Diagnostic use); PRP (Properties);
ANST (Analytical study); BIOL (Biological study); USES (Uses)
(human gene EDD specific PCR primer; human gene Edd and gene p53R2,
their polynucleotide and polypeptide sequences, protein complexes, and
diagnostic and therapeutic uses thereof for cancer)

RN 672548-49-1 HCAPLUS

CN DNA, d(T-T-A-G-G-C-T-T-T-T-G-G-T-A-A-A-T-G-G-C-T-G-C-G) (9CI) (CA INDEX
NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 672548-50-4 HCAPLUS

CN DNA, d(T-G-A-G-G-G-C-A-T-A-G-G-C-T-G-G-A-A-T-C-C-T-T-C) (9CI) (CA INDEX
NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 672548-51-5 HCAPLUS

CN DNA, d(C-A-T-T-G-C-T-G-A-C-C-C-T-A-T-C-C-C-T-G-T-G-T-T-G) (9CI) (CA INDEX
NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 672548-52-6 HCAPLUS

CN DNA, d(T-A-G-C-C-C-G-T-G-A-A-A-T-C-C-T-C-C-C-A-T-C-T-C) (9CI) (CA INDEX
NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 672548-44-6D, 5'-FAM and 3'-TAMRA labeled

RL: ARG (Analytical reagent use); DGN (Diagnostic use); PRP (Properties);
ANST (Analytical study); BIOL (Biological study); USES (Uses)
(human gene EDD specific probe EDD-433T; human gene Edd and gene p53R2,
their polynucleotide and polypeptide sequences, protein complexes, and
diagnostic and therapeutic uses thereof for cancer)

RN 672548-44-6 HCAPLUS

CN DNA, d(C-C-C-A-G-C-C-A-A-A-G-A-T-G-A-C-A-G-C-A-G-A-A-C-A-A-C) (9CI) (CA
INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 252926-72-0, GenBank AC021004

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
(Biological study)

(human gene Edd and gene p53R2, their polynucleotide and polypeptide
sequences, protein complexes, and diagnostic and therapeutic uses
thereof for cancer)

RN 252926-72-0 HCAPLUS

CN GenBank AC021004 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 672548-48-0 672548-53-7

RL: ARG (Analytical reagent use); DGN (Diagnostic use); PRP (Properties);
ANST (Analytical study); BIOL (Biological study); USES (Uses)

(human gene p53R2 specific PCR primer; human gene Edd and gene p53R2,
their polynucleotide and polypeptide sequences, protein complexes, and

diagnostic and therapeutic uses thereof for cancer)

RN 672548-48-0 HCAPLUS
CN DNA, d(T-C-T-G-T-G-G-T-T-T-C-T-G-C-C-A-T-A-A-C-T-G-C) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 672548-53-7 HCAPLUS
CN DNA, d(T-G-T-C-A-G-C-C-T-T-G-A-G-T-A-C-C-T-C-C-A-G-G-G) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 672548-37-7, DNA (human gene EDD microsatellite CEDD)
RL: ANT (Analyte); BUU (Biological use, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(nucleotide sequence; human gene Edd and gene p53R2, their polynucleotide and polypeptide sequences, protein complexes, and diagnostic and therapeutic uses thereof for cancer)

RN 672548-37-7 HCAPLUS
CN DNA (human gene EDD microsatellite CEDD) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 672548-32-2 672548-38-8
RL: ANT (Analyte); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(nucleotide sequence; human gene Edd and gene p53R2, their polynucleotide and polypeptide sequences, protein complexes, and diagnostic and therapeutic uses thereof for cancer)

RN 672548-32-2 HCAPLUS
CN DNA (human gene EDD protein 2799-amino acid isoform cDNA plus flanks) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 672548-38-8 HCAPLUS
CN DNA (human gene EDD protein 2793-amino acid isoform cDNA plus flanks) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 672555-86-1 672555-87-2 672555-88-3
672555-89-4 672555-90-7 672555-91-8
672555-92-9 672555-93-0 672555-94-1
672555-95-2 672555-96-3 672555-97-4
672555-98-5 672555-99-6 672556-00-2
672556-01-3 672556-02-4 672556-03-5
672556-04-6 672556-05-7
RL: PRP (Properties)
(unclaimed nucleotide sequence; human gene Edd and gene p53R2, their polynucleotide and polypeptide sequences, protein complexes, and diagnostic and therapeutic uses thereof for cancer)

RN 672555-86-1 HCAPLUS
CN 23: PN: WO2004022750 SEQID: 8 unclaimed DNA (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 672555-87-2 HCAPLUS
CN 25: PN: WO2004022750 SEQID: 10 unclaimed DNA (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 672555-88-3 HCAPLUS
CN 27: PN: WO2004022750 SEQID: 12 unclaimed DNA (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 672555-89-4 HCAPLUS
CN 29: PN: WO2004022750 SEQID: 14 unclaimed DNA (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 672555-90-7 HCAPLUS
CN 31: PN: WO2004022750 SEQID: 16 unclaimed DNA (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 672555-91-8 HCAPLUS
CN 33: PN: WO2004022750 SEQID: 18 unclaimed DNA (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 672555-92-9 HCAPLUS
CN 35: PN: WO2004022750 SEQID: 20 unclaimed DNA (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 672555-93-0 HCAPLUS
CN 37: PN: WO2004022750 SEQID: 22 unclaimed DNA (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 672555-94-1 HCAPLUS
CN DNA, d(C-C-A-C-C-C-C-T-C-C-T-C-T-T-C-T-G-G-A-A-T-G) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 672555-95-2 HCAPLUS
CN DNA, d(G-C-T-T-T-G-A-T-T-T-G-C-C-T-G-T-T-C-T-T-C-A-G-T-G) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 672555-96-3 HCAPLUS
CN DNA, d(G-A-C-A-T-C-A-A-G-A-A-G-G-T-G-G-T-G-A-A) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 672555-97-4 HCAPLUS
CN DNA, d(T-G-T-C-A-T-A-C-C-A-G-G-A-A-A-T-G-A-G-C) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 672555-98-5 HCAPLUS
CN DNA, d(A-C-C-C-G-C-C-T-C-A-T-G-C-C-T-C-A-G-C-C-T-T-A-C) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 672555-99-6 HCAPLUS
CN DNA, d(T-A-G-G-T-T-T-G-G-G-G-T-G-A-G-T-G-G) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 672556-00-2 HCAPLUS
CN DNA, d(A-G-T-C-T-G-T-G-G-G-C-A-G-C-A-A-G-G) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 672556-01-3 HCAPLUS
CN DNA, d(T-T-C-G-U-C-A-C-A-A-G-G-A-C-G-G-A-A-G-A-A) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 672556-02-4 HCAPLUS
CN 64: PN: WO2004022750 SEQID: 49 unclaimed DNA (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 672556-03-5 HCAPLUS
 CN 65: PN: WO2004022750 SEQID: 50 unclaimed DNA (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 672556-04-6 HCAPLUS
 CN DNA, d(C-T-A-G-G-G-A-A-G-T-G-C-A-T-T-A-G-G-T-A-A-G) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 672556-05-7 HCAPLUS
 CN DNA, d(T-A-A-G-G-G-C-A-G-G-T-G-T-T-C-C-T-C-T-G) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 672290-67-4 672290-68-5 672290-69-6
 672556-09-1 672556-10-4 672556-11-5
 672556-12-6


RL: PRP (Properties)

(unclaimed sequence; human gene Edd and gene p53R2, their polynucleotide and polypeptide sequences, protein complexes, and diagnostic and therapeutic uses thereof for cancer)


RN 672290-67-4 HCAPLUS
 CN L-Lysine, L-arginyl-L-lysyl-L-lysyl-L-methionyl-L-leucyl-L- α -glutamyl-L-lysyl-L-alanyl-L-arginyl-L-alanyl-L-lysyl-L-asparaginyl-L-lysyl-L-lysyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 672290-68-5 HCAPLUS


CN L-Arginine, L-prolyl-L-tyrosyl-L-lysyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 672290-69-6 HCAPLUS
 CN L-Arginine, L-arginyl-L-tryptophyl-L-phenylalanyl-L- α -aspartyl-L-threonyl-L-tyrosyl-L-leucyl-L-isoleucyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 672556-09-1 HCAPLUS
 CN 4: PN: WO2004022750 FIGURE: 5B unclaimed sequence (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 672556-10-4 HCAPLUS
 CN 5: PN: WO2004022750 FIGURE: 5B unclaimed sequence (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 672556-11-5 HCAPLUS
 CN 6: PN: WO2004022750 FIGURE: 5B unclaimed sequence (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 672556-12-6 HCAPLUS

CN 7: PN: WO2004022750 FIGURE: 5B unclaimed sequence (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:719650 HCAPLUS

DOCUMENT NUMBER: 139:224393

TITLE: Method for determination of therapeutic strategy by
assessing

expression of reporter gene controlled by
transcription factor-dependent promoter

INVENTOR(S): Coombes, Raoul Charles; Foxwell, Brian

PATENT ASSIGNEE(S): Imperial College Innovations Limited, UK

SOURCE: PCT Int. Appl., 98 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003074732	A2	20030912	WO 2003-GB878	20030303
WO 2003074732	A3	20040108		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: GB 2002-4967 A 20020302

AB The present invention relates to methods for the diagnosis and treatment of human disease, particularly cancer, still more particularly breast cancer, and to reagents useful in such methods. A method for providing information for deciding on a therapeutic strategy for a patient, comprising the step of assessing the activity of a transcription factor in a cell or cells from the patient, comprising the steps of (1) exposing the cell or cells to a recombinant viral vector comprising a reporter gene which comprises a promoter under the control of the transcription factor (transcription factor-dependent promoter); and (2) assessing the expression of the reporter gene in the said cell or cells. A method for characterizing the hormone dependency of a primary cancer cell or cells, comprising the steps of (1) exposing the cell or cells to a recombinant viral vector comprising a reporter gene which comprises a hormone-dependent promoter; and (2) assessing the expression of the reporter gene in the said cell or cells. A method for choosing a treatment regime for a patient with a cancer which may be hormone-dependent, comprising the steps of (1) exposing primary cancer cells from the patient to a recombinant viral vector comprising a reporter gene which comprises a hormone-dependent promoter; (2) determining the response

of the reporter gene to exposure of the cell or cells to the hormone and/or other test compound; (3) deciding on a treatment regime making use of the information on the reporter gene behavior. The cancer is preferably breast cancer or endometrial cancer. The recombinant viral vector is preferably a recombinant adenoviral vector. The method may be used to determine whether the patient should be treated using tamoxifen, an aromatase inhibitor, complete estrogen antagonist or chemotherapy.

IT 9034-40-6, LHRH

RL: BSU (Biological study, unclassified); BIOL (Biological study) (agonists; determination of therapeutic strategy by assessing expression of reporter gene controlled by transcription factor-dependent promoter and transduced by viral vector)

RN 9034-40-6 HCAPLUS

CN Luteinizing hormone-releasing factor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 10540-29-1, Tamoxifen 68047-06-3, 4-Hydroxytamoxifen

84449-90-1, Raloxifene 116057-75-1, Idoxifene

129453-61-8, Faslodex 184475-35-2, Iressa

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(determination of therapeutic strategy by assessing expression of reporter


gene

controlled by transcription factor-dependent promoter and transduced by viral vector)

RN 10540-29-1 HCAPLUS

CN Ethanamine, 2-[4-[(1Z)-1,2-diphenyl-1-butenyl]phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 68047-06-3 HCAPLUS

CN Phenol, 4-[(1Z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 84449-90-1 HCAPLUS
 CN Methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 116057-75-1 HCAPLUS
 CN Pyrrolidine, 1-[2-[4-[(1E)-1-(4-iodophenyl)-2-phenyl-1-butenyl]phenoxy]ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 129453-61-8 HCAPLUS
 CN Estra-1,3,5(10)-triene-3,17-diol, 7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]-, (7 α ,17 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184475-35-2 HCAPLUS

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-(9CI) (CA INDEX NAME)



IT 9039-48-9, Aromatase

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; determination of therapeutic strategy by assessing expression

of

reporter gene controlled by transcription factor-dependent promoter and
transduced by viral vector)

RN 9039-48-9 HCAPLUS

CN Aromatase (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 9014-00-0, Luciferase

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); BIOL
(Biological study); USES (Uses)

(reporter gene encoding; determination of therapeutic strategy by assessing
expression of reporter gene controlled by transcription
factor-dependent promoter and transduced by viral vector)

RN 9014-00-0 HCAPLUS

CN Luciferase (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 9031-11-2, β -Galactosidase

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(reporter gene encoding; determination of therapeutic strategy by assessing
expression of reporter gene controlled by transcription
factor-dependent promoter and transduced by viral vector)

RN 9031-11-2 HCAPLUS

CN Galactosidase, β - (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 137632-09-8, ErbB2 kinase 142805-58-1, MEK

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(signaling, inhibitors; determination of therapeutic strategy by assessing
expression of reporter gene controlled by transcription
factor-dependent promoter and transduced by viral vector)

RN 137632-09-8 HCAPLUS

CN Kinase (phosphorylating), protein p185neu (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 142805-58-1 HCAPLUS

CN Kinase (phosphorylating), mitogen-activated protein kinase (9CI) (CA
INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L23 ANSWER 4 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:42055 HCAPLUS

DOCUMENT NUMBER: 138:101937

TITLE: Cancer diagnosis by assay of Δ 3-AIB1 isoform of
nuclear hormone receptor coactivator protein and mRNA,
and therapeutic use of siRNA.

INVENTOR(S): Riegel, Anna T.; Reiter, Ronald; Wellstein, Anton

PATENT ASSIGNEE(S): Georgetown University Medical Center, USA

SOURCE: PCT Int. Appl., 47 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003003904	A2	20030116	WO 2002-US21066	20020703
WO 2003003904	A3	20030522		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2001-302648P P 20010705

AB This invention relates to the AIB1 protein as a coactivator that potentiates the transcriptional activity of nuclear hormone receptors. The gene is amplified in a subset of human breast cancers. One splice variant of AIB1 transcribes a mRNA that lacks the exon 3 sequence. Δ 3-AIB1 mRNA encodes a 130 kDa protein that lacks the N-terminal basic helix-loop-helix and a portion of the PAS dimerization domain. This 130 kDa protein was detected in MCF-7 breast cancer cells at levels 5-10% of the full length protein, whereas in non transformed mammary epithelium lines the Δ 3-AIB1 protein is present at significantly lower levels compared to the full length AIB1. The abundance of Δ 3-AIB1 mRNA is increased in human breast cancer specimens relative to that in normal

breast tissue. Functional reporter gene assays revealed that the ability of $\Delta 3$ -AIB1 to promote transcription mediated by the estrogen or **progesterone** receptors was significantly greater than that of the full-length protein. The Δ -AIB1 isoform was also more effective than AIB1 in promoting transcription induced by epidermal growth factor. Thus, over-expression of $\Delta 3$ -AIB1 plays an important role in sensitizing breast tumor cells to hormone or growth factor stimulation. Diagnostic methods and kits for detection and staging of cancer are described, which are based on antibodies to the AIB1 isoform or on amplification of and hybridization to mRNA coding for this isoform. Also, therapeutic approaches are described for use of small interfering RNA to inhibit expression of the IAB1 isoform.

IT 62031-54-3, Fibroblast growth factor 62229-50-9,
Epidermal growth factor

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(signaling induced by, AIB1 and; cancer diagnosis by assay of
 $\Delta 3$ -AIB1 isoform of nuclear hormone receptor coactivator protein
and mRNA, and therapeutic use of siRNA)

RN 62031-54-3 HCAPLUS

CN Fibroblast growth factor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 62229-50-9 HCAPLUS

CN Epidermal growth factor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 485885-49-2 485885-50-5 485885-51-6

RL: PRP (Properties)

(unclaimed sequence; cancer diagnosis by assay of $\Delta 3$ -AIB1 isoform
of nuclear hormone receptor coactivator protein and mRNA, and
therapeutic use of siRNA.)

RN 485885-49-2 HCAPLUS

CN DNA, d(T-G-C-C-A-T-G-T-G-A-T-A-C-T-C-C-A-G-G-A-C-A-A-G-G-G-A-A-A-A-A-C-T-A-
T-T-T-C-C-A-A-T-G-A-T-G-A-T-G-A) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 485885-50-5 HCAPLUS

CN DNA, d(T-G-C-C-A-T-G-T-G-A-T-A-C-T-C-C-A-G-G-A-C-A-A-G-G-T-C-T-T-A-C-C-T-G-
C) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 485885-51-6 HCAPLUS

CN DNA, d(A-A-G-A-G-C-A-A-G-G-A-A-A-A-C-T-A-T-T-T-C-C-A-A-T-G-A-T-G-A-T-G-
A) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L23 ANSWER 5 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:659666 HCAPLUS

DOCUMENT NUMBER: 137:367518

TITLE: Immunohistochemical analysis of 1,25-
dihydroxyvitamin-D3-receptors,
estrogen and **progesterone** receptors and
Ki-67 in **ovarian carcinoma**

AUTHOR(S): Villena-Heinsen, Carlos; Meyberg, Roland;
Axt-Fliehn, Roland; Reitnauer, Karin; Reichrath,
Joerg; Friedrich, Michael

CORPORATE SOURCE: Department of Gynecology, University of Saarland,
Homburg, D-66421, Germany

SOURCE: Anticancer Research (2002), 22(4), 2261-2267

CODEN: ANTRD4; ISSN: 0250-7005

PUBLISHER: International Institute of Anticancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English


AB Background: The aim of this study was to analyze immunohistochem. the expression of VDR in normal and carcinomatous ovarian tissue to evaluate whether ovarian tissue may be a new potential target for biol. active **vitamin D** analogs. Materials and Methods: The expression of 1,25-**dihydroxyvitamin-D3**-receptors (VDR) was immunohistochem. investigated in **ovarian carcinomas**. VDR immunoreactivity (mAb 9A7y) was compared with the staining pattern of the proliferation marker Ki-67, of the estrogen receptors (ER) and of the **progesterone** receptors (PR). The percentage of pos. tumor cells (PP), the intensity of staining (SI) and a resulting immunoreactivity score (IRS) were determined for the semiquant. evaluation of VDR-, ER- and PR-expression. Results: A total of 16.7% of the normal surface ovarian epithelium was VDR-neg., while the remaining 83.3% revealed weak to moderate VDR immunoreactivity. Moderate to strong nuclear immunoreactivity for VDR was detected in almost all **ovarian carcinomas** analyzed. Both the intensity of VDR immunostaining and the number of VDR pos. cells were significantly increased in **ovarian carcinomas** as compared to normal ovarian tissue. Analyzing coexpression of VDR with the proliferation marker Ki-67 or with the estrogen and **progesterone** receptors, no significant correlation was found. Conclusion: the authors' findings indicate that: (I) VDR expression is increased in **ovarian carcinomas** as compared to normal ovarian tissue. (II) Up-regulation of VDR in **ovarian carcinomas** is not exclusively induced by an increase of proliferation, but by different unknown mechanisms. (III) Expression of VDR in **ovarian carcinomas** is independently regulated from the expression of ER and PR. (IV) Ovarian tissue may be a new target organ for therapeutically applied **vitamin D** analogs exerting fewer calcemic side-effects. New **vitamin D** analogs may be promising drugs for the treatment of advanced **ovarian carcinomas**.

IT 32222-06-3D, Calcitriol, analogs
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(immunohistochem. anal. of 1,25-**dihydroxyvitamin-D3**-receptors, estrogen and **progesterone** receptors and Ki-67 in **ovarian carcinoma** in relation to **ovarian carcinoma** as potential target for **vitamin D** analogs)

RN 32222-06-3 HCAPLUS

CN 9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol, (1 α ,3 β ,5Z,7E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 6 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:521462 HCAPLUS

DOCUMENT NUMBER: 137:88442

TITLE: Incensole and furanogermacrene and compounds in treatment for inhibiting neoplastic lesions and microorganisms

INVENTOR(S): Shanahan-Pendergast, Elisabeth

PATENT ASSIGNEE(S): Ire.

SOURCE: PCT Int. Appl., 68 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002053138	A2	20020711	WO 2002-IE1	20020102
WO 2002053138	A3	20020919		
W: AE, AG, AT, AU, BB, BG, CA, CH, CN, CO, CU, CZ, LU, LV, MA, MD, UA, UG, US, VN, YU, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, AT, BE, CH, CY, DE, ES, FI, ML, MR, NE, SN, TD, TG				
EP 1351678	A2	20031015	EP 2002-727007	20020102
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004092583	A1	20040513	US 2004-250535	20040102
PRIORITY APPLN. INFO.:			IE 2001-2	A 20010102
			WO 2002-IE1	W 20020102

OTHER SOURCE(S): MARPAT 137:88442

AB The invention discloses the use of incensole and/or furanogermacrene, derivs. metabolites and precursors thereof in the treatment of neoplasia, particularly resistant neoplasia and immunodysregulatory disorders. These compds. can be administered alone or in combination with conventional chemotherapeutic, antiviral, antiparasite agents, radiation and/or surgery. Incensole and furanogermacrene and their mixture showed antitumor activity against various human carcinomas and melanomas and antimicrobial activity against Staphylococcus aureus and Enterococcus faecalis.

IT 37221-79-7, Vasoactive intestinal peptide

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(antagonist, pharmaceutical formulation further including; incensole
and furanogermacrens and compds. as antitumor and antimicrobial agents)

RN 37221-79-7 HCAPLUS

CN Vasoactive intestinal polypeptide (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 9002-06-6, Thymidine kinase

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(antagonists, pharmaceutical formulation further including; incensole
and furanogermacrens and compds. as antitumor and antimicrobial agents)

RN 9002-06-6 HCAPLUS

CN Kinase (phosphorylating), thymidine (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 505-60-2, Mustard

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(anticancer, pharmaceutical formulation further including; incensole
and furanogermacrens and compds. as antitumor and antimicrobial agents)

RN 505-60-2 HCAPLUS

CN Ethane, 1,1'-thiobis[2-chloro- (9CI) (CA INDEX NAME)

$\text{ClCH}_2\text{--CH}_2\text{--S--CH}_2\text{--CH}_2\text{Cl}$

IT 7585-39-9, β -Cyclodextrin 7585-39-9D,

β -Cyclodextrin, hydroxypropyl derivs. 10016-20-3,

α -Cyclodextrin 12619-70-4, Cyclodextrin 17465-86-0

, γ -Cyclodextrin


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as pharmaceutical carrier; incensole and furanogermacrens and compds.
as antitumor and antimicrobial agents)

RN 7585-39-9 HCAPLUS


CN β -Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 7585-39-9 HCAPLUS
CN β -Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 10016-20-3 HCAPLUS
CN α -Cyclodextrin (8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 12619-70-4 HCAPLUS
 CN Cyclodextrin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 17465-86-0 HCAPLUS
 CN γ -Cyclodextrin (8CI, 9CI) (CA INDEX NAME)




IT 80-62-6, Methyl methacrylate 2867-47-2,
 (2-Dimethylaminoethyl) methacrylate 9004-38-0, Cellulose acetate
 phthalate 34346-01-5, Poly(lactic acid-glycolic acid)
 441015-98-1

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(enteric coating of; incensole and furanogermacrens and compds. as
antitumor and antimicrobial agents)


RN 80-62-6 HCAPLUS

CN 2-Propenoic acid, 2-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 2867-47-2 HCAPLUS

CN 2-Propenoic acid, 2-methyl-, 2-(dimethylamino)ethyl ester (9CI) (CA INDEX NAME)



RN 9004-38-0 HCAPLUS

CN Cellulose, acetate hydrogen 1,2-benzenedicarboxylate (9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6

CMF Unspecified


CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 88-99-3


CMF C8 H6 O4



CM 3

CRN 64-19-7

CMF C2 H4 O2




RN 34346-01-5 HCAPLUS

CN Propanoic acid, 2-hydroxy-, polymer with hydroxyacetic acid (9CI) (CA INDEX NAME)


CM 1

CRN 79-14-1
CMF C2 H4 O3



CM 2

CRN 50-21-5
CMF C3 H6 O3



RN 441015-98-1 HCAPLUS

CN Cellulose, hydrogen 1,2-benzenedicarboxylate, 2-hydroxypropyl methyl ether, mixt. with butyl 2-methyl-2-propenoate homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 9050-31-1
CMF C8 H6 O4 . x C3 H8 O2 . x C H4 O . x Unspecified


CM 2

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


CM 3

CRN 88-99-3
CMF C8 H6 O4




CM 4

CRN 67-56-1
CMF C H4 O



CM 5

CRN 57-55-6
CMF C3 H8 O2




CM 6

CRN 9003-63-8
CMF (C8 H14 O2)x
CCI PMS

CM 7

CRN 97-88-1
CMF C8 H14 O2




IT 121749-39-1

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(epharmaceutical formulation further including; incensole and
furanogermacrene and compds. as antitumor and antimicrobial agents)

RN 121749-39-1 HCAPLUS

CN 1,3-Propanediamine, N,N'-bis[3-(ethylamino)propyl]- (9CI) (CA INDEX NAME)



IT 54-47-7D, Pyridoxal phosphate, reaction products with Hb
conjugates 76-49-3, Bornyl acetate 80-57-9, Verbenone

87-44-5, β -Caryophyllene 88-84-6, β -Guaiene

99-49-0, Carvone 99-83-2, α -Phellandrene

99-87-6, p-Cymene 112-14-1, Octyl acetate

123-35-3, Myrcene 473-11-0, Eudesmane 489-80-5

, Guaiane 495-61-4, β -Bisabolene 502-61-4,

Farnesene 507-70-0, Borneol 511-59-1, β -Santalene

512-61-8, α -Santalene 515-12-8, Elemene

523-47-7, β -Cadinene 555-10-2, β -Phellandrene


562-74-3, Terpinen-4-ol 1335-14-4 1674-08-4,

trans-Pinocarveol 1820-09-3, trans-Ver-benol 2867-05-2
 , α -Thujene 3856-25-5, α -Copaene 4602-84-0
 , Farnesol 5208-59-3, β -Bourbonene 6753-98-6,
 Humulene 6895-56-3, β -Bergamotene 7663-66-3,
 Bergamotane 8007-35-0, Terpinyl acetate 8013-00-1,
 Terpinene 10178-38-8, Echinodol 14998-63-1D,
 Rhenium-186, etidronate complexes, biological studies 17627-44-0
 , α -Bisabolene 18794-84-8, β -Farnesene
 19912-61-9, Furanodiene 20479-06-5, β -Ylangene
 21698-66-8, Incensole oxide 21698-67-9, Incensole oxide
 acetate 22419-74-5, Incensole 25269-16-3, Isocembrene
 25322-68-3D, conjugates with pyridoxylated Hb 28028-64-0
 , Germacrene 29063-28-3, Octanol 29350-73-0, Cadinene
 31570-39-5, Cembrene-A 34701-53-6 35731-88-5,
 Isoincensole oxide 67921-02-2, Cembrenol 94325-73-2
 94325-73-2D, compds. 122537-31-9, Oplopane
 441771-56-8, Isoincensole 441771-57-9, Isoincensole
 acetate 441771-74-0, SKB 4

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (incensole and furanogermacrene and compds. as antitumor and
 antimicrobial agents)

RN 54-47-7 HCAPLUS


CN 4-Pyridinecarboxaldehyde, 3-hydroxy-2-methyl-5-[(phosphonoxy)methyl]-
 (9CI) (CA INDEX NAME)



RN 76-49-3 HCAPLUS


CN Bicyclo[2.2.1]heptan-2-ol, 1,7,7-trimethyl-, acetate, (1R,2S,4R)-rel-
 (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 80-57-9 HCAPLUS

CN Bicyclo[3.1.1]hept-3-en-2-one, 4,6,6-trimethyl- (9CI) (CA INDEX NAME)




RN 87-44-5 HCAPLUS

CN Bicyclo[7.2.0]undec-4-ene, 4,11,11-trimethyl-8-methylene-, (1R,4E,9S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as described by E or Z.



RN 88-84-6 HCAPLUS


CN Azulene, 1,2,3,4,5,6,7,8-octahydro-1,4-dimethyl-7-(1-methylethylidene)-,
(1S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 99-49-0 HCAPLUS


CN 2-Cyclohexen-1-one, 2-methyl-5-(1-methylethenyl)- (9CI) (CA INDEX NAME)



RN 99-83-2 HCAPLUS
 CN 1,3-Cyclohexadiene, 2-methyl-5-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 99-87-6 HCAPLUS
 CN Benzene, 1-methyl-4-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 112-14-1 HCAPLUS
 CN Acetic acid, octyl ester (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 123-35-3 HCAPLUS
 CN 1,6-Octadiene, 7-methyl-3-methylene- (8CI, 9CI) (CA INDEX NAME)




RN 473-11-0 HCAPLUS
 CN Naphthalene, decahydro-1,4a-dimethyl-7-(1-methylethyl)-, (1R,4aR,7R,8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 489-80-5 HCAPLUS
 CN Azulene, decahydro-1,4-dimethyl-7-(1-methylethyl)-, (1S,3aS,4S,7R,8aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 495-61-4 HCAPLUS

CN Cyclohexene, 1-methyl-4-(5-methyl-1-methylene-4-hexenyl)-, (4S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 502-61-4 HCAPLUS

CN 1,3,6,10-Dodecatetraene, 3,7,11-trimethyl-, (3E,6E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 507-70-0 HCAPLUS

CN Bicyclo[2.2.1]heptan-2-ol, 1,7,7-trimethyl-, (1R,2S,4R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 511-59-1 HCAPLUS

CN Bicyclo[2.2.1]heptane, 2-methyl-3-methylene-2-(4-methyl-3-pentenyl)-, (1S,2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 512-61-8 HCAPLUS

CN Tricyclo[2.2.1.02,6]heptane, 1,7-dimethyl-7-(4-methyl-3-pentenyl)-, (-)-
(8CI, 9CI) (CA INDEX NAME)


Rotation (-).



RN 515-12-8 HCAPLUS

CN Cyclohexane, 1-ethyl-1-methyl-2,4-bis(1-methylethyl)-, (1R,2S,4R)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 523-47-7 HCAPLUS


CN Naphthalene, 1,2,4a,5,8,8a-hexahydro-4,7-dimethyl-1-(1-methylethyl)-,
(1S,4aR,8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 555-10-2 HCAPLUS

CN Cyclohexene, 3-methylene-6-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 562-74-3 HCAPLUS

CN 3-Cyclohexen-1-ol, 4-methyl-1-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 1335-14-4 HCAPLUS

CN Cyclohexadienemethanol, 4-(1-methylethyl)- (9CI) (CA INDEX NAME)

CM 1

CRN 536-60-7


CMF C10 H14 O



RN 1674-08-4 HCAPLUS

CN Bicyclo[3.1.1]heptan-3-ol, 6,6-dimethyl-2-methylene-, (1R,3S,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 1820-09-3 HCAPLUS

CN Bicyclo[3.1.1]hept-3-en-2-ol, 4,6,6-trimethyl-, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 2867-05-2 HCAPLUS
 CN Bicyclo[3.1.0]hex-2-ene, 2-methyl-5-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 3856-25-5 HCAPLUS
 CN Tricyclo[4.4.0.0^{2,7}]dec-3-ene, 1,3-dimethyl-8-(1-methylethyl)-, (1R,2S,6S,7S,8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 4602-84-0 HCAPLUS
 CN 2,6,10-Dodecatrien-1-ol, 3,7,11-trimethyl- (8CI, 9CI) (CA INDEX NAME)



RN 5208-59-3 HCAPLUS
 CN Cyclobuta[1,2:3,4]dicyclopentene, decahydro-3a-methyl-6-methylene-1-(1-methylethyl)-, (1S,3aS,3bR,6aS,6bR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 6753-98-6 HCAPLUS

CN 1,4,8-Cycloundecatriene, 2,6,6,9-tetramethyl-, (1E,4E,8E)- (9CI) (CA INDEX NAME)


Double bond geometry as described by E or Z.



RN 6895-56-3 HCAPLUS


CN Bicyclo[3.1.1]heptane, 6-methyl-2-methylene-6-(4-methyl-3-pentenyl)- (9CI) (CA INDEX NAME)

Currently available stereo shown.



RN 7663-66-3 HCAPLUS

CN Bicyclo[3.1.1]heptane, 2,6-dimethyl-6-(4-methylpentenyl)- (9CI) (CA INDEX NAME)



RN 8007-35-0 HCAPLUS

CN Terpineol, acetate (6CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 8013-00-1 HCAPLUS


CN Terpinene (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 10178-38-8 HCAPLUS

CN Lanosta-8,24-diene-3,22-diol, 16,23-epoxy-, 22-acetate,
(3 β ,16 α ,22R,23S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 14998-63-1 HCAPLUS

CN Rhenium, isotope of mass 186 (8CI, 9CI) (CA INDEX NAME)

^{186}Re

RN 17627-44-0 HCAPLUS


CN Cyclohexene, 4-(1,5-dimethyl-1,4-hexadienyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 18794-84-8 HCAPLUS

CN 1,6,10-Dodecatriene, 7,11-dimethyl-3-methylene-, (6E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 19912-61-9 HCAPLUS

CN Cyclodeca[b]furan, 4,7,8,11-tetrahydro-3,6,10-trimethyl-, (5E,9Z)- (9CI) (CA INDEX NAME)


Double bond geometry as described by E or Z.



RN 20479-06-5 HCAPLUS


CN Tricyclo[4.4.0.0^{2,7}]decane, 1-methyl-3-methylene-8-(1-methylethyl)-,
(1R,2S,6S,7S,8R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 21698-66-8 HCAPLUS

CN 4,16-Dioxatricyclo[11.2.1.0^{3,5}]hexadec-8-en-12-ol, 5,9,13-trimethyl-1-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 21698-67-9 HCAPLUS


CN 4,16-Dioxatricyclo[11.2.1.0^{3,5}]hexadec-8-en-12-ol, 5,9,13-trimethyl-1-(1-methylethyl)-, acetate (9CI) (CA INDEX NAME)



RN 22419-74-5 HCAPLUS

CN 15-Oxabicyclo[10.2.1]pentadeca-5,9-dien-2-ol, 1,5,9-trimethyl-12-(1-methylethyl)-, (1R*,2S*,5E,9E,12S*)- (9CI) (CA INDEX NAME)

Currently available stereo shown.




RN 25269-16-3 HCAPLUS

CN 1,5,10-Cyclotetradecatriene, 1,5-dimethyl-9-methylene-12-(1-methylethyl)-, (1E,5E,10E,12S) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as described by E or Z.



RN 25322-68-3 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), α -hydro- ω -hydroxy- (9CI) (CA INDEX NAME)




RN 28028-64-0 HCAPLUS

CN 1,5-Cyclodecadiene, 1,5-dimethyl-8-(1-methylethenyl)-, (1E,5E,8R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

Double bond geometry as described by E or Z.



RN 29063-28-3 HCAPLUS
 CN Octanol (9CI) (CA INDEX NAME)

Me- (CH₂)₆-Me


D1-OH

RN 29350-73-0 HCAPLUS
 CN Naphthalene, decahydro-1,6-dimethyl-4-(1-methylethyl)-,
 (1S,4S,4aS,6S,8aS)-, didehydro deriv. (9CI) (CA INDEX NAME)

CM 1


CRN 483-73-8
 CMF C15 H28

Absolute stereochemistry.




RN 31570-39-5 HCAPLUS
 CN 1,5,9-Cyclotetradecatriene, 1,5,9-trimethyl-12-(1-methylethenyl)-,
 (1E,5E,9E,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 34701-53-6 HCAPLUS
 CN 15-Oxabicyclo[10.2.1]pentadeca-5,9-dien-2-ol, 1,5,9-trimethyl-12-(1-methylethyl)-, acetate, (1R*,2S*,5E,9E,12S*)- (9CI) (CA INDEX NAME)


Currently available stereo shown.



RN 35731-88-5 HCAPLUS

CN 15,16-Dioxatricyclo[10.2.1.12,5]hexadec-9-en-6-ol, 1,5,9-trimethyl-12-(1-methylethyl)-, (1R,2S,5R,6R,9E,12S)-rel- (9CI) (CA INDEX NAME)


Currently available stereo shown.



RN 67921-02-2 HCAPLUS


CN 3,7,11-Cyclotetradecatrien-1-ol, 4,8,12-trimethyl-1-(1-methylethyl)-, (3E,7E,11E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.
Currently available stereo shown.




RN 94325-73-2 HCAPLUS

CN Cyclodeca[b]furan, 4,5,6,7,8,9,10,11-octahydro- (9CI) (CA INDEX NAME)




RN 94325-73-2 HCAPLUS
 CN Cyclodeca[b]furan, 4,5,6,7,8,9,10,11-octahydro- (9CI) (CA INDEX NAME)



RN 122537-31-9 HCAPLUS
 CN 1H-Indene, 1-ethyloctahydro-4-methyl-7-(1-methylethyl)-, (1S,3aS,4R,7S,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441771-56-8 HCAPLUS
 CN Isoincensole (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 441771-57-9 HCAPLUS
 CN Isoincensole acetate (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 441771-74-0 HCAPLUS
 CN SKB 4 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **141436-78-4**, Protein kinase C
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitor, pharmaceutical formulation further including; incensole and
 furanogermacrene and compds. as antitumor and antimicrobial agents)
 RN 141436-78-4 HCAPLUS
 CN Kinase (phosphorylating), protein, cPKC (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **52660-18-1**, Casein kinase 1 **366806-33-9**, Casein kinase 2
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors (ICOS), pharmaceutical formulation further including;
 incensole and furanogermacrene and compds. as antitumor and
 antimicrobial agents)
 RN 52660-18-1 HCAPLUS
 CN Kinase (phosphorylating), casein, I (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 366806-33-9 HCAPLUS
 CN Kinase (phosphorylating), casein, II (9CI) (CA INDEX NAME)


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 144114-21-6, HIV-1 Protease
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors, pharmaceutical formulation further containing; incensole and
 furanogermacrens and compds. as antitumor and antimicrobial agents)
 RN 144114-21-6 HCAPLUS
 CN Retropepsin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 70-18-8, Glutathione, biological studies 9030-21-1,
 Purine nucleoside phosphorylase 9040-48-6, Gelatinase
 79747-53-8, Protein tyrosine phosphatase 79955-99-0,
 Stromelysin 80449-02-1, Tyrosine kinase 106096-93-9,
 Basic fibroblast growth factor 120178-12-3, Telomerase
 131384-38-8, Ras farnesyltransferase 140879-24-9,
 Proteasome 141256-52-2, Matrilysin 141907-41-7, Matrix
 metalloproteinase 375798-61-1, Phosphatase, phosphoprotein
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors, pharmaceutical formulation further including; incensole
 and furanogermacrens and compds. as antitumor and antimicrobial agents)
 RN 70-18-8 HCAPLUS
 CN Glycine, L-γ-glutamyl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 9030-21-1 HCAPLUS
 CN Phosphorylase, purine nucleoside (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 9040-48-6 HCAPLUS
 CN Gelatinase (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 79747-53-8 HCAPLUS
 CN Phosphatase, phosphoprotein (phosphotyrosine) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 79955-99-0 HCAPLUS
 CN Stromelysin 1 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 80449-02-1 HCAPLUS
 CN Kinase (phosphorylating), protein (tyrosine) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 106096-93-9 HCAPLUS
 CN Fibroblast growth factor, basic (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 120178-12-3 HCAPLUS
 CN Nucleotidyltransferase, terminal deoxyribo- (telomeric DNA) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 131384-38-8 HCAPLUS

CN Farnesyltransferase, protein (cysteine) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 140879-24-9 HCAPLUS

CN Proteinase, multicatalytic (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 141256-52-2 HCAPLUS

CN Matrilysin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 141907-41-7 HCAPLUS

CN Proteinase, matrix metallo- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 375798-61-1 HCAPLUS

CN Phosphatase, phosphoprotein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 10102-43-9, Nitric oxide, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(modulators, pharmaceutical formulation further including; incensole
and furanogermacrene and compds. as antitumor and antimicrobial agents)

RN 10102-43-9 HCAPLUS

CN Nitrogen oxide (NO) (8CI, 9CI) (CA INDEX NAME)

N=O

IT 9002-61-3, Chorionic gonadotrophin

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(monoclonal antibody to human, pharmaceutical formulation further
including; incensole and furanogermacrene and compds. as antitumor and
antimicrobial agents)

RN 9002-61-3 HCAPLUS

CN Gonadotropin, chorionic (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 9068-38-6, Reverse transcriptase

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(nonnucleoside inhibitors of, pharmaceutical formulation further
containing; incensole and furanogermacrene and compds. as antitumor and
antimicrobial agents)

RN 9068-38-6 HCAPLUS

CN Nucleotidyltransferase, deoxyribonucleate, RNA-dependent (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 1406-18-4, Vitamin E

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oil, as pharmaceutical carrier; incensole and furanogermacrene and
compds. as antitumor and antimicrobial agents)


RN 1406-18-4 HCAPLUS

CN Vitamin E (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 54-05-7, Chloroquine 54-42-2, Idoxuridine
60-54-8, Tetracycline 69-74-9, Cytarabine Hydrochloride
70-00-8, Trifluridine 80-08-0, Dapsone 90-34-6
, Primaquine 100-33-4, Pentamidine 130-95-0, Quinine
443-48-1, Metronidazole 494-79-1, Melarsoprol
665-66-7, Amantadine Hydrochloride 1501-84-4,
Rimantadine Hydrochloride 1910-68-5, Methisazone
3056-17-5, d4T 3736-81-0, Diloxanide furoate
5536-17-4, Vidarabine 7481-89-2, DdC 8064-90-2
9004-70-0, HE-2000 10500-82-0, Famotidine Hydrochloride
10540-97-3, Memotidine Hydrochloride 11006-77-2, Statolon
15176-29-1, Edoxudine 15185-43-0, DOTC
19387-91-8, Tinidazole 19885-51-9, Aranotin
22994-85-0, Benznidazole 23256-30-6, Nifurtimox
25526-93-6, Alovudine 27591-69-1, Tilorone Hydrochloride
27762-78-3, Kethoxal 29984-33-6, Vidarabine Phosphate
30516-87-1, AZT 35607-20-6, Avridine 36791-04-5
, Ribavirin 36983-81-0, Fosfonet Sodium 37338-39-9
39809-25-1, Penciclovir 51867-87-9 53230-10-7,
Mefloquine 56219-57-9, Arildone 59277-89-3, Acyclovir
63198-97-0, Viroxime 63585-09-1, Foscarnet Sodium
63968-64-9D, Artemisinin, derivs. 68693-30-1,
Somantadine Hydrochloride 69123-90-6, Fiacitabine
69123-98-4, Fialuridine 69655-05-6, DdI
69657-51-8, Acyclovir Sodium 69756-53-2, Halofantrine
72301-78-1, Zinviroxime 72301-79-2, Enviroxime
73514-87-1, Fosarilate 77181-69-2, Sorivudine
80883-55-2, Envirodene 82410-32-0, Ganciclovir
84408-37-7, Desciclovir 85087-20-3, Doxycycline
87495-31-6, Disoxaril 95233-18-4, Atovaquone
100817-46-7, Stibogluconic acid 104227-87-4, Famciclovir
106362-32-7, Peptide T 106941-25-7, PMEA
107910-75-8, Ganciclovir Sodium 110042-95-0, Acemannan
110143-10-7, Lodenosine 113852-37-2, Cidofovir
124436-59-5, Pirodavidir 124832-27-5, Valacyclovir
Hydrochloride 127759-89-1, Lobucavir 127779-20-8,
Saqunavir 129618-40-2, Nevirapine 132210-43-6,
Cipamfylline 134678-17-4, 3TC 136470-78-5, Abacavir
136817-59-9, Delavirdine 137487-62-8, Alvircept Sudotox
138540-32-6, Atevirdine Mesylate 141204-94-6,
Co-artemether 142340-99-6 142632-32-4, Calanolide A
143491-57-0, Coviracil 145514-04-1, DAPD
147127-20-6, Tenofovir 147221-93-0, Delavirdine Mesylate
147318-81-8, KNI-272 147362-57-0, Loviride
149845-06-7, Saquinavir Mesylate 149950-60-7, Emivirine
150378-17-9, Indinavir 153127-49-2, ALX40-4C
154598-52-4, DMP 266 155148-31-5, AMD 3100
155213-67-5, Ritonavir 156879-70-8 159519-65-0
, Pentafuside 159989-64-7, Nelfinavir 163451-80-7
170020-61-8, FP-21399 174484-41-4, Tipranavir
177932-89-7, DMP-450 178979-85-6, AG 1549
185220-03-5, PNU142721 192725-17-0, ABT-378
214287-88-4, DPC961 216863-66-0, L-756423
251562-00-2, T-1249 383198-56-9, BW 141
383198-57-0, BMS-232630 383198-58-1, PRO 542
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(pharmaceutical formulation further containing; incensole and
furanogermacrens and compds. as antitumor and antimicrobial agents)
RN 54-05-7 HCAPLUS


CN 1,4-Pentanediamine, N4-(7-chloro-4-quinolinyl)-N1,N1-diethyl- (9CI) (CA INDEX NAME)



RN 54-42-2 HCAPLUS

CN Uridine, 2'-deoxy-5-iodo- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 60-54-8 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aS,5aS,6S,12aS) - (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 69-74-9 HCAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-β-D-arabinofuranosyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.




● HCl

RN 70-00-8 HCAPLUS
CN Thymidine, α,α,α -trifluoro- (8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 80-08-0 HCAPLUS
CN Benzenamine, 4,4'-sulfonylbis- (9CI) (CA INDEX NAME)



RN 90-34-6 HCAPLUS
CN 1,4-Pentanediamine, N4-(6-methoxy-8-quinolinyl)- (9CI) (CA INDEX NAME)




RN 100-33-4 HCAPLUS
CN Benzenecarboximidamide, 4,4'-[1,5-pentanediybis(oxy)]bis- (9CI) (CA INDEX NAME)



RN 130-95-0 HCAPLUS


CN Cinchonan-9-ol, 6'-methoxy-, (8 α ,9R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443-48-1 HCAPLUS

CN 1H-Imidazole-1-ethanol, 2-methyl-5-nitro- (9CI) (CA INDEX NAME)




RN 494-79-1 HCAPLUS

CN 1,3,2-Dithiarsolane-4-methanol, 2-[4-[(4,6-diamino-1,3,5-triazin-2-yl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 665-66-7 HCAPLUS

CN Tricyclo[3.3.1.1^{3,7}]decan-1-amine, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 1501-84-4 HCAPLUS

CN Tricyclo[3.3.1.1^{3,7}]decane-1-methanamine, α -methyl-, hydrochloride
(9CI) (CA INDEX NAME)

● HCl


RN 1910-68-5 HCAPLUS

CN Hydrazinecarbothioamide, 2-(1,2-dihydro-1-methyl-2-oxo-3H-indol-3-ylidene)-
(9CI) (CA INDEX NAME)

RN 3056-17-5 HCAPLUS

CN Thymidine, 2',3'-didehydro-3'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 3736-81-0 HCAPLUS

CN 2-Furancarboxylic acid, 4-[(dichloroacetyl)methylamino]phenyl ester (9CI)


(CA INDEX NAME)



RN 5536-17-4 HCAPLUS

CN 9H-Purin-6-amine, 9-β-D-arabinofuranosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 7481-89-2 HCAPLUS

CN Cytidine, 2',3'-dideoxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 8064-90-2 HCAPLUS

CN Benzenesulfonamide, 4-amino-N-(5-methyl-3-isoxazolyl)-, mixt. with 5-[(3,4,5-trimethoxyphenyl)methyl]-2,4-pyrimidinediamine (9CI) (CA INDEX NAME)

CM 1

CRN 738-70-5


CMF C14 H18 N4 O3



CM 2

CRN 723-46-6

CMF C10 H11 N3 O3 S



RN 9004-70-0 HCAPLUS

CN Cellulose, nitrate (9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6

CMF Unspecified


CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2


CRN 7697-37-2

CMF H N O3




RN 10500-82-0 HCAPLUS

CN Isoquinoline, 1-[(4-chlorophenoxy)methyl]-3,4-dihydro-, hydrochloride
(9CI) (CA INDEX NAME)



● HCl

RN 10540-97-3 HCAPLUS
 CN Isoquinoline, 3,4-dihydro-1-[(4-methoxyphenoxy)methyl]-, hydrochloride
 (9CI) (CA INDEX NAME)




● HCl

RN 11006-77-2 HCAPLUS
 CN Statolon (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 15176-29-1 HCAPLUS
 CN Uridine, 2'-deoxy-5-ethyl- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 15185-43-0 HCAPLUS


CN Benzoxazolium, 3-ethyl-2-[7-(3-ethyl-2(3H)-benzoxazolylidene)-1,3,5-heptatrienyl]-, iodide (9CI) (CA INDEX NAME)



● I⁻


RN 19387-91-8 HCAPLUS

CN 1H-Imidazole, 1-[2-(ethylsulfonyl)ethyl]-2-methyl-5-nitro- (9CI) (CA INDEX NAME)




RN 19885-51-9 HCAPLUS


CN 8H,16H-7a,15a-Epidithio-7H,15H-bisoxepino[3',4':4,5]pyrrolo[1,2-a:1',2'-d]pyrazine-7,15-dione, 5-(acetyloxy)-5,5a,13,13a-tetrahydro-13-hydroxy-, (5S,5aS,7aR,13S,13aS,15aR) - (9CI) (CA INDEX NAME)



RN 22994-85-0 HCAPLUS
 CN 1H-Imidazole-1-acetamide, 2-nitro-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 23256-30-6 HCAPLUS
 CN 4-Thiomorpholinamine, 3-methyl-N-[(5-nitro-2-furanyl)methylene]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 25526-93-6 HCAPLUS
 CN Thymidine, 3'-deoxy-3'-fluoro- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 27591-69-1 HCAPLUS
 CN 9H-Fluoren-9-one, 2,7-bis[2-(diethylamino)ethoxy]-, dihydrochloride (9CI)
 (CA INDEX NAME)




● 2 HCl

RN 27762-78-3 HCAPLUS
 CN 2-Butanone, 3-ethoxy-1,1-dihydroxy- (8CI, 9CI) (CA INDEX NAME)



RN 29984-33-6 HCAPLUS
 CN 9H-Purin-6-amine, 9-(5-O-phosphono-beta-D-arabinofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 30516-87-1 HCAPLUS


CN Thymidine, 3'-azido-3'-deoxy- (7CI, 8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 35607-20-6 HCAPLUS


CN Ethanol, 2,2'-[[3-(dioctadecylamino)propyl]imino]bis- (9CI) (CA INDEX NAME)



RN 36791-04-5 HCAPLUS


CN 1H-1,2,4-Triazole-3-carboxamide, 1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 36983-81-0 HCAPLUS

CN Acetic acid, phosphono-, disodium salt (9CI) (CA INDEX NAME)




●2 Na

RN 37338-39-9 HCAPLUS

CN Benzenesulfonamide, 4-amino-N-(5,6-dimethoxy-4-pyrimidinyl)-, mixt. with 5-(4-chlorophenyl)-6-ethyl-2,4-pyrimidinediamine (9CI) (CA INDEX NAME)


CM 1

CRN 2447-57-6
CMF C12 H14 N4 O4 S




CM 2

CRN 58-14-0
CMF C12 H13 Cl N4




RN 39809-25-1 HCAPLUS
CN 6H-Purin-6-one, 2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)butyl]-(9CI) (CA INDEX NAME)



RN 51867-87-9 HCAPLUS
CN 9H-Purin-6-amine, 9-(5-O-phosphono-β-D-arabinofuranosyl)-, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Na

RN 53230-10-7 HCAPLUS


CN 4-Quinolinemethanol, α -(2R)-2-piperidinyl-2,8-bis(trifluoromethyl)-, (α S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 56219-57-9 HCAPLUS

CN 3,5-Heptanedione, 4-[6-(2-chloro-4-methoxyphenoxy)hexyl]- (9CI) (CA INDEX NAME)




RN 59277-89-3 HCAPLUS

CN 6H-Purin-6-one, 2-amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 63198-97-0 HCAPLUS

CN 1H-Benzimidazol-2-amine, 6-[(hydroxyimino)phenylmethyl]-1-[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 63585-09-1 HCAPLUS

CN Phosphinecarboxylic acid, dihydroxy-, oxide, trisodium salt (9CI) (CA INDEX NAME)




●3 Na


RN 63968-64-9 HCAPLUS

CN 3,12-Epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10(3H)-one, octahydro-3,6,9-trimethyl-, (3R,5aS,6R,8aS,9R,12S,12aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 68693-30-1 HCAPLUS


CN Tricyclo[3.3.1.1.3,7]decane-1-ethanamine, α,α -dimethyl-, hydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 69123-90-6 HCAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-(2-deoxy-2-fluoro- β -D-arabinofuranosyl)-5-iodo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 69123-98-4 HCAPLUS


CN 2,4(1H,3H)-Pyrimidinedione, 1-(2-deoxy-2-fluoro- β -D-arabinofuranosyl)-5-iodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 69655-05-6 HCAPLUS
 CN Inosine, 2',3'-dideoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 69657-51-8 HCAPLUS
 CN 6H-Purin-6-one, 2-amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-,
 monosodium salt (9CI) (CA INDEX NAME)



● Na


RN 69756-53-2 HCAPLUS
 CN 9-Phenanthrenemethanol, 1,3-dichloro-α-[2-(dibutylamino)ethyl]-6-(
 trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 72301-78-1 HCAPLUS

CN 1H-Benzimidazol-2-amine, 6-[(Z)-(hydroxyimino)phenylmethyl]-1-[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 72301-79-2 HCAPLUS


CN 1H-Benzimidazol-2-amine, 6-[(E)-(hydroxyimino)phenylmethyl]-1-[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 73514-87-1 HCAPLUS

CN Phosphonic acid, [6-(2-chloro-4-methoxyphenoxy)hexyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 77181-69-2 HCAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-β-D-arabinofuranosyl-5-[(1E)-2-

bromoethenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 80883-55-2 HCAPLUS


CN 1H-Benzimidazol-2-amine, 1-[(1-methylethyl)sulfonyl]-6-[(1E)-1-phenyl-1-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 82410-32-0 HCAPLUS

CN 6H-Purin-6-one, 2-amino-1,9-dihydro-9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]- (9CI) (CA INDEX NAME)



RN 84408-37-7 HCAPLUS


CN Ethanol, 2-[(2-amino-9H-purin-9-yl)methoxy]- (9CI) (CA INDEX NAME)



RN 85087-20-3 HCAPLUS
 CN Doxycycline (9CI) (CA INDEX NAME)


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 87495-31-6 HCAPLUS
 CN Isoxazole, 5-[7-[4-(4,5-dihydro-2-oxazolyl)phenoxy]heptyl]-3-methyl- (9CI)
 (CA INDEX NAME)




RN 95233-18-4 HCAPLUS
 CN 1,4-Naphthalenedione, 2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 100817-46-7 HCAPLUS
 CN D-Gluconic acid, 2,4:2',4'-O-[oxybis(dioxidostibylidyne)]bis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 104227-87-4 HCAPLUS
 CN 1,3-Propanediol, 2-[2-(2-amino-9H-purin-9-yl)ethyl]-, diacetate (ester)
 (9CI) (CA INDEX NAME)




RN 106362-32-7 HCAPLUS
 CN L-Threonine, L-alanyl-L-seryl-L-threonyl-L-threonyl-L-threonyl-L-asparaginyl-L-tyrosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 106941-25-7 HCAPLUS
 CN Phosphonic acid, [[2-(6-amino-9H-purin-9-yl)ethoxy]methyl]- (9CI) (CA INDEX NAME)



RN 107910-75-8 HCAPLUS
 CN 6H-Purin-6-one, 2-amino-1,9-dihydro-9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 110042-95-0 HCAPLUS
 CN α-D-Galacto-β-D-mannan, (1→4), (1→6)-, acetate (9CI) (CA INDEX NAME)


CM 1

CRN 115426-79-4
 CMF Unspecified
 CCI MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


CM 2

CRN 64-19-7
 CMF C2 H4 O2



RN 110143-10-7 HCAPLUS
 CN 9H-Purin-6-amine, 9-(2,3-dideoxy-2-fluoro-β-D-threo-pentofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 113852-37-2 HCAPLUS

CN Phosphonic acid, [[[1S]-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 124436-59-5 HCAPLUS

CN Benzoic acid, 4-[2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 124832-27-5 HCAPLUS

CN L-Valine, 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 127759-89-1 HCAPLUS

CN 6H-Purin-6-one, 2-amino-9-[(1R,2R,3S)-2,3-bis(hydroxymethyl)cyclobutyl]-1,9-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 127779-20-8 HCAPLUS


CN Butanediamide, N1-[(1S,2R)-3-[(3S,4aS,8aS)-3-[[[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 129618-40-2 HCAPLUS

CN 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 132210-43-6 HCAPLUS


CN 1H-Purine-2,6-dione, 8-amino-1,3-bis(cyclopropylmethyl)-3,7-dihydro- (9CI) (CA INDEX NAME)



RN 134678-17-4 HCAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 136470-78-5 HCAPLUS


CN 2-Cyclopentene-1-methanol, 4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-, (1S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 136817-59-9 HCAPLUS

CN Piperazine, 1-[3-[(1-methylethyl)amino]-2-pyridinyl]-4-[[5-[(methylsulfonyl)amino]-1H-indol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 137487-62-8 HCAPLUS

CN 1-178-Antigen CD 4 (human clone pT4B protein moiety reduced), N2-L-methionyl-, (178-248')-protein with 248-L-histidine-249-L-methionine-250-L-alanine-251-L-glutamic acid-248-613-exotoxin A (Pseudomonas aeruginosa reduced) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 138540-32-6 HCAPLUS

CN Piperazine, 1-[3-(ethylamino)-2-pyridinyl]-4-[(5-methoxy-1H-indol-2-yl)carbonyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 136816-75-6


CMF C21 H25 N5 O2



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 141204-94-6 HCAPLUS


CN 9H-Fluorene-4-methanol, 2,7-dichloro-9-[(4-chlorophenyl)methylene]- α -[(dibutylamino)methyl]-, (9Z)-, mixt. with (3R,5aS,6R,8aS,9R,10S,12R,12aR)-decahydro-10-methoxy-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin (9CI) (CA INDEX NAME)

CM 1

CRN 82186-77-4

CMF C30 H32 Cl3 N O

Double bond geometry as shown.




CM 2

CRN 71963-77-4


CMF C16 H26 O5

Absolute stereochemistry.



RN 142340-99-6 HCAPLUS


CN Propanoic acid, 2,2-dimethyl-, [[[2-(6-amino-9H-purin-9-yl)ethoxy)methyl]phosphinylidene]bis(oxymethylene) ester (9CI) (CA INDEX NAME)



RN 142632-32-4 HCAPLUS

CN 2H,6H,10H-Benzo[1,2-b:3,4-b':5,6-b'']tripyran-2-one, 11,12-dihydro-12-hydroxy-6,6,10,11-tetramethyl-4-propyl-, (10R,11S,12S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 143491-57-0 HCAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 145514-04-1 HCAPLUS

CN 1,3-Dioxolane-2-methanol, 4-(2,6-diamino-9H-purin-9-yl)-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 147127-20-6 HCAPLUS

CN Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 147221-93-0 HCAPLUS

CN Piperazine, 1-[3-[(1-methylethyl)amino]-2-pyridinyl]-4-[[5-[(methylsulfonyl)amino]-1H-indol-2-yl]carbonyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 136817-59-9


CMF C22 H28 N6 O3 S



CM 2

CRN 75-75-2


CMF C H4 O3 S



RN 147318-81-8 HCAPLUS


CN 4-Thiazolidinecarboxamide, N-(1,1-dimethylethyl)-3-[(2S,3S)-2-hydroxy-3-[[[(2R)-2-[[[5-isoquinolinyloxy]acetyl]amino]-3-(methylthio)-1-oxopropyl]amino]-1-oxo-4-phenylbutyl]-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 147362-57-0 HCAPLUS

CN Benzeneacetamide, α -[(2-acetyl-5-methylphenyl)amino]-2,6-dichloro-
(9CI) (CA INDEX NAME)



RN 149845-06-7 HCAPLUS


CN Butanediamide, N1-[(1S,2R)-3-[(3S,4aS,8aS)-3-[[[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)-, monomethanesulfonate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 127779-20-8

CMF C38 H50 N6 O5


Absolute stereochemistry.



CM 2


CRN 75-75-2

CMF C H4 O3 S



RN 149950-60-7 HCAPLUS


CN 2,4(1H,3H)-Pyrimidinedione, 1-(ethoxymethyl)-5-(1-methylethyl)-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 150378-17-9 HCAPLUS

CN D-erythro-Pentonamide, 2,3,5-trideoxy-N-[(1S,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-5-[(2S)-2-[[[(1,1-dimethylethyl)amino]carbonyl]-4-(3-pyridinylmethyl)-1-piperazinyl]-2-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 153127-49-2 HCAPLUS

CN D-Argininamide, N2-acetyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-, nonaacetate (9CI) (CA INDEX NAME)


CM 1

CRN 143413-49-4


CMF C56 H113 N37 O10

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2

CRN 64-19-7


CMF C2 H4 O2



RN 154598-52-4 HCAPLUS


CN 2H-3,1-Benzoxazin-2-one, 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 155148-31-5 HCAPLUS

CN 1,4,8,11-Tetraazacyclotetradecane, 1,1'-[1,4-phenylenebis(methylene)]bis-, octahydrochloride (9CI) (CA INDEX NAME)



● 8 HCl

RN 155213-67-5 HCAPLUS

CN 2,4,7,12-Tetraazatridecan-13-oic acid, 10-hydroxy-2-methyl-5-(1-methylethyl)-1-[2-(1-methylethyl)-4-thiazolyl]-3,6-dioxo-8,11-bis(phenylmethyl)-, 5-thiazolylmethyl ester, (5S,8S,10S,11S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


glutaminy-L- α -glutamyl-L-lysyl-L-asparaginy-L- α -glutamyl-L-glutaminy-L- α -glutamyl-L-leucyl-L-leucyl-L- α -glutamyl-L-leucyl-L- α -aspartyl-L-lysyl-L-tryptophyl-L-alanyl-L-seryl-L-leucyl-L-tryptophyl-L-asparaginy-L-tryptophyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 159989-64-7 HCAPLUS

CN 3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-, (3S,4aS,8aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 163451-80-7 HCAPLUS


CN 1(2H)-Quinoxalinecarboxylic acid, 3,4-dihydro-7-methoxy-2-[(methylthio)methyl]-3-thioxo-, 1-methylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 170020-61-8 HCAPLUS

CN 2,7-Naphthalenedisulfonic acid, 5-[(2,3-dichlorobenzoyl)amino]-3-[[4-[[8-[(2,4-dichlorobenzoyl)amino]-1-hydroxy-3,6-disulfo-2-naphthalenyl]azo]-2,5-dimethoxyphenyl]azo]-4-hydroxy-, tetrasodium salt (9CI) (CA INDEX NAME)




● 4. Na

RN 174484-41-4 HCAPLUS

CN 2-Pyridinesulfonamide, N-[3-[(1R)-1-[(6R)-5,6-dihydro-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-2H-pyran-3-yl]propyl]phenyl]-5-(trifluoromethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 177932-89-7 HCAPLUS


CN 2H-1,3-Diazepin-2-one, 1,3-bis[(3-aminophenyl)methyl]hexahydro-5,6-dihydroxy-4,7-bis(phenylmethyl)-, (4R,5S,6S,7R)-, dimethanesulfonate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 174391-92-5

CMF C33 H36 N4 O3


Absolute stereochemistry.



CM 2


CRN 75-75-2

CMF C H4 O3 S



RN 178979-85-6 HCAPLUS


CN 1H-Imidazole-2-methanol, 5-[(3,5-dichlorophenyl)thio]-4-(1-methylethyl)-1-(4-pyridinylmethyl)-, carbamate (ester) (9CI) (CA INDEX NAME)



RN 185220-03-5 HCAPLUS

CN 4-Pyrimidinamine, 6-chloro-2-[[[(1S)-1-furo[2,3-c]pyridin-5-ylethyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 192725-17-0 HCAPLUS

CN 1(2H)-Pyrimidineacetamide, N-[(1S,3S,4S)-4-[[[(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-α-(1-methylethyl)-2-oxo-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 214287-88-4 HCAPLUS

CN 2(1H)-Quinazolinone, 6-chloro-4-(cyclopropylethynyl)-3,4-dihydro-4-(trifluoromethyl)-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 216863-66-0 HCAPLUS

CN D-erythro-Pentonamide, 5-[(2S)-4-(2-benzofuranylmethyl)-2-[[[(1,1-dimethylethyl)amino]carbonyl]-1-piperazinyl]-2,3,5-trideoxy-N-[(1S,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-2-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 251562-00-2 HCAPLUS

CN L-Phenylalaninamide, N-acetyl-L-tryptophyl-L-glutaminy-L- α -glutamyl-L-tryptophyl-L- α -glutamyl-L-glutaminy-L-lysyl-L-isoleucyl-L-threonyl-L-alanyl-L-leucyl-L-leucyl-L- α -glutamyl-L-glutaminy-L-alanyl-L-glutaminy-L-isoleucyl-L-glutaminy-L-glutaminy-L- α -glutamyl-L-lysyl-L-asparaginy-L- α -glutamyl-L-tyrosyl-L- α -glutamyl-L-leucyl-L-glutaminy-L-lysyl-L-leucyl-L- α -aspartyl-L-lysyl-L-tryptophyl-L-alanyl-L-seryl-L-leucyl-L-tryptophyl-L- α -glutamyl-L-tryptophyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 383198-56-9 HCAPLUS

CN BW 141 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 383198-57-0 HCAPLUS

CN BMS 232630 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 383198-58-1 HCAPLUS

CN PRO 542 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


IT 50-07-7, Mutamycin 50-18-0, Cyclophosphamide
50-28-2, Estradiol, biological studies 50-35-1,
Thalidomide 50-76-0, Dactinomycin 50-91-9, Floxuridine
51-21-8, Fluorouracil 51-75-2, Mechlorethamine
52-24-4, Thiotepa 53-19-0, Mitotane 53-43-0,
DHEA 53-79-2, Puromycin 54-71-7, Pilocarpine
hydrochloride 54-91-1, Pipobroman 55-21-0D, Benzamide,
N-substituted compds. 55-86-7, Mechlorethamine Hydrochloride
55-86-7D, Nitrogen mustard, derivs. 55-98-1, Busulfan
56-53-1, Diethylstilbestrol 57-22-7, Vincristine
57-63-6, Ethinyl oestradiol 57-83-0,
Progesterone, biological studies 58-05-9, Leucovorin
58-58-2, Puromycin Hydrochloride 59-05-2, Methotrexate
66-75-1, Uracil Mustard 83-89-6, Acridine
101-60-0, Porphyrin 106-60-5, Aminolevulinic acid
114-70-5, Sodium phenylacetate 122-79-2, Phenylacetate
125-45-1, Azetepa 125-84-8, Aminoglutethimide
127-07-1, Hydroxyurea 143-67-9, Vinblastine Sulfate
145-63-1, Suramin 147-94-4, Cytarabine 148-82-3
, Melfalan 154-42-7, Thioguanine 154-93-8, Carmustine
302-49-8, Uredepia 302-79-4, Tretinoin 305-03-3

, Chlorambucil 320-67-2, Azacitidine 359-83-1,
Pentazocine 364-62-5, Metoclopramide 366-70-1,
Procarbazine Hydrochloride 378-44-9, Betamethasone
423-55-2, Perflubron 459-86-9, Mitoguazone
465-65-6, Naloxone 472-15-1, Betulinic acid
481-29-8, Epiandrosterone 518-28-5, Podophyllotoxin
520-85-4, Medroxyprogesterone 521-12-0, Dromostanolone
Propionate 536-59-4, Perillyl alcohol 548-04-9,
Hypericin 566-48-3, Formestane 569-57-3,
Chlorotrianisene 578-95-0D, Acridone, imidazo derivs.
595-33-5, Megestrol Acetate 645-05-6, Altretamine
646-08-2, β -Alethine 671-16-9, Procarbazine
801-52-5, Porfiromycin 865-21-4, Vinblastine
911-45-5, Clomifene 968-93-4, Testolactone
1271-19-8, Titanocene dichloride 1402-81-9, Ambomycin
1403-99-2, Mitogillin 1404-00-8, Mitomycin
1404-15-5, Nogalamycin 1404-20-2, Peliomycin
1404-64-4, Sparsomycin 1661-29-6, Meturedopa
1972-08-3, Dronabinol 1980-45-6, Benzodepa
2068-78-2, Vincristine Sulfate 2353-33-5, Decitabine
2508-89-6 2608-24-4, Pipo sulfan 2809-21-4D,
Etidronic acid, rhenium-186 complexes 2919-66-6, Melengestrol
acetate 2998-57-4, Estramustine 2998-57-4D,
Estramustine, analogs 3073-59-4, Hexamethylene bisacetamide
3094-09-5, Doxifluridine 3562-63-8, Megestrol
3778-73-2, Ifosfamide 3930-19-6, Streptonigrin
4105-38-8 4291-63-8, Cladribine 4342-03-4,
Dacarbazine 4342-07-8 4803-27-4, Anthramycin
5072-26-4, Buthionine sulfoximine 5373-42-2,
Thaliblastine 5508-58-7, Andrographolide 5579-27-1,
Simtrazene 5581-52-2, Thiamiprine 5696-17-3,
Epipropidine 6157-87-5, Trestolone Acetate 7281-31-4,
Vinglycinatate Sulfate 7440-06-4D, Platinum, lipophilic compds. or
complexes 7644-67-9, Azotomycin 7689-03-4D,
Camptothecin, derivs. 7724-76-7, Riboprine 7761-45-7,
Metoprine 8052-16-2, Cactinomycin 9002-71-5,
Thyroid-stimulating hormone 9014-02-2, Zinostatin
9014-42-0, Thrombopoietin 9014-42-0D, Thrombopoietin,
mimetics 9015-68-3, Asparaginase 9027-98-9
9041-93-4, Bleomycin Sulfate 9050-67-3, Sizofiran
10043-49-9, Gold-198, biological studies 10087-89-5,
Enpromate 10318-26-0, Mitolactol 10403-51-7,
Mitindomide 10540-29-1, Tamoxifen 11002-22-5, Apurinic
acid 11029-06-4, Elemene 11043-98-4, Mitocromin
11043-99-5, Mitomalcin 11056-06-7, Bleomycin
11056-12-5, Cirolemycin 11056-14-7, Mitocarcin
11056-15-8, Mitosper 12713-07-4D, Verdin, compds.
13010-47-4, Lomustine 13311-84-7, Flutamide
13494-90-1, Gallium nitrate 13665-88-8, Mopidamol
13909-09-6, Semustine 14769-73-4, Levamisole
15475-56-6, Methotrexate Sodium 15639-50-6, Safingol
15663-27-1, Cisplatin 17021-26-0, Calusterone
17902-23-7, Tegafur 18378-89-7, Plicamycin
18416-85-8, Lombricine 18556-44-0, Vinrosidine Sulfate
18588-57-3, Etoprine 18883-66-4, Streptozocin
19916-73-5, O6-Benzylguanine 20098-14-0, Idramantone
20537-88-6, Amifostine 20638-84-0, Retinamide
20830-81-3, Daunorubicin 21059-48-3, Veramine
21679-14-1, Fludarabine 22668-01-5, Etanidazole
23214-92-8, Doxorubicin 23541-50-6, Daunorubicin

Hydrochloride 23593-75-1, Clotrimazole 24280-93-1,
Mycophenolic Acid 24584-09-6, Dexrazoxane 25316-40-9,
Adriamycin 27302-90-5, Oxisuran 27314-97-2,
Tirapazamine 27548-93-2D, Baccatin III, derivs.
27686-84-6, Masoprostol 29069-24-7, Prednimustine
29767-20-2, Teniposide 30303-65-2, Docosanol
30387-51-0, Asperlin 30868-30-5, Pyrazofurin
31430-18-9, Nocodazole 31441-78-8, Mercaptopurine
32954-58-8, Ipomeanol 33069-62-4, Paclitaxel
33069-62-4D, Paclitaxel, analogs and derivs. 33419-42-0,
Etoposide 35301-24-7, Cedefingol 35846-53-8,
Maytansine 35943-35-2, Triciribine 36508-71-1,
Zorubicin Hydrochloride 37717-21-8, Flurocitabine
38270-90-5, Strontium Chloride Sr 89 38321-02-7,
Dexverapamil 39325-01-4, Picibanil 40391-99-9,
Pamidronic acid 41575-94-4, Carboplatin 41729-52-6,
Dezaguanine 41992-22-7, Spirogermanium Hydrochloride
42228-92-2, Acivicin 42616-25-1, Methioninase
50264-69-2, Lonidamine 51264-14-3, Amsacrine
51321-79-0, Sparfosic acid 52128-35-5, Trimetrexate
52205-73-9, Estramustine Phosphate Sodium 52794-97-5,
Carubicin Hydrochloride 53643-48-4, Vindesine 53714-56-0
, Leuprolide 53910-25-1, Pentostatin 54081-68-4,
Vinleurosine Sulfate 54824-17-8, Mitonafide 55435-65-9
, Acodazole Hydrochloride 56390-09-1, Epirubicin Hydrochloride
56420-45-2, Epirubicin 56605-16-4, Spiromustine
56741-95-8, Bopiridine 57381-26-7, Irsogladine
57576-44-0, Aclarubicin 57773-63-4, Triptorelin
57773-65-6, Deslorelin 57852-57-0, Idamycin
57998-68-2, Diaziquone 58066-85-6, Miltefosine
58525-82-9, Azatyrosine 58957-92-9, Idarubicin
58970-76-6, Ubenimex 59653-73-5, Teroxirone
59917-39-4, Vindesine Sulfate 59989-18-3,
5-Ethynyluracil 60084-10-8, Tiazofurin 60203-57-8,
Prostaglandin J2 60940-34-3, Ebselen 61825-94-3,
Oxaliplatin 61966-08-3, Triciribine Phosphate 62304-98-7
, Thymalfasin 62435-42-1, Perfosfamide 62488-57-7
62816-98-2, Ormaplatin 62928-11-4, Iproplatin
63590-19-2, Balanol 63612-50-0, Nilutamide
63950-06-1, Esorubicin Hydrochloride 65057-90-1,
Talisomycin 65093-40-5, Cytarabine ocfosfate 65222-35-7
, Pazelliptine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(pharmaceutical formulation further including; incensole and
furanogermacrens and compds. as antitumor and antimicrobial agents)


RN 50-07-7 HCAPLUS
CN Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-8-
[[[aminocarbonyl]oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-
, (1aS,8S,8aR,8bS) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 50-18-0 HCAPLUS


CN 2H-1,3,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide (9CI) (CA INDEX NAME)



RN 50-28-2 HCAPLUS


CN Estr-1,3,5(10)-triene-3,17-diol (17β) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 50-35-1 HCAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl) - (9CI) (CA INDEX NAME)




RN 50-76-0 HCAPLUS
CN Actinomycin D (8CI, 9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 50-91-9 HCAPLUS
CN Uridine, 2'-deoxy-5-fluoro- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 51-21-8 HCAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 5-fluoro- (9CI) (CA INDEX NAME)




RN 51-75-2 HCAPLUS

CN Ethanamine, 2-chloro-N-(2-chloroethyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 52-24-4 HCAPLUS

CN Aziridine, 1,1',1''-phosphinothioylidynetris- (9CI) (CA INDEX NAME)



RN 53-19-0 HCAPLUS


CN Benzene, 1-chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 53-43-0 HCAPLUS

CN Androst-5-en-17-one, 3-hydroxy-, (3 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 53-79-2 HCAPLUS

CN Adenosine, 3'-[[[(2S)-2-amino-3-(4-methoxyphenyl)-1-oxopropyl]amino]-3'-deoxy-N,N-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 54-71-7 HCAPLUS

CN 2(3H)-Furanone, 3-ethylidihydro-4-[(1-methyl-1H-imidazol-5-yl)methyl]-, monohydrochloride, (3S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




● HCl

RN 54-91-1 HCAPLUS


CN Piperazine, 1,4-bis(3-bromo-1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 55-21-0 HCAPLUS
 CN Benzamide (8CI, 9CI) (CA INDEX NAME)




RN 55-86-7 HCAPLUS
 CN Ethanamine, 2-chloro-N-(2-chloroethyl)-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 55-86-7 HCAPLUS
 CN Ethanamine, 2-chloro-N-(2-chloroethyl)-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 55-98-1 HCAPLUS
 CN 1,4-Butanediol, dimethanesulfonate (8CI, 9CI) (CA INDEX NAME)




RN 56-53-1 HCAPLUS
 CN Phenol, 4,4'-[(1E)-1,2-diethyl-1,2-ethenediyl]bis- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 57-22-7 HCAPLUS
 CN Vincaleukoblastine, 22-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 57-63-6 HCAPLUS
 CN 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 57-83-0 HCAPLUS
 CN Pregn-4-ene-3,20-dione (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 58-05-9 HCAPLUS
 CN L-Glutamic acid, N-[4-[[[2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridiny]methyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 58-58-2 HCAPLUS
 CN Adenosine, 3'-[[[(2S)-2-amino-3-(4-methoxyphenyl)-1-oxopropyl]amino]-3'-deoxy-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 59-05-2 HCAPLUS


CN L-Glutamic acid, N-[4-[[[(2,4-diamino-6-pteridinyloxy)methyl]methylamino]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 66-75-1 HCAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 5-[bis(2-chloroethyl)amino]- (9CI) (CA INDEX NAME)




RN 83-89-6 HCAPLUS


CN 1,4-Pentanediamine, N4-(6-chloro-2-methoxy-9-acridinyl)-N1,N1-diethyl- (9CI) (CA INDEX NAME)




RN 101-60-0 HCAPLUS
 CN 21H,23H-Porphine (9CI) (CA INDEX NAME)



RN 106-60-5 HCAPLUS
 CN Pentanoic acid, 5-amino-4-oxo- (9CI) (CA INDEX NAME)




RN 114-70-5 HCAPLUS
 CN Benzeneacetic acid, sodium salt (9CI) (CA INDEX NAME)




● Na

RN 122-79-2 HCAPLUS
 CN Acetic acid, phenyl ester (6CI, 8CI, 9CI) (CA INDEX NAME)




RN 125-45-1 HCAPLUS
 CN Phosphinic amide, P,P-bis(1-aziridinyl)-N-ethyl-N-1,3,4-thiadiazol-2-yl- (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 125-84-8 HCAPLUS

CN 2,6-Piperidinedione, 3-(4-aminophenyl)-3-ethyl- (9CI) (CA INDEX NAME)



RN 127-07-1 HCAPLUS

CN Urea, hydroxy- (6CI, 8CI, 9CI) (CA INDEX NAME)




RN 143-67-9 HCAPLUS

CN Vincaloblastine, sulfate (1:1) (salt) (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 7664-93-9

CMF H2 O4 S




CM 2

CRN 865-21-4

CMF C46 H58 N4 O9


Absolute stereochemistry. Rotation (+).




RN 145-63-1 HCAPLUS

CN 1,3,5-Naphthalenetrisulfonic acid, 8,8'-[carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis- (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 147-94-4 HCAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-β-D-arabinofuranosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 148-82-3 HCAPLUS


CN L-Phenylalanine, 4-[bis(2-chloroethyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 154-42-7 HCAPLUS

CN 6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI) (CA INDEX NAME)




RN 154-93-8 HCAPLUS

CN Urea, N,N'-bis(2-chloroethyl)-N-nitroso- (9CI) (CA INDEX NAME)



RN 302-49-8 HCAPLUS


CN Carbamic acid, [bis(1-aziridinyl)phosphinyl]-, ethyl ester (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 302-79-4 HCAPLUS


CN Retinoic acid (6CI, 9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 305-03-3 HCAPLUS


CN Benzenebutanoic acid, 4-[bis(2-chloroethyl)amino]- (9CI) (CA INDEX NAME)



RN 320-67-2 HCAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 359-83-1 HCAPLUS


CN 2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-, (2R,6R,11R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Currently available stereo shown.




RN 364-62-5 HCAPLUS

CN Benzamide, 4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy- (9CI)
(CA INDEX NAME)



RN 366-70-1 HCAPLUS

CN Benzamide, N-(1-methylethyl)-4-[(2-methylhydrazino)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 378-44-9 HCAPLUS

CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-,
(11 β ,16 β) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 423-55-2 HCAPLUS

CN Octane, 1-bromo-1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptafluoro- (9CI)
(CA INDEX NAME)Br- (CF₂)₇-CF₃


RN 459-86-9 HCAPLUS

CN Hydrazinecarboximidamide, 2,2'-(1-methyl-1,2-ethanediylidene)bis- (9CI)
(CA INDEX NAME)

RN 465-65-6 HCAPLUS

CN Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)-, (5 α)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 472-15-1 HCAPLUS

CN Lup-20(29)-en-28-oic acid, 3-hydroxy-, (3β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 481-29-8 HCAPLUS

CN Androstan-17-one, 3-hydroxy-, (3β,5α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 518-28-5 HCAPLUS


CN Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-9-hydroxy-5-(3,4,5-trimethoxyphenyl)-, (5R,5aR,8aR,9R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 520-85-4 HCAPLUS
 CN Pregn-4-ene-3,20-dione, 17-hydroxy-6-methyl-, (6 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 521-12-0 HCAPLUS
 CN Androstan-3-one, 2-methyl-17-(1-oxopropoxy)-, (2 α ,5 α ,17 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 536-59-4 HCAPLUS

CN 1-Cyclohexene-1-methanol, 4-(1-methylethenyl)- (9CI) (CA INDEX NAME)



RN 548-04-9 HCAPLUS


CN Phenanthro[1,10,9,8-opqra]perylene-7,14-dione, 1,3,4,6,8,13-hexahydroxy-10,11-dimethyl-, stereoisomer (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 566-48-3 HCAPLUS


CN Androst-4-ene-3,17-dione, 4-hydroxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 569-57-3 HCAPLUS

CN Benzene, 1,1',1''-(1-chloro-1-ethenyl-2-ylidene)tris[4-methoxy- (9CI) (CA INDEX NAME)




RN 578-95-0 HCAPLUS
 CN 9(10H)-Acridinone (9CI) (CA INDEX NAME)




RN 595-33-5 HCAPLUS
 CN Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645-05-6 HCAPLUS
 CN 1,3,5-Triazine-2,4,6-triamine, N,N,N',N',N'',N''-hexamethyl- (9CI) (CA INDEX NAME)




RN 646-08-2 HCAPLUS

CN Propanamide, N,N'-(dithiodi-2,1-ethanediyl)bis[3-amino- (9CI) (CA INDEX NAME)



RN 671-16-9 HCAPLUS


CN Benzamide, N-(1-methylethyl)-4-[(2-methylhydrazino)methyl]- (9CI) (CA INDEX NAME)



RN 801-52-5 HCAPLUS

CN Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-8-[[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-1,5-dimethyl-, (1aS,8S,8aR,8bS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 865-21-4 HCAPLUS

CN Vincaleukoblastine (6CI, 8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 911-45-5 HCAPLUS

CN Ethanamine, 2-[4-(2-chloro-1,2-diphenylethenyl)phenoxy]-N,N-diethyl- (9CI)
(CA INDEX NAME)

RN 968-93-4 HCAPLUS


CN 2H-Phenanthro[2,1-b]pyran-2,8(4bH)-dione, 3,4,4a,5,6,10a,10b,11,12,12a-decahydro-10a,12a-dimethyl-, (4aS,4bR,10aR,10bS,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 1271-19-8 HCAPLUS

CN Titanium, dichlorobis(η5-2,4-cyclopentadien-1-yl)- (9CI) (CA INDEX NAME)



RN 1402-81-9 HCAPLUS
 CN Ambomycin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 1403-99-2 HCAPLUS
 CN Mitogillin (9CI) (CA INDEX NAME)


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 1404-00-8 HCAPLUS
 CN Mitomycin (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 1404-15-5 HCAPLUS
 CN 2,6-Epoxy-2H-naphthaceno[1,2-b]oxocin-14-carboxylic acid,
 11-[(6-deoxy-3-C-methyl-2,3,4-tri-O-methyl- α -L-mannopyranosyl)oxy]-4-(
 (dimethylamino)-3,4,5,6,9,11,12,13,14,16-decahydro-3,5,8,10,13-
 pentahydroxy-6,13-dimethyl-9,16-dioxo-, methyl ester,
 (2R,3S,4R,5R,6R,11S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 1404-20-2 HCAPLUS
 CN Peliomycin (7CI, 8CI, 9CI) (CA INDEX NAME)


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 1404-64-4 HCAPLUS
 CN 2-Propenamide, N-[(1S)-1-(hydroxymethyl)-2-[(R)-[(methylthio)methyl]sulfinyl]ethyl]-3-(1,2,3,4-tetrahydro-6-methyl-2,4-dioxo-5-pyrimidinyl)-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RN 1661-29-6 HCAPLUS
 CN Carbamic acid, [bis(2,2-dimethyl-1-aziridinyl)phosphinyl]-, ethyl ester (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 1972-08-3 HCAPLUS
 CN 6H-Dibenzo[b,d]pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, (6aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 1980-45-6 HCAPLUS
 CN Carbamic acid, [bis(1-aziridinyl)phosphinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 2068-78-2 HCAPLUS

CN Vincalurekoblamine, 22-oxo-, sulfate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 7664-93-9

CMF H2 O4 S




CM 2

CRN 57-22-7

CMF C46 H56 N4 O10


Absolute stereochemistry.



RN 2353-33-5 HCAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 2508-89-6 HCAPLUS


CN L-Norleucine, N-acetyl-6-diazo-5-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 2608-24-4 HCAPLUS

CN Piperazine, 1,4-bis[3-[(methylsulfonyl)oxy]-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 2809-21-4 HCAPLUS


CN Phosphonic acid, (1-hydroxyethylidene)bis- (9CI) (CA INDEX NAME)



RN 2919-66-6 HCAPLUS

CN Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl-16-methylene- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 2998-57-4 HCAPLUS

CN Estradiol-1,3,5(10)-triene-3,17-diol (17 β)-, 3-[bis(2-chloroethyl)carbamate] (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 2998-57-4 HCAPLUS

CN Estradiol-1,3,5(10)-triene-3,17-diol (17 β)-, 3-[bis(2-chloroethyl)carbamate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 3073-59-4 HCAPLUS


CN Acetamide, N,N'-1,6-hexanediylbis- (9CI) (CA INDEX NAME)

AcNH-(CH₂)₆-NHAc

RN 3094-09-5 HCAPLUS

CN Uridine, 5'-deoxy-5-fluoro- (8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 3562-63-8 HCAPLUS


CN Pregna-4,6-diene-3,20-dione, 17-hydroxy-6-methyl- (6CI, 7CI, 8CI, 9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 3778-73-2 HCAPLUS


CN 2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-,
2-oxide (9CI) (CA INDEX NAME)



RN 3930-19-6 HCAPLUS

CN 2-Pyridinecarboxylic acid, 5-amino-6-(7-amino-5,8-dihydro-6-methoxy-5,8-dioxo-2-quinolinyl)-4-(2-hydroxy-3,4-dimethoxyphenyl)-3-methyl- (9CI) (CA


INDEX NAME)



RN 4105-38-8 HCAPLUS

CN Uridine, 2',3',5'-triacetate (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 4291-63-8 HCAPLUS


CN Adenosine, 2-chloro-2'-deoxy- (7CI, 8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 4342-03-4 HCAPLUS

CN 1H-Imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazenyl)- (9CI) (CA INDEX NAME)



RN 4342-07-8 HCAPLUS


CN 1H-1,2,3-Triazole-4-carboxamide, 5-amino- (9CI) (CA INDEX NAME)



RN 4803-27-4 HCAPLUS


CN 2-Propenamide, 3-[(11R,11aS)-5,10,11,11a-tetrahydro-9,11-dihydroxy-8-methyl-5-oxo-1H-pyrrolo[2,1-c][1,4]benzodiazepin-2-yl]-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 5072-26-4 HCAPLUS


CN Butanoic acid, 2-amino-4-(S-butylsulfonimidoyl)- (9CI) (CA INDEX NAME)



RN 5373-42-2 HCAPLUS

CN 4H-Dibenzo[de,g]quinoline, 9-[4,5-dimethoxy-2-[(1S)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolinyl]methyl]phenoxy]-5,6,6a,7-tetrahydro-1,2,10-trimethoxy-6-methyl-, (6aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 5508-58-7 HCAPLUS


CN 2 (3H)-Furanone, 3-[2-[(1R,4aS,5R,6R,8aS)-decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl]ethylidene]dihydro-4-hydroxy-, (3E,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 5579-27-1 HCAPLUS

CN 2-Tetrazene, 1,4-dimethyl-1,4-diphenyl- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)




RN 5581-52-2 HCAPLUS

CN 1H-Purin-2-amine, 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]- (9CI) (CA INDEX NAME)



RN 5696-17-3 HCAPLUS


CN 4,4'-Bipiperidine, 1,1'-bis(oxiranylmethyl)- (9CI) (CA INDEX NAME)



RN 6157-87-5 HCAPLUS

CN Estr-4-en-3-one, 17-(acetyloxy)-7-methyl-, (7 α ,17 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 7281-31-4 HCAPLUS

CN Vincalukoblastine, 04-deacetyl-, 4-ester with N,N-dimethylglycine, sulfate (2:3) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 7664-93-9



CMF H2 O4 S



CM 2

CRN 865-24-7

CMF C48 H63 N5 O9



RN 7440-06-4 HCAPLUS


CN Platinum (8CI, 9CI) (CA INDEX NAME)

Pt

RN 7644-67-9 HCAPLUS

CN L-Norleucine, L-γ-glutamyl-6-diazo-5-oxo-L-norleucyl-6-diazo-5-oxo-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 7689-03-4 HCAPLUS

CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione,
4-ethyl-4-hydroxy-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 7724-76-7 HCAPLUS


CN Adenosine, N-(3-methyl-2-butenyl)- (7CI, 8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 7761-45-7 HCAPLUS

CN 2,4-Pyrimidinediamine, 5-(3,4-dichlorophenyl)-6-methyl- (9CI) (CA INDEX NAME)



RN 8052-16-2 HCAPLUS
CN Actinomycin C (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 9002-71-5 HCAPLUS
CN Thyrotropin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 9014-02-2 HCAPLUS
CN Neocarzinostatin (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 9014-42-0 HCAPLUS
CN Thrombopoietin (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 9014-42-0 HCAPLUS
CN Thrombopoietin (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 9015-68-3 HCAPLUS
CN Asparaginase (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 9027-98-9 HCAPLUS
CN Deiminase, arginine (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 9041-93-4 HCAPLUS
CN Bleomycin, sulfate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 11056-06-7
CMF Unspecified
CCI MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 7664-93-9
CMF H2 O4 S




RN 9050-67-3 HCAPLUS
CN Sizofiran (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 10043-49-9 HCAPLUS
CN Gold, isotope of mass 198 (8CI, 9CI) (CA INDEX NAME)


¹⁹⁸Au

RN 10087-89-5 HCAPLUS
CN Carbamic acid, cyclohexyl-, 1,1-diphenyl-2-propynyl ester (9CI) (CA INDEX NAME)




RN 10318-26-0 HCAPLUS
CN Galactitol, 1,6-dibromo-1,6-dideoxy- (7CI, 8CI, 9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 10403-51-7 HCAPLUS
CN 4,8-Ethenopyrrolo[3',4':3,4]cyclobut[1,2-f]isoindole-1,3,5,7(2H,6H)-
tetrone, 3a,3b,4,4a,7a,8,8a,8b-octahydro-, (3aR,3bS,4R,4aR,7aS,8S,8aR,8bS) -
rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 10540-29-1 HCAPLUS
 CN Ethanamine, 2-[4-[(1Z)-1,2-diphenyl-1-butenyl]phenoxy]-N,N-dimethyl- (9CI)
 (CA INDEX NAME)

Double bond geometry as shown.



RN 11002-22-5 HCAPLUS
 CN Apurinic acid (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 11029-06-4 HCAPLUS
 CN Elemene (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 11043-98-4 HCAPLUS
 CN Mitochromin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 11043-99-5 HCAPLUS
 CN Mitomalicin (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 11056-06-7 HCAPLUS
 CN Bleomycin (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 11056-12-5 HCAPLUS
 CN Cirolemycin (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 11056-14-7 HCAPLUS
 CN Mitocarcin (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 11056-15-8 HCAPLUS
 CN Mitosper (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 12713-07-4 HCAPLUS

CN Verdin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 13010-47-4 HCAPLUS

CN Urea, N-(2-chloroethyl)-N'-cyclohexyl-N-nitroso- (9CI) (CA INDEX NAME)




RN 13311-84-7 HCAPLUS

CN Propanamide, 2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 13494-90-1 HCAPLUS


CN Nitric acid, gallium salt (8CI, 9CI) (CA INDEX NAME)




● 1/3 Ga

RN 13665-88-8 HCAPLUS

CN Ethanol, 2,2',2'',2'''-[[4-(1-piperidinyl)pyrimido[5,4-d]pyrimidine-2,6-diyl]dinitrilo]tetrakis- (9CI) (CA INDEX NAME)




RN 13909-09-6 HCAPLUS
 CN Urea, N-(2-chloroethyl)-N'-(4-methylcyclohexyl)-N-nitroso- (9CI) (CA INDEX NAME)




RN 14769-73-4 HCAPLUS
 CN Imidazo[2,1-b]thiazole, 2,3,5,6-tetrahydro-6-phenyl-, (6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 15475-56-6 HCAPLUS
 CN L-Glutamic acid, N-[4-[[[(2,4-diamino-6-pteridiny)methyl]methylamino]benzoyl]-, sodium salt (9CI) (CA INDEX NAME)


Absolute stereochemistry.




● x Na

RN 15639-50-6 HCAPLUS
CN 1,3-Octadecanediol, 2-amino-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 15663-27-1 HCAPLUS
CN Platinum, diamminedichloro-, (SP-4-2)- (9CI) (CA INDEX NAME)




RN 17021-26-0 HCAPLUS
CN Androst-4-en-3-one, 17-hydroxy-7,17-dimethyl-, (7β,17β)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 17902-23-7 HCAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)- (9CI) (CA INDEX NAME)




RN 18378-89-7 HCAPLUS

CN D-threo-2-Pentulose, 5-deoxy-1-C-[(2S,3S)-7-[[2,6-dideoxy-3-O-(2,6-dideoxy-β-D-arabino-hexopyranosyl)-β-D-arabino-hexopyranosyl]oxy]-3-[(O-2,6-dideoxy-3-C-methyl-β-D-ribo-hexopyranosyl-(1→3)-O-2,6-dideoxy-β-D-lyxo-hexopyranosyl-(1→3)-2,6-dideoxy-β-D-arabino-hexopyranosyl)oxy]-1,2,3,4-tetrahydro-5,10-dihydroxy-6-methyl-4-oxo-2-anthracenyl]-1-O-methyl-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 18416-85-8 HCAPLUS

CN L-Serine, 2-[(aminoiminomethyl)amino]ethyl hydrogen phosphate (ester)
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 18556-44-0 HCAPLUS


CN Vincaleukoblastine, (4'α)-, sulfate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 15228-71-4

CMF C46 H58 N4 O9


Absolute stereochemistry.



CM 2


CRN 7664-93-9

CMF H2 O4 S



RN 18588-57-3 HCAPLUS


CN 2,4-Pyrimidinediamine, 5-(3,4-dichlorophenyl)-6-ethyl- (9CI) (CA INDEX NAME)



RN 18883-66-4 HCAPLUS


CN D-Glucose, 2-deoxy-2-[[[(methylnitrosoamino)carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 19916-73-5 HCAPLUS

CN 1H-Purin-2-amine, 6-(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 20098-14-0 HCAPLUS

CN Tricyclo[3.3.1.1.3,7]decanone, 5-hydroxy- (9CI) (CA INDEX NAME)



RN 20537-88-6 HCAPLUS


CN Ethanethiol, 2-[(3-aminopropyl)amino]-, dihydrogen phosphate (ester) (9CI) (CA INDEX NAME)



RN 20638-84-0 HCAPLUS

CN Retinamide (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 20830-81-3 HCAPLUS

CN 5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy- α -L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 21059-48-3 HCAPLUS

CN 18-Norspirosola-5,12-dien-3-ol, 17-methyl-, (3 β ,16 β ,17 β ,22S,25S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 21679-14-1 HCAPLUS


CN 9H-Purin-6-amine, 9- β -D-arabinofuranosyl-2-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 22668-01-5 HCAPLUS


CN 1H-Imidazole-1-acetamide, N-(2-hydroxyethyl)-2-nitro- (9CI) (CA INDEX NAME)



RN 23214-92-8 HCAPLUS

CN 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy- α -L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 23541-50-6 HCAPLUS

CN 5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy- α -L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, hydrochloride, (8S,10S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 23593-75-1 HCAPLUS


CN 1H-Imidazole, 1-[(2-chlorophenyl)diphenylmethyl]- (9CI) (CA INDEX NAME)



RN 24280-93-1 HCAPLUS

CN 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, (4E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 24584-09-6 HCAPLUS

CN 2,6-Piperazinedione, 4,4'-[(1S)-1-methyl-1,2-ethanediyl]bis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 25316-40-9 HCAPLUS

CN 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S,10S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 27302-90-5 HCAPLUS

CN Ethanone, 2-(methylsulfinyl)-1-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 27314-97-2 HCAPLUS

CN 1,2,4-Benzotriazin-3-amine, 1,4-dioxide (9CI) (CA INDEX NAME)


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 27548-93-2 HCAPLUS

CN 7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxet-5-one, 6,12b-bis(acetyloxy)-


12-(benzoyloxy)-1,2a,3,4,4a,6,9,10,11,12,12a,12b-dodecahydro-4,9,11-trihydroxy-4a,8,13,13-tetramethyl-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 27686-84-6 HCAPLUS
CN 1,2-Benzenediol, 4,4'-(2,3-dimethyl-1,4-butanediyl)bis-, (R*,S*)-(9CI)
(CA INDEX NAME)

Relative stereochemistry.



RN 29069-24-7 HCAPLUS
CN Pregna-1,4-diene-3,20-dione, 21-[4-[4-[bis(2-chloroethyl)amino]phenyl]-1-oxobutoxy]-11,17-dihydroxy-, (11β)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 29767-20-2 HCAPLUS

CN Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-[[4,6-O-[(R)-2-thienylmethylene]-β-D-glucopyranosyl]oxy]-, (5R,5aR,8aR,9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 30303-65-2 HCAPLUS

CN Docosanol (7CI, 8CI, 9CI) (CA INDEX NAME)


Me- (CH₂)₂₀-Me

D1-OH

RN 30387-51-0 HCAPLUS

CN D-galacto-Oct-2-enonic acid, 6,7-anhydro-2,3,8-trideoxy-, δ -lactone, 4-acetate (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 30868-30-5 HCAPLUS


CN 1H-Pyrazole-5-carboxamide, 4-hydroxy-3- β -D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 31430-18-9 HCAPLUS

CN Carbamic acid, [5-(2-thienylcarbonyl)-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 31441-78-8 HCAPLUS

CN Purinethiol (8CI, 9CI) (CA INDEX NAME)




D1-SH

RN 32954-58-8 HCAPLUS

CN 1-Pentanone, 1-(3-furanyl)-4-hydroxy- (9CI) (CA INDEX NAME)


Currently available stereo shown.



RN 33069-62-4 HCAPLUS

CN Benzenepropanoic acid, β -(benzoylamino)- α -hydroxy-,
 (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-
 2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-
 tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl
 ester, (α R, β S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 33069-62-4 HCAPLUS

CN Benzenepropanoic acid, β -(benzoylamino)- α -hydroxy-,
 (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-
 2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-
 tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl
 ester, (α R, β S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 33419-42-0 HCAPLUS

CN Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 9-[[4,6-O-(1R)-ethylidene-β-D-glucopyranosyl]oxy]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-, (5R,5aR,8aR,9S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 35301-24-7 HCAPLUS


CN Acetamide, N-[(1S,2S)-2-hydroxy-1-(hydroxymethyl)heptadecyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 35846-53-8 HCAPLUS
 CN Maytansine (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 35943-35-2 HCAPLUS
 CN 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 36508-71-1 HCAPLUS
 CN Benzoic acid, [1-[(2S,4S)-4-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]ethylidene]hydrazide, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 37717-21-8 HCAPLUS

CN 6H-Furo[2',3':4,5]oxazolo[3,2-a]pyrimidine-2-methanol,
7-fluoro-2,3,3a,9a-tetrahydro-3-hydroxy-6-imino-, (2R,3R,3aS,9aR) - (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 38270-90-5 HCAPLUS


CN Strontium chloride (89SrCl₂) (9CI) (CA INDEX NAME)

Cl-89Sr-Cl

RN 38321-02-7 HCAPLUS

CN Benzeneacetoneitrile, α-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]
propyl]-3,4-dimethoxy-α-(1-methylethyl)-, (αR) - (9CI) (CA
INDEX NAME)


Absolute stereochemistry.




RN 39325-01-4 HCAPLUS
 CN Picibanil (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 40391-99-9 HCAPLUS
 CN Phosphonic acid, (3-amino-1-hydroxypropylidene)bis- (9CI) (CA INDEX NAME)




RN 41575-94-4 HCAPLUS
 CN Platinum, diammine[1,1-cyclobutanedi(carboxylato-κO)(2-)]-,
 (SP-4-2)- (9CI) (CA INDEX NAME)



RN 41729-52-6 HCAPLUS
 CN 4H-Imidazo[4,5-c]pyridin-4-one, 6-amino-1,5-dihydro- (9CI) (CA INDEX NAME)



RN 41992-22-7 HCAPLUS
 CN 2-Aza-8-germaspiro[4.5]decane-2-propanamine, 8,8-diethyl-N,N-dimethyl-,
 dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 42228-92-2 HCAPLUS

CN 5-Isioxazoleacetic acid, α -amino-3-chloro-4,5-dihydro-,
(α S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 42616-25-1 HCAPLUS

CN Lyase, methionine (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 50264-69-2 HCAPLUS

CN 1H-Indazole-3-carboxylic acid, 1-[(2,4-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 51264-14-3 HCAPLUS


CN Methanesulfonamide, N-[4-(9-acridinylamino)-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 51321-79-0 HCAPLUS


CN L-Aspartic acid, N-(phosphonoacetyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 52128-35-5 HCAPLUS


CN 2,4-Quinazolinediamine, 5-methyl-6-[[[(3,4,5-trimethoxyphenyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 52205-73-9 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17β)-, 3-[bis(2-chloroethyl)carbamate] 17-(dihydrogen phosphate), disodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 Na

RN 52794-97-5 HCAPLUS

CN 5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy- α -L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-1,6,8,11-tetrahydroxy-, hydrochloride, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 53643-48-4 HCAPLUS


CN Vincalurekoblantine, 3-(aminocarbonyl)-O4-deacetyl-3-de(methoxycarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 53714-56-0 HCAPLUS


CN 1-9-Luteinizing hormone-releasing factor (swine), 6-D-leucine-9-(N-ethyl-L-prolinamide)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

PAGE 1-A




PAGE 1-B



RN 53910-25-1 HCAPLUS
 CN Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy-β-D-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 54081-68-4 HCAPLUS
 CN Vincaleukoblastine, 4'-deoxy-3',4'-epoxy-, (3'α,4'α)-, sulfate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 23360-92-1
 CMF C46 H56 N4 O9


Absolute stereochemistry.



CM 2


CRN 7664-93-9

CMF H2 O4 S




RN 54824-17-8 HCAPLUS

CN 1H-Benz[de]isoquinoline-1,3(2H)-dione, 2-[2-(dimethylamino)ethyl]-5-nitro-(9CI) (CA INDEX NAME)



RN 55435-65-9 HCAPLUS


CN Acetamide, N-methyl-N-[4-[(7-methyl-1H-imidazo[4,5-f]quinolin-9-yl)aminophenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 56390-09-1 HCAPLUS
 CN 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy- α -L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S,10S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 56420-45-2 HCAPLUS
 CN 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy- α -L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 56605-16-4 HCAPLUS

CN 1,3-Diazaspiro[4.5]decane-2,4-dione, 3-[2-[bis(2-chloroethyl)amino]ethyl]-(9CI) (CA INDEX NAME)




RN 56741-95-8 HCAPLUS

CN 4(1H)-Pyrimidinone, 2-amino-5-bromo-6-phenyl- (9CI) (CA INDEX NAME)



RN 57381-26-7 HCAPLUS

CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)




RN 57576-44-0 HCAPLUS

CN 1-Naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-O-[2,6-dideoxy-4-O-[(2R,6S)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl]-alpha-L-lyxo-hexopyranosyl]-3-


(dimethylamino)- α -L-lyxo-hexopyranosyl]oxy]-, methyl ester,
(1R,2R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 57773-63-4 HCAPLUS
CN Luteinizing hormone-releasing factor (swine), 6-D-tryptophan- (9CI) (CA
INDEX NAME)

Absolute stereochemistry. Rotation (-).


PAGE 1-A



PAGE 1-B




PAGE 2-A




RN 57773-65-6 HCAPLUS
 CN 1-9-Luteinizing hormone-releasing factor (swine), 6-D-tryptophan-9-(N-ethyl-L-prolinamide)- (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 1-B




PAGE 2-A




RN 57852-57-0 HCAPLUS
 CN 5,12-Naphthacenedione, 9-acetyl-7-[(3-amino-2,3,6-trideoxy- α -L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-, hydrochloride, (7S,9S) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 57998-68-2 HCAPLUS
 CN Carbamic acid, [2,5-bis(1-aziridinyl)-3,6-dioxo-1,4-cyclohexadiene-1,4-diyl]bis-, diethyl ester (9CI) (CA INDEX NAME)




RN 58066-85-6 HCAPLUS
 CN Ethanaminium, 2-[[[(hexadecyloxy)hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (9CI) (CA INDEX NAME)



RN 58525-82-9 HCAPLUS

CN 2-Pyridinepropanoic acid, α -amino-5-hydroxy-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 58957-92-9 HCAPLUS

CN 5,12-Naphthacenedione, 9-acetyl-7-[(3-amino-2,3,6-trideoxy- α -L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-, (7S,9S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 58970-76-6 HCAPLUS


CN L-Leucine, N-[(2S,3R)-3-amino-2-hydroxy-1-oxo-4-phenylbutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 59653-73-5 HCAPLUS
 CN 1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3-bis[(2R)-oxiranylmethyl]-5-
 [(2S)-oxiranylmethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 59917-39-4 HCAPLUS
 CN Vincalukoblastine, 3-(aminocarbonyl)-O4-deacetyl-3-de(methoxycarbonyl)-, sulfate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 53643-48-4
 CMF C43 H55 N5 O7

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2


CRN 7664-93-9

CMF H2 O4 S



RN 59989-18-3 HCAPLUS


CN 2,4(1H,3H)-Pyrimidinedione, 5-ethynyl- (9CI) (CA INDEX NAME)




RN 60084-10-8 HCAPLUS

CN 4-Thiazolecarboxamide, 2-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 60203-57-8 HCAPLUS

CN Prosta-5,9,13-trien-1-oic acid, 15-hydroxy-11-oxo-, (5Z,13E,15S)- (9CI)
(CA INDEX NAME)Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.


RN 60940-34-3 HCAPLUS

CN 1,2-Benzisoselenazol-3(2H)-one, 2-phenyl- (9CI) (CA INDEX NAME)



RN 61825-94-3 HCAPLUS


CN Platinum, [(1R,2R)-1,2-cyclohexanediamine-κN,κN'] [ethanedioato (2-)-κO1,κO2]-, (SP-4-2)- (9CI) (CA INDEX NAME)



RN 61966-08-3 HCAPLUS

CN 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 62304-98-7 HCAPLUS

CN Thymosin α1 (cattle) (9CI) (CA INDEX NAME)


PAGE 1-C




PAGE 1-D




PAGE 2-A




PAGE 2-B




PAGE 2-C



PAGE 3-A




PAGE 3-B



RN 62435-42-1 HCAPLUS

CN Hydroperoxide, (2R,4R)-2-[bis(2-chloroethyl)amino]tetrahydro-2-oxido-2H-1,3,2-oxazaphosphorin-4-yl, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 62488-57-7 HCAPLUS

CN 1,3,5-Triazin-2(1H)-one, 4-amino-3,6-dihydro-1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 62816-98-2 HCAPLUS
 CN Platinum, tetrachloro[rel-(1R,2R)-1,2-cyclohexanediamine-
 κN,κN']-, (OC-6-22)- (9CI) (CA INDEX NAME)




RN 62928-11-4 HCAPLUS
 CN Platinum, dichlorodihydroxybis(2-propanamine)-, (OC-6-33)- (9CI) (CA
 INDEX NAME)




RN 63590-19-2 HCAPLUS
 CN Benzoic acid, 4-(2-carboxy-6-hydroxybenzoyl)-3,5-dihydroxy-,
 1-[(3R,4R)-hexahydro-3-[(4-hydroxybenzoyl)amino]-1H-azepin-4-yl] ester
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 2-A




RN 63612-50-0 HCAPLUS
 CN 2,4-Imidazolidinedione, 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-
 (9CI) (CA INDEX NAME)



RN 63950-06-1 HCAPLUS
 CN 5,12-Naphthacenedione, 10-[[[(2S,4R,6S)-4-aminotetrahydro-6-methyl-2H-pyran-

2-yl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl


RN 65057-90-1 HCAPLUS

CN Bleomycinamide, N1-[4-amino-6-[[3-[(4-aminobutyl)amino]propyl]amino]-6-oxohexyl]-13-[(4-amino-4,6-dideoxy- α -L-talopyranosyl)oxy]-19-demethyl-12-hydroxy- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B




PAGE 2-A



RN 65093-40-5 HCAPLUS


CN 2(1H)-Pyrimidinone, 4-amino-1-[5-O-[hydroxy(octadecyloxy)phosphinyl]-β-D-arabinofuranosyl]-, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

RN 65222-35-7 HCAPLUS
 CN 1,3-Propanediamine, N,N-diethyl-N'-(6-methyl-5H-pyrido[3',4':4,5]pyrrolo[2,3-g]isoquinolin-10-yl)- (9CI) (CA INDEX NAME)



Et₂N- (CH₂)₃-NH

IT 65271-80-9, Mitoxantrone 65646-68-6, Fenretinide
 65807-02-5, Goserelin 65886-71-7, Fazarabine
 66569-27-5, Sparfosate Sodium 66849-34-1, Dexifosfamide
 67699-41-6, Vinzolidine Sulfate 68278-23-9, Eflornithine
 Hydrochloride 68475-42-3, Anagrelide 69839-83-4, Didox
 70052-12-9, Eflornithine 70384-29-1, Peplomycin Sulfate
 70476-82-3, Mitoxantrone Hydrochloride 70641-51-9,
 Edelfosine 70711-40-9, Ametantrone Acetate 71294-60-5,
 Rohitukine 71439-68-4, Bisantrene Hydrochloride
 71486-22-1, Vinorelbine 71522-58-2, Forfenimex
 71628-96-1, Menogaril 72238-02-9D, Retelliptine,
 demethyl derivs. 72496-41-4, Pirarubicin 72629-69-7,
 Sarcophytol A 72732-56-0, Piritrexim 72741-87-8,
 Swainsonine 73105-03-0, Pentamustine 74149-70-5,
 Parabactin 74381-53-6, Leuprolide Acetate 74790-08-2,
 Spiroplatin 75219-46-4, Atrimustine 75330-75-5,
 Lovastatin 75607-67-9, Fludarabine Phosphate 75775-33-6D
 , Purpurin, compds. 75957-60-7, Splenopentin 76932-56-4
 , Nafarelin 77016-85-4, Plomestane 77327-05-0,
 Didemnin B 77599-17-8, Panomifene 77858-21-0,
 Velaresol 78113-36-7, Romurtide 78186-34-2, Bisantrene
 79778-41-9, Neridronic acid 79831-76-8, Castanospermine
 80451-05-4, Cecropin B 80576-83-6, Edatrexate
 80663-95-2 80841-47-0, Asulacrine 81424-67-1,
 Caracemide 81965-43-7, SarcNU 82230-03-3, Carbetimer
 82413-20-5, Droloxifene 82707-54-8, Neutral
 endopeptidase 82855-09-2D, Combretastatin, analogs
 82952-64-5, Trimetrexate Glucuronate 83086-73-1,
 Tubulozole Hydrochloride 83150-76-9, Octreotide
 83200-11-7, Vinepidine Sulfate 83519-04-4, Ilmofofine
 83997-75-5, Iododoxorubicin 84030-84-2, Telluropyrylium
 84088-42-6, Roquinimex 84371-65-3, Mifepristone
 84412-94-2, Ruboxyl 85465-82-3, Thymotrinan
 85622-93-1, Temozolomide 85754-59-2, Ambamustine
 85969-07-9, Budotitane 85977-49-7, Tauromustine
 86976-56-9, Betaclamycins 87005-03-6, Panaxytriol
 87434-82-0, Dezaguanine Mesylate 87806-31-3, Porfimer
 Sodium 87810-56-8, Fostriecin 87860-39-7, Fostriecin
 Sodium 88303-60-0, Losoxantrone 88303-61-1,
 Losoxantrone Hydrochloride 89565-68-4, Tropisetron
 89778-26-7, Toremifene 89778-27-8, Toremifene Citrate
 90357-06-5, Bicalutamide 90996-54-6, Rhizoxin
 92047-76-2, Tetrachlorodecaoxide 92118-27-9, Fotemustine
 92788-10-8, Rogletimide 92803-82-2, Aphidicolin
 glycinate 94079-80-8, Cicaprost 95058-81-4,

Gemcitabine 95734-82-0, Nedaplatin 95933-72-5, Amidox
96201-88-6, Brequinar Sodium 96301-34-7, Atamestane
96346-61-1, Onapristone 96389-68-3, Crisnatol
96389-69-4, Crisnatol Mesylate 96392-96-0, Dexormaplatin
96892-57-8, Hepsulfam 97068-30-9, Elsamitrucin
97534-21-9, Merbarone 97682-44-5, Irinotecan
97752-20-0, Droloxifene Citrate 97919-22-7
98319-26-7, Finasteride 98383-18-7, Ecomustine
98631-95-9, Sobuzoxane 99009-20-8, Pyrazoloacridine
99011-02-6, Imiquimod 99283-10-0, Molgramostim
99614-02-5, Ondansetron 100286-90-6, Irinotecan
Hydrochloride 100324-81-0, Lisofylline 102396-24-7,
Jasplakinolide 102676-31-3, Fadrozole Hydrochloride
102676-47-1, Fadrozole 102822-56-0, Mannostatin A
103222-11-3, Vapreotide 103612-80-2 104493-13-2
, Adeacypenol 105118-12-5, Piroxantrone Hydrochloride
105149-04-0, Osaterone 105615-58-5, Oxaunomycin
105844-41-5, Plasminogen activator inhibitor 106096-93-9D
, Basic Fibroblast growth factor, saporin conjugates 106400-81-1
, Lometrexol 107000-34-0, Zanoterone 107256-99-5,
Tamoxifen methiodide 107868-30-4, Exemestane 108736-35-2
, Lanreotide 108852-90-0, Nemorubicin 109837-67-4,
Cycloplatam 110267-81-7, Amrubicin 110311-27-8,
Sulofenur 110314-48-2, Adozelesin 110690-43-2,
Emitetur 110942-02-4, Aldesleukin 110942-08-0,
Luprolide 111490-36-9, Ziniplatin 111523-41-2,
Enloplatin 112515-43-2, Topsisentin 112522-64-2,
Acetyldinaline 112809-51-5, Letrozole 112859-71-9,
Fluasterone 112887-68-0, Raltitrexed 112965-21-6,
Calcipotriol 114084-78-5, Ibandronic acid 114285-68-6,
Lentinan sulfate 114517-02-1, Fosquidone 114977-28-5,
Taxotere 115150-59-9, Antagonist G 115308-98-0,
Tallimustine 115566-02-4, Bistratene A 115575-11-6,
Liarozole 115956-12-2, Dolasetron 116057-75-1,
Idoxifene 117048-59-6, Combretastatin A4 117091-64-2,
Etoposide Phosphate 118292-40-3, Tazarotene 119169-78-7
, Epristeride 119413-54-6, Topotecan Hydrochloride
119813-10-4, Carzelesin 120287-85-6, Cetorelix
120408-07-3, Lometrexol Sodium 120500-15-4, Leinamycin
120511-73-1, Anastrozole 120685-11-2,
Benzoylstauosporine 121181-53-1, Filgrastim 121263-19-2
, Calphostin C 121288-39-9, Loxoribine 121547-04-4,
Mirimostim 122111-03-9, Gemcitabine Hydrochloride
122341-38-2, Temoporfin 122431-96-3 122898-63-9
, Phenazinomycin 123040-69-7, Azasetron 123258-84-4,
Itasetron 123760-07-6, Zinostatin stimalamer 123774-72-1
, Sargramostim 123830-79-5, Teloxantrone Hydrochloride
123948-87-8, Topotecan 124012-42-6, Galocitabine
124689-65-2D, Cryptophycin A, derivs. 124784-31-2,
Erbulazole 124904-93-4, Ganirelix 125317-39-7,
Vinorelbine Tartrate 125392-76-9, Acylfulvene
125533-88-2, Mofarotene 126297-39-0, Lissoclinamide 7
126443-96-7, Napavin 127984-74-1, Lanreotide Acetate
128505-88-4, Naphterpin 128768-09-2, Placatin A
128768-11-6, Placatin B 129497-78-5, Verteporfin
129564-92-7, Azatoxin 129655-21-6, Bizelesin
129731-10-8, Vorozole 130167-69-0, Pegaspargase
130288-24-3, Duocarmycin SA 130364-39-5, Rubiginone B1
130370-60-4, Batimastat 131190-63-1, Saintopin
132036-88-5, Ramosetron 132073-72-4, Tetrastomine


133432-71-0, Peldesine 134088-74-7, Nartograstim
 134381-30-9, Conagenin 134523-84-5 134633-29-7
 , Tecogalan Sodium 134861-62-4, Dioxamycin 135257-45-3
 , Crambescidin 816 135381-77-0, Flezelastine 135383-02-7
 , Stipiamide 135558-11-1, Lobaplatin 135819-69-1
 135968-09-1, Lenograstim 137018-54-3, Okicenone
 137099-09-3, Turosteride 137219-37-5, Dehydrodidemnin B
 137647-92-8, Axinastatin 1 137964-32-0
 139755-79-6, Safingol Hydrochloride 140207-93-8,
 Pentosan polysulfate sodium 140703-49-7, Meterelin
 142880-36-2, Ilomastat 144885-51-8, Sodium borocaptate
 144916-42-7, Sonermin 145124-30-7, Bisnafide dimesylate
 145858-50-0, Liarozole Hydrochloride 146426-40-6,
 Flavopiridol 148317-76-4, Oracin 148584-53-6
 148717-58-2, Palauamine 148717-90-2, Squalamine
 149204-42-2, Kahalalide F 149260-80-0, Mycaperoxide B
 149355-77-1, Lamellarin-N triacetate 149633-91-0,
 Leptolstatin 149715-96-8, Spongistatin 1

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(pharmaceutical formulation further including; incensole and
 furanogermacrens and compds. as antitumor and antimicrobial agents)

RN 65271-80-9 HCAPLUS


CN 9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis[[2-[(2-
 hydroxyethyl)amino]ethyl]amino]- (9CI) (CA INDEX NAME)



RN 65646-68-6 HCAPLUS

CN Retinamide, N-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 65807-02-5 HCAPLUS


CN 1-9-Luteinizing hormone-releasing factor (swine), 6-[O-(1,1-dimethylethyl)-
 D-serine]-, 2-(aminocarbonyl)hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN	65886-71-7	HCAPLUS	
CN	1,3,5-Triazin-2(1H)-one, 4-amino-1-β-D-arabinofuranosyl- (9CI) (CA INDEX NAME)		


Absolute stereochemistry.



RN 66569-27-5 HCAPLUS

CN L-Aspartic acid, N-(phosphonoacetyl)-, disodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 Na

RN 66849-34-1 HCAPLUS

CN 2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 67699-41-6 HCAPLUS

CN 2H-3,7-Methanoazacycloundecino[5,4-b]indole-9-carboxylic acid, 9-[(2β,3β,4β,5α,12R,19α)-4-(acetyloxy)-3'-(2-chloroethyl)-6,7-didehydro-16-methoxy-1-methyl-2',4'-dioxospiro[aspidospermidine-3,5'-oxazolidin]-15-yl]-5-ethyl-1,4,5,6,7,8,9,10-octahydro-5-hydroxy-, methyl ester, (3R,5S,7R,9S)-, sulfate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 67699-40-5


CMF C48 H58 Cl N5 O9



CM 2


CRN 7664-93-9

CMF H2 O4 S



RN 68278-23-9 HCAPLUS


CN Ornithine, 2-(difluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 68475-42-3 HCAPLUS


CN Imidazo[2,1-b]quinazolin-2(3H)-one, 6,7-dichloro-1,5-dihydro- (9CI) (CA INDEX NAME)



RN 69839-83-4 HCAPLUS
 CN Benzamide, N,3,4-trihydroxy- (9CI) (CA INDEX NAME)



RN 70052-12-9 HCAPLUS
 CN Ornithine, 2-(difluoromethyl)- (9CI) (CA INDEX NAME)




RN 70384-29-1 HCAPLUS
 CN Bleomycinamide, N1-[3-[[[(1S)-1-phenylethyl]amino]propyl]-, sulfate (1:1)
 (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 68247-85-8
 CMF C61 H88 N18 O21 S2

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




CM 2

CRN 7664-93-9

CMF H2 O4 S




RN 70476-82-3 HCAPLUS
 CN 9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 70641-51-9 HCAPLUS
 CN 3,5,9-Trioxa-4-phosphaheptacosan-1-aminium, 4-hydroxy-7-methoxy-N,N,N-trimethyl-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 70711-40-9 HCAPLUS
 CN 9,10-Anthracenedione, 1,4-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-, diacetate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 64862-96-0
 CMF C22 H28 N4 O4



CM 2

CRN 64-19-7


CMF C2 H4 O2



RN 71294-60-5 HCAPLUS

CN 4H-1-Benzopyran-4-one, 5,7-dihydroxy-8-[(3R,4S)-3-hydroxy-1-methyl-4-piperidinyl]-2-methyl-, rel- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 71439-68-4 HCAPLUS

CN 9,10-Anthracenedicarboxaldehyde, bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone], dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A





● 2 HCl


RN 71486-22-1 HCAPLUS
 CN Aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-
 [(2R,6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycarbonyl)-2,6-methano-
 2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-, methyl ester,
 (2β,3β,4β,5α,12R,19α) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 71522-58-2 HCAPLUS
 CN Benzeneacetic acid, α -amino-3-hydroxy-4-(hydroxymethyl)-,
 (α S) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 71628-96-1 HCAPLUS
 CN 2,6-Epoxy-2H-naphthaceno[1,2-b]oxocin-9,16-dione, 4-(dimethylamino)-
 3,4,5,6,11,12,13,14-octahydro-3,5,8,10,13-pentahydroxy-11-methoxy-6,13-
 dimethyl-, (2R,3S,4R,5R,6R,11R,13R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 72238-02-9 HCAPLUS

CN 1,3-Propanediamine, N,N-diethyl-N'-(9-methoxy-5,11-dimethyl-6H-pyrido[4,3-b]carbazol-1-yl)-(9CI) (CA INDEX NAME)




Et₂N-(CH₂)₃-NH Me

RN 72496-41-4 HCAPLUS

CN 5,12-Naphthacenedione, 10-[[3-amino-2,3,6-trideoxy-4-O-[(2S)-tetrahydro-2H-pyran-2-yl]-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 72629-69-7 HCAPLUS

CN 2,4,8,12-Cyclotetradecatetraen-1-ol, 5,9,13-trimethyl-2-(1-methylethyl)-, (1S,2Z,4E,8E,12E) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as described by E or Z.



RN 72732-56-0 HCAPLUS


CN Pyrido[2,3-d]pyrimidine-2,4-diamine, 6-[(2,5-dimethoxyphenyl)methyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 72741-87-8 HCAPLUS


CN 1,2,8-Indolizinetriol, octahydro-, (1S,2R,8R,8aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 73105-03-0 HCAPLUS

CN Urea, N-(2-chloroethyl)-N'-(2,2-dimethylpropyl)-N-nitroso- (9CI) (CA INDEX NAME)



RN 74149-70-5 HCAPLUS


Absolute stereochemistry.




CMF C59 H84 N16 O12

Absolute stereochemistry. Rotation (-).

PAGE 1-A




PAGE 1-B




CM 2

CRN 64-19-7
CMF C2 H4 O2




RN 74790-08-2 HCAPLUS
CN Platinum, (1,1-cyclohexanedimethanamine-κN,κN') [sulfato(2-)-κO,κO']-, (SP-4-2) - (9CI) (CA INDEX NAME)



RN 75219-46-4 HCAPLUS
CN Estradiol 17-[[4-[4-[bis(2-chloroethyl)amino]phenyl]-1-oxobutoxy]acetate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—CH₂Cl

RN 75330-75-5 HCAPLUS

CN Butanoic acid, 2-methyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 75607-67-9 HCAPLUS

CN 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-β-D-arabinofuranosyl)-

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 75775-33-6 HCAPLUS

CN 4H-Furo[3',2':4,5]furo[2,3-h]-1-benzopyran-4-one, 10-(acetyloxy)-2,3,7a,9,10,10a-hexahydro-9,9-dimethyl-2-phenyl- (9CI) (CA INDEX NAME)


Currently available stereo shown.



RN 75957-60-7 HCAPLUS

CN L-Tyrosine, L-arginyl-L-lysyl-L- α -glutamyl-L-valyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 76932-56-4 HCAPLUS


CN Luteinizing hormone-releasing factor (swine), 6-[3-(2-naphthalenyl)-D-alanine]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 77016-85-4 HCAPLUS


CN Estr-4-ene-3,17-dione, 10-(2-propynyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 77327-05-0 HCAPLUS
 CN Didemnin B (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 77599-17-8 HCAPLUS
 CN Ethanol, 2-[[2-[4-[(1E)-3,3,3-trifluoro-1,2-diphenyl-1-propenyl]phenoxy]ethyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 77858-21-0 HCAPLUS
 CN Pentanoic acid, 5-(2-formyl-3-hydroxyphenoxy)- (9CI) (CA INDEX NAME)



RN 78113-36-7 HCAPLUS

CN L-Lysine, N-(N-acetylmuramoyl)-L-alanyl-D-α-glutaminy-N6-(1-oxooctadecyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 78186-34-2 HCAPLUS

CN 9,10-Anthracenedicarboxaldehyde, bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 79778-41-9 HCAPLUS


CN Phosphonic acid, (6-amino-1-hydroxyhexylidene)bis- (9CI) (CA INDEX NAME)



RN 79831-76-8 HCAPLUS

CN 1,6,7,8-Indolizinetetrol, octahydro-, (1S,6S,7R,8R,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 80451-05-4 HCAPLUS


CN Cecropin B (Platysamia cecropia antibacterial peptide) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 80576-83-6 HCAPLUS


CN L-Glutamic acid, N-[4-[1-[(2,4-diamino-6-pteridiny]methyl]propyl]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 80663-95-2 HCAPLUS

CN Guanidine, [(3-iodophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 80841-47-0 HCAPLUS


CN 4-Acridinecarboxamide, 9-[[2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino]-N,5-dimethyl- (9CI) (CA INDEX NAME)



RN 81424-67-1 HCAPLUS
 CN Acetamide, N-[(methyamino)carbonyl]-N-[(methyamino)carbonyloxy]- (9CI)
 (CA INDEX NAME)



RN 81965-43-7 HCAPLUS
 CN Acetamide, 2-[[[(2-chloroethyl)nitrosoamino]carbonyl]methyamino]- (9CI)
 (CA INDEX NAME)




RN 82230-03-3 HCAPLUS
 CN Carbetimer (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 82413-20-5 HCAPLUS
 CN Phenol, 3-[(1E)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 82707-54-8 HCAPLUS
 CN Neprilysin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 82855-09-2 HCAPLUS
 CN Benzeneethanol, 3-hydroxy-4-methoxy- α -(3,4,5-trimethoxyphenyl)-,
 (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 82952-64-5 HCAPLUS
 CN D-Glucuronic acid, compd. with 5-methyl-6-[[[(3,4,5-trimethoxyphenyl)amino]methyl]-2,4-quinazolinediamine (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 52128-35-5
 CMF C19 H23 N5 O3



CM 2


CRN 6556-12-3
CMF C6 H10 O7

Absolute stereochemistry.




RN 83086-73-1 HCAPLUS
CN Carbamic acid, [4-[[[(2R,4R)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methyl]thio]phenyl]-, ethyl ester, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 83150-76-9 HCAPLUS
CN L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-, cyclic (2→7)-disulfide (9CI) (CA INDEX NAME)




RN 83200-11-7 HCAPLUS
 CN Vincaleukoblastine, 4'-deoxy-22-oxo-, (4'α)-, sulfate (1:1) (salt)
 (9CI) (CA INDEX NAME)

CM 1


CRN 68170-69-4
 CMF C46 H56 N4 O9

Absolute stereochemistry.




CM 2

CRN 7664-93-9
 CMF H2 O4 S




RN 83519-04-4 HCAPLUS
 CN 3,5-Dioxa-9-thia-4-phosphapentacosan-1-aminium, 4-hydroxy-7-(methoxymethyl)-N,N,N-trimethyl-, inner salt, 4-oxide (9CI) (CA INDEX NAME)




RN 83997-75-5 HCAPLUS
 CN 5,12-Naphthacenedione, 10-[[[(2R,4S,5S,6S)-4-aminotetrahydro-5-iodo-6-methyl-2H-pyran-2-yl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 84030-84-2 HCAPLUS
CN Tellurinium (9CI) (CA INDEX NAME)




RN 84088-42-6 HCAPLUS
CN 3-Quinolinecarboxamide, 1,2-dihydro-4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-
(9CI) (CA INDEX NAME)



RN 84371-65-3 HCAPLUS
CN Estra-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-propynyl)-, (11 β ,17 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 84412-94-2 HCAPLUS

CN 1-Piperidinyloxy, 4-[[1-[(2S,4S)-4-[(3-amino-2,3,6-trideoxy- α -L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]ethylidene]hydrazono]-2,2,6,6-tetramethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 85465-82-3 HCAPLUS

CN L-Aspartic acid, L-arginyl-L-lysyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 85622-93-1 HCAPLUS

CN Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo-


(9CI) (CA INDEX NAME)



RN 85754-59-2 HCAPLUS


CN L-Methionine, 4-fluoro-L-phenylalanyl-3-[bis(2-chloroethyl)amino]-L-phenylalanyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 85969-07-9 HCAPLUS

CN Titanium, diethoxybis(1-phenyl-1,3-butanedionato-κO,κO') - (9CI) (CA INDEX NAME)



RN 85977-49-7 HCAPLUS


CN Ethanedisulfonamide, 2-[[[(2-chloroethyl)nitrosoamino]carbonyl]amino]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 86976-56-9 HCAPLUS

CN 5,12-Naphthacenedione, 8-ethyl-7,8,9,10-tetrahydro-1,6,7,8,11-pentahydroxy-10-[[2,3,6-trideoxy-4-O-(2,6-dideoxy- α -L-lyxo-hexopyranosyl)-3-(dimethylamino)- α -L-lyxo-hexopyranosyl]oxy]-, (7R,8R,10S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 87005-03-6 HCAPLUS

CN 1-Heptadecene-4,6-diyne-3,9,10-triol, (3R,9R,10R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 87434-82-0 HCAPLUS

CN 4H-Imidazo[4,5-c]pyridin-4-one, 6-amino-1,5-dihydro-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 41729-52-6


CMF C6 H6 N4 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 87806-31-3 HCAPLUS


CN Photofrin Porfimer sodium (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 87810-56-8 HCAPLUS

CN 2H-Pyran-2-one, 5,6-dihydro-6-[(1E,3R,4R,6R,7Z,9Z,11E)-3,6,13-trihydroxy-3-methyl-4-(phosphonoxy)-1,7,9,11-tridecatetraenyl]-, (6R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 87860-39-7 HCAPLUS

CN 2H-Pyran-2-one, 5,6-dihydro-6-[(1E,3R,4R,6R,7Z,9Z,11E)-3,6,13-trihydroxy-3-methyl-4-(phosphonoxy)-1,7,9,11-tridecatetraenyl]-, monosodium salt, (6R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



● Na


RN 88303-60-0 HCAPLUS

CN Anthra[1,9-cd]pyrazol-6(2H)-one, 7-hydroxy-2-[2-[(2-hydroxyethyl)amino]ethyl]-5-[[2-[(2-hydroxyethyl)amino]ethyl]amino]- (9CI)
(CA INDEX NAME)



RN 88303-61-1 HCAPLUS

CN Anthra[1,9-cd]pyrazol-6(2H)-one, 7-hydroxy-2-[2-[(2-hydroxyethyl)amino]ethyl]-5-[[2-[(2-hydroxyethyl)amino]ethyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 89565-68-4 HCAPLUS

CN 1H-Indole-3-carboxylic acid, (3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 89778-26-7 HCAPLUS

CN Ethanamine, 2-[4-[(1Z)-4-chloro-1,2-diphenyl-1-butenyl]phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 89778-27-8 HCAPLUS


CN Ethanamine, 2-[4-[(1Z)-4-chloro-1,2-diphenyl-1-butenyl]phenoxy]-N,N-dimethyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 89778-26-7

CMF C26 H28 Cl N O


Double bond geometry as shown.



CM 2


CRN 77-92-9

CMF C6 H8 O7



RN 90357-06-5 HCAPLUS


CN Propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl- (9CI) (CA INDEX NAME)



RN 90996-54-6 HCAPLUS

CN Rhizoxin (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 92047-76-2 HCAPLUS

CN Tetrachlorodecaoxide (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 92118-27-9 HCAPLUS

CN Phosphonic acid, [1-[[[(2-chloroethyl)nitrosoamino]carbonyl]amino]ethyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 92788-10-8 HCAPLUS


CN 2,6-Piperidinedione, 3-ethyl-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 92803-82-2 HCAPLUS

CN Glycine, [(3R,4R,4aR,6aS,8R,9R,11aS,11bS)-tetradecahydro-3,9-dihydroxy-4-(hydroxymethyl)-4,11b-dimethyl-8,11a-methano-11aH-cyclohepta[a]naphthalen-9-yl]methyl ester, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 94079-80-8 HCAPLUS


CN Acetic acid, [(2E)-2-[(3aS,4S,5R,6aS)-hexahydro-5-hydroxy-4-[(3S,4S)-3-hydroxy-4-methyl-1,6-nonadiynyl]-2(1H)-pentalenyldene]ethoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 95058-81-4 HCAPLUS
 CN Cytidine, 2'-deoxy-2',2'-difluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 95734-82-0 HCAPLUS
 CN Platinum, diammine[(hydroxy-κO)acetato(2-)-κO]-, (SP-4-3)- (9CI) (CA INDEX NAME)



RN 95933-72-5 HCAPLUS
 CN Benzenecarboximidamide, N,3,4-trihydroxy- (9CI) (CA INDEX NAME)



RN 96201-88-6 HCAPLUS
 CN 4-Quinolinecarboxylic acid, 6-fluoro-2-(2'-fluoro[1,1'-biphenyl]-4-yl)-3-methyl-, sodium salt (9CI) (CA INDEX NAME)




● Na

RN 96301-34-7 HCAPLUS

CN Androsta-1,4-diene-3,17-dione, 1-methyl- (9CI) (CA INDEX NAME).


Absolute stereochemistry.



RN 96346-61-1 HCAPLUS


CN Estra-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-, (11 β ,13 α ,17 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 96389-68-3 HCAPLUS


CN 1,3-Propanediol, 2-[(6-chrysenylmethyl)amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 96389-69-4 HCAPLUS
 CN 1,3-Propanediol, 2-[(6-chrysenylmethyl)amino]-2-methyl-, methanesulfonate
 (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 96389-68-3
 CMF C23 H23 N O2




CM 2

CRN 75-75-2
 CMF C H4 O3 S




RN 96392-96-0 HCAPLUS
 CN Platinum, tetrachloro[(1R,2R)-1,2-cyclohexanediamine-κN,κN']-,
 (OC-6-22)- (9CI) (CA INDEX NAME)



RN 96892-57-8 HCAPLUS


CN Sulfamic acid, 1,7-heptanediyl ester (9CI) (CA INDEX NAME)



RN 97068-30-9 HCAPLUS


CN Benzo[h][1]benzopyrano[5,4,3-cde][1]benzopyran-5,12-dione,
10-[[2-O-(2-amino-2,6-dideoxy-3-O-methyl- α -D-galactopyranosyl)-6-
deoxy-3-C-methyl- β -D-galactopyranosyl]oxy]-6-hydroxy-1-methyl- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 97534-21-9 HCAPLUS


CN 5-Pyrimidinecarboxamide, hexahydro-4,6-dioxo-N-phenyl-2-thioxo- (9CI) (CA INDEX NAME)



RN 97682-44-5 HCAPLUS

CN [1,4'-Bipiperidine]-1'-carboxylic acid, (4S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 97752-20-0 HCAPLUS


CN Phenol, 3-[(1E)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]-2-hydroxy-1,2,3-propanetricarboxylate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 82413-20-5


CMF C26 H29 N O2

Double bond geometry as shown.




CM 2

CRN 77-92-9
CMF C6 H8 O7



RN 97919-22-7 HCAPLUS


CN Benzenesulfonamide, 4-amino-N-(5-chloro-2-quinoxaliny)- (9CI) (CA INDEX NAME)



RN 98319-26-7 HCAPLUS

CN 1H-Indeno[5,4-f]quinoline-7-carboxamide, N-(1,1-dimethylethyl)-
2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-2-oxo-,
(4aR,4bS,6aS,7S,9aS,9bS,11aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 98383-18-7 HCAPLUS


CN α -D-arabino-Hexopyranoside, methyl 3-[[[(2-chloroethyl)nitrosoamino]carbonyl]amino]-2,3-dideoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 98631-95-9 HCAPLUS


CN Carbonic acid, 1,2-ethanediylbis[(2,6-dioxo-4,1-piperazinediyl)methylene] bis(2-methylpropyl) ester (9CI) (CA INDEX NAME)



RN 99009-20-8 HCAPLUS
 CN Pyrazolo[3,4,5-kl]acridine-2(6H)-propanamine, 9-methoxy-N,N-dimethyl-5-nitro- (9CI) (CA INDEX NAME)




RN 99011-02-6 HCAPLUS
 CN 1H-Imidazo[4,5-c]quinolin-4-amine, 1-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 99283-10-0 HCAPLUS
 CN Colony-stimulating factor 2 (human clone pHG25 protein moiety reduced) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 99614-02-5 HCAPLUS
 CN 4H-Carbazol-4-one, 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 100286-90-6 HCAPLUS
 CN [1,4'-Bipiperidine]-1'-carboxylic acid, (4S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

PAGE 1-A




PAGE 2-A

● HCl

RN 100324-81-0 HCAPLUS
 CN 1H-Purine-2,6-dione, 3,7-dihydro-1-[(5R)-5-hydroxyhexyl]-3,7-dimethyl-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 102396-24-7 HCAPLUS
 CN Cyclo[(3R)-3-(4-hydroxyphenyl)-β-alanyl-(2S,4E,6R,8S)-8-hydroxy-2,4,6-trimethyl-4-nonenoyl-L-alanyl-2-bromo-N-methyl-D-tryptophyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as described by E or Z.

The chemical structure of compound 10 is a macrocycle. It features a 2-bromo-3-(4-hydroxyphenyl)-1H-indole-5-yl group attached to a carbon atom (labeled 'R') in the macrocyclic chain. This carbon is also bonded to a nitrogen atom (labeled 'N') which is substituted with a methyl group (Me). The macrocycle includes two amide groups (NH) and a chiral center (labeled 'S') with a methyl group (Me) and a hydrogen atom (H) attached. The other end of the macrocycle is attached to a carbon atom (labeled 'R') which is bonded to a 4-hydroxyphenyl group (HO-C₆H₄).

[illegible]


Page 209



● HCl

RN 102676-47-1 HCAPLUS


CN Benzonitrile, 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)- (9CI) (CA INDEX NAME)



RN 102822-56-0 HCAPLUS


CN 1,2,3-Cyclopentanetriol, 4-amino-5-(methylthio)-, (1R,2R,3R,4S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 103222-11-3 HCAPLUS


CN L-Tryptophanamide, D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-, cyclic (2-7)-disulfide (9CI) (CA INDEX NAME)



RN 103612-80-2 HCAPLUS


CN 2(1H)-Pyrimidinone, 4-amino-1-[5-O-[1,3-dihydroxy-1,3-dioxido-6-[(1-oxohexadecyl)oxy]-2,4-dioxa-8-thia-1,3-diphosphahexacos-1-yl]-β-D-arabinofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 104493-13-2 HCAPLUS

CN 3-Cyclopentene-1,2-diol, 5-(7,8-dihydro-8-hydroxyimidazo[4,5-d][1,3]diazepin-3(4H)-yl)-3-(hydroxymethyl)- (9CI) (CA INDEX NAME)



RN 105118-12-5 HCAPLUS


CN Anthra[1,9-cd]pyrazol-6(2H)-one, 5-[(3-aminopropyl)amino]-7,10-dihydroxy-2-[2-[(2-hydroxyethyl)amino]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 105149-04-0 HCAPLUS
 CN Cyclopenta[5,6]naphtho[1,2-c]pyran-2(4H)-one, 7-acetyl-11-chloro-4a,4b,5,6,6a,7,8,9,9a,9b-decahydro-7-hydroxy-4a,6a-dimethyl-, (4aR,4bS,6aS,7R,9aS,9bR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 105615-58-5 HCAPLUS
 CN 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy- α -L-lyxo-hexopyranosyl)oxy]-8-ethyl-7,8,9,10-tetrahydro-1,6,7,8,11-pentahydroxy-, (7R,8R,10S) - (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 105844-41-5 HCAPLUS
CN Proteinase inhibitor, PAI (9CI) (CA INDEX NAME)


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 106096-93-9 HCAPLUS
CN Fibroblast growth factor, basic (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 106400-81-1 HCAPLUS
CN L-Glutamic acid, N-[4-[2-[(6R)-2-amino-1,4,5,6,7,8-hexahydro-4-oxopyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 107000-34-0 HCAPLUS
CN 1'H-Pregn-20-yno[3,2-c]pyrazol-17-ol, 1'-(methylsulfonyl)-, (5 α ,17 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 107256-99-5 HCAPLUS
 CN Ethanaminium, 2-[4-[(1Z)-1,2-diphenyl-1-butenyl]phenoxy]-N,N,N-trimethyl-,
 iodide (9CI) (CA INDEX NAME)


Double bond geometry as shown.




● I⁻

RN 107868-30-4 HCAPLUS
 CN Androsta-1,4-diene-3,17-dione, 6-methylene- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 108736-35-2 HCAPLUS
 CN L-Threoninamide, 3-(2-naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-
 tryptophyl-L-lysyl-L-valyl-L-cysteinyl-, cyclic (2-7)-disulfide
 (9CI) (CA INDEX NAME)




RN 108852-90-0 HCAPLUS
 CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[(2S)-2-methoxy-4-morpholinyl]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 109837-67-4 HCAPLUS
 CN Platinum, ammine(cyclopentanamine) [hydroxybutanedioato(2-)-κO1,κO4]- (9CI) (CA INDEX NAME)



RN 110267-81-7 HCAPLUS


CN 5,12-Naphthacenedione, 9-acetyl-9-amino-7-[(2-deoxy-β-D-erythro-pentopyranosyl)oxy]-7,8,9,10-tetrahydro-6,11-dihydroxy-, (7S,9S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 110311-27-8 HCAPLUS

CN 1H-Indene-5-sulfonamide, N-[[[(4-chlorophenyl)amino]carbonyl]-2,3-dihydro-(9CI) (CA INDEX NAME)




RN 110314-48-2 HCAPLUS

CN 2-Benzofurancarboxamide, N-[2-[[[(7bR,8aS)-4,5,8,8a-tetrahydro-7-methyl-4-oxocyclopropa[c]pyrrolo[3,2-e]indol-2(1H)-yl]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 110690-43-2 HCAPLUS

CN Benzoic acid, 3-[[3-(ethoxymethyl)-5-fluoro-3,6-dihydro-2,6-dioxo-1(2H)-pyrimidinyl]carbonyl]-, 6-(benzoyloxy)-3-cyano-2-pyridinyl ester (9CI)
(CA INDEX NAME)



RN 110942-02-4 HCAPLUS

CN 2-133-Interleukin 2 (human reduced), 125-L-serine- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 110942-08-0 HCAPLUS

CN Luprolide (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 111490-36-9 HCAPLUS

CN Platinum, [2,2-bis[(amino-κN)methyl]-1,3-propanediol][1,1-cyclobutanedi(carboxylato-κO)(2-)]-, (SP-4-2)- (9CI) (CA INDEX NAME)




RN 111523-41-2 HCAPLUS

CN Platinum, [1,1-cyclobutanedi(carboxylato-κO)(2-)](tetrahydro-4H-pyran-4,4-dimethanamine-κN4,κN4')-, (SP-4-2)- (9CI) (CA INDEX NAME)




RN 112515-43-2 HCAPLUS

CN Methanone, (6-hydroxy-1H-indol-3-yl) [4-(1H-indol-3-yl)-1H-imidazol-2-yl] - (9CI) (CA INDEX NAME)




RN 112522-64-2 HCAPLUS

CN Benzamide, 4-(acetylamino)-N-(2-aminophenyl)- (9CI) (CA INDEX NAME)



RN 112809-51-5 HCAPLUS


CN Benzonitrile, 4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis- (9CI) (CA INDEX NAME)



RN 112859-71-9 HCAPLUS


CN Androst-5-en-17-one, 16-fluoro-, (16α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 112887-68-0 HCAPLUS
 CN L-Glutamic acid, N-[[5-[[[(1,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]methylamino]-2-thienyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 112965-21-6 HCAPLUS
 CN 9,10-Secochola-5,7,10(19),22-tetraene-1,3,24-triol, 24-cyclopropyl-, (1α,3β,5Z,7E,22E,24S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 114084-78-5 HCAPLUS
 CN Phosphonic acid, [1-hydroxy-3-(methylpentylamino)propylidene]bis- (9CI) (CA INDEX NAME)



RN 114285-68-6 HCAPLUS
CN Lentinan, hydrogen sulfate (9CI) (CA INDEX NAME)


CM 1

CRN 37339-90-5
CMF Unspecified
CCI PMS, MAN


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 7664-93-9
CMF H2 O4 S




RN 114517-02-1 HCAPLUS
CN Phosphoric acid, mono(phenylmethyl) mono(5,8,13,14-tetrahydro-14-methyl-8,13-dioxobenz[5,6]isoindolo[2,1-b]isoquinolin-9-yl) ester (9CI) (CA INDEX NAME)



RN 114977-28-5 HCAPLUS
CN Benzenepropanoic acid, β -[[[(1,1-dimethylethoxy)carbonyl]amino]- α -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (α R, β S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 115150-59-9 HCAPLUS

CN L-Methioninamide, L-arginyl-D-tryptophyl-N-methyl-L-phenylalanyl-D-tryptophyl-L-leucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 115308-98-0 HCAPLUS

CN 1H-Pyrrole-2-carboxamide, N-[5-[[[(3-amino-3-iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-4-[[[4-[4-[bis(2-chloroethyl)amino]benzoyl]amino]-1-methyl-1H-pyrrol-2-yl]carbonyl]amino]-1-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 115566-02-4 HCAPLUS
 CN 2H-Pyran-2-acetamide, tetrahydro-N-[2-hydroxy-4-[[3-[8-(6-hydroxy-3,5-dimethyl-4-heptenyl)-3-methyl-1,7-dioxaspiro[5.5]undec-2-yl]propyl]amino]-3-methyl-4-oxobutyl]-3-methyl-6-(2-oxo-3-pentenyl)-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 115575-11-6 HCAPLUS

CN 1H-Benzimidazole, 5-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]- (9CI) (CA INDEX NAME)




RN 115956-12-2 HCAPLUS

CN 1H-Indole-3-carboxylic acid, (2α,6α,8α,9αβ)-octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl ester (9CI) (CA INDEX NAME)

(NAME)


Relative stereochemistry.



RN 116057-75-1 HCAPLUS

CN Pyrrolidine, 1-[2-[4-[(1E)-1-(4-iodophenyl)-2-phenyl-1-butenyl]phenoxy]ethyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 117048-59-6 HCAPLUS


CN Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 117091-64-2 HCAPLUS
 CN Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 5-[3,5-dimethoxy-4-(phosphonooxy)phenyl]-9-[[4,6-O-(1R)-ethylidene-β-D-glucopyranosyl]oxy]-5,8,8a,9-tetrahydro-, (5R,5aR,8aR,9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 118292-40-3 HCAPLUS
 CN 3-Pyridinecarboxylic acid, 6-[(3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 119169-78-7 HCAPLUS
 CN Androsta-3,5-diene-3-carboxylic acid, 17-[[[(1,1-dimethylethyl)amino]carbonyl]-, (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 119413-54-6 HCAPLUS
 CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione,
 10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-, monohydrochloride,
 (4S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 119813-10-4 HCAPLUS
 CN 2-Benzofurancarboxamide, N-[2-[[[(1S)-1-(chloromethyl)-1,6-dihydro-8-methyl-5-[[[(phenylamino)carbonyl]oxy]benzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-1H-indol-5-yl]-6-(diethylamino)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 120287-85-6 HCAPLUS


CN D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N5-(aminocarbonyl)-D-ornithyl-L-leucyl-L-arginyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 120408-07-3 HCAPLUS

CN L-Glutamic acid, N-[4-[2-[(6R)-2-amino-1,4,5,6,7,8-hexahydro-4-oxopyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]-, disodium salt (9CI) (CA INDEX NAME)


Absolute stereochemistry.




● 2 Na

RN 120500-15-4 HCAPLUS

CN Spiro[1,2-dithiolane-3,6'-[19]thia[3,20]diazabicyclo[15.2.1]eicosa[1(20),9,13,15,17]pentaene]-4',5,12'-trione, 4,11'-dihydroxy-2',4,9'-trimethyl-, 2-oxide, (2S,2'R,3R,4R,9'E,11'R,13'E,15'Z)- (9CI) (CA INDEX NAME)




RN 120511-73-1 HCAPLUS
 CN 1,3-Benzenediacetonitrile, $\alpha,\alpha,\alpha',\alpha'$ -tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)- (9CI) (CA INDEX NAME)



RN 120685-11-2 HCAPLUS
 CN Benzamide, N-[(9S,10R,11R,13R)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 121181-53-1 HCAPLUS
 CN Colony-stimulating factor (human clone 1034), N-L-methionyl- (9CI) (CA

INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 121263-19-2 HCAPLUS


CN Carbonic acid, (1R)-2-[12-[(2R)-2-(benzoyloxy)propyl]-3,10-dihydro-4,9-dihydroxy-2,6,7,11-tetramethoxy-3,10-dioxo-1-perylenyl]-1-methylethyl 4-hydroxyphenyl ester, stereoisomer (9CI) (CA INDEX NAME)



RN 121288-39-9 HCAPLUS

CN Guanosine, 7,8-dihydro-8-oxo-7-(2-propenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 121547-04-4 HCAPLUS


CN 1-214-Colony-stimulating factor 1 (human clone p3ACSF-69 protein moiety reduced) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 122111-03-9 HCAPLUS

CN Cytidine, 2'-deoxy-2',2'-difluoro-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 122341-38-2 HCAPLUS


CN Phenol, 3,3',3'',3'''-(7,8-dihydro-21H,23H-porphine-5,10,15,20-tetrayl)tetrakis- (9CI) (CA INDEX NAME)



RN 122431-96-3 HCAPLUS

CN L-Ascorbic acid, 5,6-O-(phenylmethylene-d) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 122898-63-9 HCAPLUS


CN 1(5H)-Phenazinone, 5-[(2E)-5-[(1R)-2,2-dimethyl-6-methylenecyclohexyl]-3-methyl-2-pentenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 123040-69-7 HCAPLUS
 CN 2H-1,4-Benzoxazine-8-carboxamide, N-1-azabicyclo[2.2.2]oct-3-yl-6-chloro-3,4-dihydro-4-methyl-3-oxo- (9CI) (CA INDEX NAME)



RN 123258-84-4 HCAPLUS
 CN 1H-Benzimidazole-1-carboxamide, 2,3-dihydro-N-[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-2-oxo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 123760-07-6 HCAPLUS
 CN Zinostatin stimalamer (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 123774-72-1 HCAPLUS
 CN Colony-stimulating factor 2 (human clone pHG25 protein moiety),

23-L-leucine- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 123830-79-5 HCAPLUS

CN Anthra[1,9-cd]pyrazol-6(2H)-one, 7,10-dihydroxy-2-[2-[(2-hydroxyethyl)amino]ethyl]-5-[[2-(methylamino)ethyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 123948-87-8 HCAPLUS

CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 124012-42-6 HCAPLUS

CN Cytidine, 5'-deoxy-5-fluoro-N-(3,4,5-trimethoxybenzoyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 124689-65-2 HCAPLUS

CN Cyclo[(2R)-2-methyl-β-alanyl-(2S)-2-hydroxy-4-methylpentanoyl-(2E,5S,6S)-5-hydroxy-6-[(2R,3R)-3-phenyloxiranyl]-2-heptenoyl-3-chloro-O-methyl-D-tyrosyl] (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 124784-31-2 HCAPLUS

CN Carbamic acid, [4-[[[(2R,4R)-2-(1H-imidazol-1-ylmethyl)-2-(4-methoxyphenyl)-1,3-dioxolan-4-yl]methyl]thio]phenyl]-, ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 124904-93-4 HCAPLUS


CN D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N6-[bis(ethylamino)methylene]-D-lysyl-L-leucyl-N6-[bis(ethylamino)methylene]-L-lysyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 125317-39-7 HCAPLUS

CN Aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-
 [(2R,6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycarbonyl)-2,6-methano-
 2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-, methyl ester,
 (2β,3β,4β,5α,12R,19α)-, (2R,3R)-2,3-
 dihydroxybutanedioate (1:2) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 71486-22-1


CMF C45 H54 N4 O8

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2

CRN 87-69-4
CMF C4 H6 O6


Absolute stereochemistry.



RN 125392-76-9 HCAPLUS

CN Spiro[cyclopropane-1,5'-[5H]inden]-7'(6'H)-one, 6'-hydroxy-2',4',6'-trimethyl-, (6'R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 125533-88-2 HCAPLUS

CN Morpholine, 4-[2-[4-[(1E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl]phenoxy]ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 126297-39-0 HCAPLUS

CN 3H,10H-4,1:11,8:18,15-Trinitrilo-1H-pyrrolo[2,1-c][1,11,18,4,7,14,21]oxadithiatetraazacyclotetracosine-5,12,19,22(4H,11H)-tetrone, 6,7,13,14,17,18,20,21,24,25,26,26a-dodecahydro-3-methyl-7-(1-methylethyl)-14,21-bis(phenylmethyl)-, (3R,4S,7R,11R,14R,18R,21S,26aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

PAGE 1-A




PAGE 1-B

=O



RN 126443-96-7 HCAPLUS

CN Vincalukoblastine, 3-[[[2-[(4-azido-2-nitrophenyl)amino]ethyl]amino]carboxyl]-O4-deacetyl-3-de(methoxycarbonyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 127984-74-1 HCAPLUS
 CN L-Threoninamide, 3-(2-naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-, cyclic (2→7)-disulfide, acetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 108736-35-2
 CMF C54 H69 N11 O10 S2




CM 2

CRN 64-19-7
CMF C2 H4 O2

RN 128505-88-4 HCAPLUS
 CN 4H-Benzo[d]naphtho[2,3-b]pyran-7,12-dione, 3,4a,5,12b-tetrahydro-8,10-dihydroxy-2,5,5,9-tetramethyl-, (4aS,12bR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 128768-09-2 HCAPLUS
 CN Placetin A (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 128768-11-6 HCAPLUS
 CN Placetin B (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 129497-78-5 HCAPLUS


CN 23H,25H-Benzo[b]porphine-9,13-dipropionic acid, 18-ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-, monomethyl ester, (4R,4aS)-rel- (9CI) (CA INDEX NAME)

CM 1

CRN 121310-58-5

CMF C40 H40 N4 O8

Relative stereochemistry.
Double bond geometry unknown.



CM 2

CRN 67-56-1


CMF C H4 O

H₃C-OH

RN 129564-92-7 HCAPLUS

CN 1H,3H-Oxazolo[3',4':1,6]pyrido[3,4-b]indol-3-one, 5,6,11,11a-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-, (5R,11aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 129655-21-6 HCAPLUS


CN Benzo[1,2-b:4,3-b']dipyrrol-4-ol, 6,6'-[carbonylbis(imino-1H-indole-5,2-diylcarbonyl)]bis[8-(chloromethyl)-3,6,7,8-tetrahydro-1-methyl-, (8S,8'S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 129731-10-8 HCAPLUS

CN 1H-Benzotriazole, 6-[(S)-(4-chlorophenyl)-1H-1,2,4-triazol-1-ylmethyl]-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 130167-69-0 HCAPLUS


CN Pegaspargase (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 130288-24-3 HCAPLUS

CN Cyclopropa[c]pyrrolo[3,2-e]indole-6-carboxylic acid, 1,2,4,5,8,8a-hexahydro-4-oxo-2-[(5,6,7-trimethoxy-1H-indol-2-yl)carbonyl]-, methyl ester, (7bR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 130364-39-5 HCAPLUS

CN Benz[a]anthracene-7,12-dione, 1,2,3,4-tetrahydro-1-hydroxy-8-methoxy-3-methyl-, (1S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 130370-60-4 HCAPLUS


CN Butanediamide, N4-hydroxy-N1-[(1S)-2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl]-2-(2-methylpropyl)-3-[(2-thienylthio)methyl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 131190-63-1 HCAPLUS


CN 5,12-Naphthacenedione, 1,3,8,10,11-pentahydroxy- (9CI) (CA INDEX NAME)



RN 132036-88-5 HCAPLUS

CN Methanone, (1-methyl-1H-indol-3-yl)[(5R)-4,5,6,7-tetrahydro-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 132073-72-4 HCAPLUS


CN 2-Piperidinecarboxamide, 3-hydroxy-N-[(2aR,3S,5R,6R,6aS,11bR)-2a,3,4,5,6,6a,7,11b-octahydro-5-(hydroxymethyl)-11-methoxy-12-methyl-3,6-imino-1H-2-oxa-11c-azanaphth[1,2,3-cd]azulen-10-yl]-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 133432-71-0 HCAPLUS

CN 4H-Pyrrolo[3,2-d]pyrimidin-4-one, 2-amino-1,5-dihydro-7-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 134088-74-7 HCAPLUS

CN Colony-stimulating factor (human clone 1034), 1-(N-L-methionyl-L-alanine)-3-L-threonine-4-L-tyrosine-5-L-arginine-17-L-serine- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 134381-30-9 HCAPLUS


CN L-Serine, N-(3,5-dideoxy-3-methyl-D-xylonoyl)-2-methyl- (9CI) (CA INDEX NAME)



RN 134523-84-5 HCAPLUS

CN 9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol, (1α,3β,5Z,7E,20S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 134633-29-7 HCAPLUS
 CN Tecogalan sodium (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 134861-62-4 HCAPLUS
 CN 1,3-Dioxolane-2-carboxylic acid, 2,4-dimethyl-5-[(1E,3E,5E)-7-oxo-7-
 [[(2R,3S,6R)-tetrahydro-2-methyl-6-[(2R,3R,4aR,12bS)-1,2,3,4,4a,7,12,12b-
 octahydro-2,3,4a,8,12b-pentahydroxy-3-methyl-1,7,12-trioxobenz[a]anthracen-
 9-yl]-2H-pyran-3-yl]oxy]-1,3,5-heptatrienyl]-, (2S,4S,5S)-rel-(+)- (9CI)
 (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
 Double bond geometry as shown.


PAGE 1-A




PAGE 1-B



RN 135257-45-3 HCAPLUS
 CN Dispiro[oxepin-2(3H),4'-[4H-5,6,8b]triazacacenaphthylene-7'(5'H),2''-[2H]pyran]-8'-carboxylic acid, 7-ethyl-1',2',2'a,3',3'',4,4'',5'',6'',7,8',8'a-dodecahydro-8'a-hydroxy-6''-methyl-, 16-[[[(2S)-4-amino-2-hydroxybutyl](3-aminopropyl)amino]-16-oxohexadecyl ester, (2S,2''R,2'aS,6''R,7S,8'S,8'aS) - (9CI) (CA INDEX NAME)



RN 135381-77-0 HCAPLUS
 CN 1(2H)-Phthalazinone, 4-[(4-fluorophenyl)methyl]-2-[hexahydro-1-(2-phenylethyl)-1H-azepin-4-yl]- (9CI) (CA INDEX NAME)




RN 135383-02-7 HCAPLUS


CN 2,4,6,8,10,14-Octadecahexaenamide, 13-hydroxy-N-[(1S)-2-hydroxy-1-methylethyl]-2,10,12,14,16-pentamethyl-18-phenyl-, (2E,4E,6Z,8E,10E,12R,13R,14E,16S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



RN 135558-11-1 HCAPLUS


CN Platinum, [rel-(1R,2R)-1,2-cyclobutanedimethanamine-κN,κN'] [(2S)-2-(hydroxy-κO)propanoato(2-)-κO]-, (SP-4-3)- (9CI) (CA INDEX NAME)




RN 135819-69-1 HCAPLUS

CN Rhizoxin, 13-hexadecanoate (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 135968-09-1 HCAPLUS

CN Lenograstim (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 137018-54-3 HCAPLUS


CN 1(2H)-Anthracenone, 3,4-dihydro-4,6,9-trihydroxy-8-methyl- (9CI) (CA INDEX NAME)



RN 137099-09-3 HCAPLUS

CN 1H-Indeno[5,4-f]quinoline-7-carboxamide, hexadecahydro-1,4a,6a-trimethyl-N-(1-methylethyl)-N-[[[(1-methylethyl)amino]carbonyl]-2-oxo-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 137219-37-5 HCAPLUS


CN Aplidine (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 137647-92-8 HCAPLUS
 CN Axinastatin 1 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 137964-32-0 HCAPLUS
 CN 1,3-Diazaspiro[4.5]decane-2,4-dione, 3-[2-[bis(2-chloroethyl)amino]ethyl]-
 , diphenyl deriv. (9CI) (CA INDEX NAME)




2 (D1- Ph)

RN 139755-79-6 HCAPLUS

CN 1,3-Octadecanediol, 2-amino-, hydrochloride, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

RN 140207-93-8 HCAPLUS

CN 4-O-Methyl- α -D-glucurono- β -D-xylan, hydrogen sulfate, sodium salt (9CI) (CA INDEX NAME)

CM 1

CRN 9062-57-1

CMF Unspecified


CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 7664-93-9

CMF H2 O4 S




RN 140703-49-7 HCAPLUS


CN 1-9-Luteinizing hormone-releasing factor (swine), 6-(2-methyl-D-tryptophan)-9-(N-ethyl-L-prolinamide)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A



PAGE 1-B




PAGE 2-A




RN 142880-36-2 HCAPLUS
 CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 144885-51-8 HCAPLUS
 CN Dodecaborate(2-), 1,2,3,4,5,6,7,8,9,10,11-undecahydro-12-mercapto-, disodium (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

● 2 Na⁺

RN 144916-42-7 HCAPLUS
 CN 3-157-Tumor necrosis factor (human) (9CI) (CA INDEX NAME)


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 145124-30-7 HCAPLUS
 CN 1H-Benz[de]isoquinoline-1,3(2H)-dione, 2,2'-[1,2-ethanediylbis[imino[(1R)-1-methyl-2,1-ethanediyl]]]bis[5-nitro-, dimethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 144849-63-8
 CMF C32 H28 N6 O8


Absolute stereochemistry.



CM 2


CRN 75-75-2

CMF C H4 O3 S



RN 145858-50-0 HCAPLUS

CN 1H-Benzimidazole, 5-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 146426-40-6 HCAPLUS


CN 4H-1-Benzopyran-4-one, 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methyl-4-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 148317-76-4 HCAPLUS


CN 5H-Indeno[1,2-c]isoquinoline-5,11(6H)-dione, 6-[2-[(2-hydroxyethyl)amino]ethyl]- (9CI) (CA INDEX NAME)



RN 148584-53-6 HCAPLUS

CN Benzenepropanoic acid, β -(benzoylamino)- α -hydroxy-, (2aR,4S,4aS,5R,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,5,11-trihydroxy-4a,8,13,13-tetramethyl-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (α R, β S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 148717-58-2 HCAPLUS

CN Spiro[8H-cyclopenta[3,4]pyrrolo[1,2-a]imidazo[4,5-b]pyrrolo[1,2-d]pyrazine-13(10H),4'-[4H]imidazol]-8-one, 2,2'-diamino-11-(aminomethyl)-12-chloro-1,1',3a,5',10a,11,12,13a-octahydro-5'-hydroxy-, (3aR,4'R,5'R,10aR,11S,12R,13aS,13bR)-rel-(-)-(9CI) (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.
Currently available stereo shown.



RN 148717-90-2 HCAPLUS

CN Cholestane-7,24-diol, 3-[[3-[(4-aminobutyl)amino]propyl]amino]-, 24-(hydrogen sulfate), (3 β ,5 α ,7 α ,24R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 149204-42-2 HCAPLUS


CN Kahalalide F (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


PAGE 1-A




PAGE 1-B



RN 149260-80-0 HCAPLUS
 CN 1,2-Dioxane-3-acetic acid, 6-[2-[(1R,2R,4aS,8aS)-decahydro-1-hydroxy-2,5,5,8a-tetramethyl-1-naphthalenyl]ethyl]- α ,6-dimethyl-,
 (α S,3S,6S)-(9CI) (CA INDEX NAME)




RN 149355-77-1 HCAPLUS
 CN 6H-[1]Benzopyrano[4',3':4,5]pyrrolo[2,1-a]isoquinolin-6-one,
 3,11-bis(acetyloxy)-14-[3-(acetyloxy)-4-methoxyphenyl]-2,12-dimethoxy-
 (9CI) (CA INDEX NAME)




RN 149633-91-0 HCAPLUS
 CN 2H-Pyran-2-one, 6-(14,19-dihydroxy-3,5,9,11,13,15,17-heptamethyl-12-oxo-
 3,7,9,17-nonadecatetraenyl)-5,6-dihydro- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B




RN 149715-96-8 HCAPLUS


CN 8,12,45,46,47,48,50-Heptaoxaheptacyclo[39.3.1.11,5.19,13.115,19.125,29.129,33]pentacont-23-ene-7,35-dione, 3,37-bis(acetyloxy)-11-[(4S,5E)-7-chloro-4-hydroxy-2-methylene-5,7-octadienyl]-10,14,15,17,27,43-hexahydroxy-31-methoxy-18,36,38,43,49-pentamethyl-39-methylene-, (1S,3S,5R,9R,10R,11R,13R,14S,15R,17S,18R,19R,23Z,25R,27S,29S,31S,33S,36S,37S,38R,41S,43S,49S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

PAGE 1-A




PAGE 2-A



IT 149882-10-0, Lurtotecan 150829-93-9, Nisamycin
 151272-78-5, Antarelix 152923-56-3, Dacliximab
 153723-34-3, Axinastatin 2 153723-35-4, Axinastatin 3
 154039-60-8, Marimastat 154229-19-3, Abiraterone
 154248-96-1, Iroplact 154277-21-1, Cypemycin
 154361-50-9, Capecitabine 155233-30-0, Curacin A
 156586-89-9, Edrecolomab 156790-85-1, Variolin B
 156856-30-3, Cytostatin 157078-48-3, Isohomohalichondrin
 B 157857-21-1, Maspin 158792-24-6, Collismycin A
 158792-25-7, Collismycin B 168482-36-8, Cryptophycin 8
 172793-30-5 173046-02-1, Thiocoraline
 174305-65-8, Breflate 181887-82-1, Nitrullin
 188364-40-1, CARN 700 200139-38-4, Suradista
 212894-59-2, Pentrozole 246252-04-0, Lutetium texaphyrin
 246252-06-2, Gadolinium texaphyrin 284041-10-7
 324740-00-3, Vitaxin 441070-87-7, 1,2,3-
 Triazolecarboxamide 441070-88-8 441070-92-4
 441772-39-0, Isobengazole 441772-43-6, Nagrestip
 441772-66-3, Vinxaltine 441772-81-2, Sulfmosine
 441774-07-8, Spicamycin D 441774-77-2, Solverol
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (pharmaceutical formulation further including; incensole and
 furanogermacrens and compds. as antitumor and antimicrobial agents)
 RN 149882-10-0 HCAPLUS
 CN 11H-1,4-Dioxino[2,3-g]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-
 9,12(8H,14H)-dione, 8-ethyl-2,3-dihydro-8-hydroxy-15-[(4-methyl-1-
 piperazinyl)methyl]-, (8S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 150829-93-9 HCAPLUS

CN 2,4,6-Heptatrienoic acid, 7-[(1S,2R,6R)-4-[[[(2E,4E)-5-cyclohexyl-1-oxo-2,4-pentadienyl]amino]-2-hydroxy-5-oxo-7-oxabicyclo[4.1.0]hept-3-en-2-yl]-, (2E,4E,6E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 151272-78-5 HCAPLUS


CN D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N6-(aminocarbonyl)-D-lysyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 152923-56-3 HCAPLUS


CN Immunoglobulin G1, anti-(human interleukin 2 receptor) (human-mouse monoclonal clone 1H4 γ 1-chain), disulfide with human-mouse monoclonal clone 1H4 light chain, dimer (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 153723-34-3 HCAPLUS


CN Axinastatin 2 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 153723-35-4 HCAPLUS
CN Axinastatin 3 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 154039-60-8 HCAPLUS
CN Butanediamide, N4-[(1S)-2,2-dimethyl-1-[(methylamino)carbonyl]propyl]-N1,2-dihydroxy-3-(2-methylpropyl)-, (2S,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 154229-19-3 HCAPLUS
CN Androsta-5,16-dien-3-ol, 17-(3-pyridinyl)-, (3β)- (9CI) (CA INDEX NAME)

NAME)

Absolute stereochemistry.



RN 154248-96-1 HCAPLUS


CN Blood platelet factor 4 (human subunit), N-L-methionyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 154277-21-1 HCAPLUS


CN Cypemycin (9CI) (CA INDEX NAME)

PAGE 1-A




[illegible]CC(C)CNC(=O)C(=C)CNC(=O)C1CCCC1C(=O)NCC(=O)C(C)CNC(=O)C1CCCC1C(=O)NCC(=O)C(C)C

PAGE 2-B




RN 154361-50-9 HCAPLUS
 CN Cytidine, 5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 155233-30-0 HCAPLUS
 CN Thiazole, 4,5-dihydro-4-[(1Z,5E,7E,11R)-11-methoxy-8-methyl-1,5,7,13-tetradecatetraenyl]-2-[(1R,2S)-2-methylcyclopropyl]-, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 156586-89-9 HCAPLUS
 CN Immunoglobulin G2a, anti-(human colon cancer tumor-associated antigen) (mouse monoclonal 17-1A γ2a-chain), disulfide with mouse monoclonal 17-1A light chain, dimer (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 156790-85-1 HCAPLUS
 CN Pyrido[3',2':4,5]pyrrolo[1,2-c]pyrimidin-4-ol, 9-amino-5-(2-amino-4-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 156856-30-3 HCAPLUS

CN 2H-Pyran-2-one, 5,6-dihydro-6-[(1S,7Z,9Z,11E)-6-hydroxy-1,5-dimethyl-4-(phosphonooxy)-7,9,11-tridecatrienyl]-5-methyl-, (5S,6S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.




RN 157078-48-3 HCAPLUS

CN Dispiro[pyrano[3,2-b]pyran-2(3H),5'-[5H]furo[3,2-b]pyran-2'(3'H),23''(6''H)-[1,5:8,11:14,18]triepoxy[30,32]ethano[2,5]methano[2H,5H,28H]furo[2',3':5,6]pyrano[4,3-b]furo[2'',3'':5',6']pyrano[2',3':5,6]pyran-6-(4-hydroxy-2-oxobutyl)-4,7',16'',26''-tetramethyl-10'',17''-bis(methylene)-, (1''S,2R,2'R,2''R,3'aS,3''aR,3''bS,4S,4aS,5''S,6R,7R,7'S,7'aS,8''S,8aS,11''S,14''S,16''R,18''R,19''aS,20''aS,21''aR,24''aR,25''aS,26''S,26''aR,30''R,31''aS,32''S,33''aR)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 2-B




RN 157857-21-1 HCAPLUS
 CN Proteinase inhibitor, maspin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 158792-24-6 HCAPLUS
 CN [2,2'-Bipyridine]-6-carboxaldehyde, 4-methoxy-5-(methylthio)-, oxime, (E)-
 (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 158792-25-7 HCAPLUS
 CN [2,2'-Bipyridine]-6-carboxaldehyde, 4-methoxy-5-(methylthio)-, oxime, (Z)-

(9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 168482-36-8 HCAPLUS

CN Pentanoic acid, 3-chloro-N-[(2E,5S,6R,7R,8S)-8-chloro-5,7-dihydroxy-6-methyl-1-oxo-8-phenyl-2-octenyl]-O-methyl-D-tyrosyl-(2R)-2-methyl-β-alanyl-2-hydroxy-4-methyl-, (3→15)-lactone, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.



RN 172793-30-5 HCAPLUS

CN 1,4-Butanediamine, N,N'-bis[3-(1-aziridinyl)propyl]- (9CI) (CA INDEX NAME)




RN 173046-02-1 HCAPLUS

CN L-Cysteine, N-[(3-hydroxy-2-quinolinyl)carbonyl]-D-cysteinyglycyl-N-methyl-L-cysteiny-N,S-dimethyl-, bimol. (4→1'), (4'→1)-bis(thiolactone), cyclic (3→3')-disulfide' (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).

PAGE 1-A


MeS



PAGE 1-B




PAGE 1-C



RN 174305-65-8 HCAPLUS
 CN Glycine, N,N-dimethyl-, (1R,2E,6S,10E,11aS,13S,14aR) -
 4,6,7,8,9,11a,12,13,14,14a-decahydro-1-hydroxy-6-methyl-4-oxo-1H-
 cyclopent[f]oxacyclotridecin-13-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 181887-82-1 HCAPLUS
 CN Nitrullin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 188364-40-1 HCAPLUS

CN CARN 700 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 200139-38-4 HCAPLUS

CN Suradista (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 212894-59-2 HCAPLUS

CN 2-Thiophenecarbonitrile, 5-(cyclopentylidene-1H-imidazol-1-ylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 246252-04-0 HCAPLUS

CN Lutetium, bis(acetato- κ O) [9,10-diethyl-20,21-bis[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]-4,15-dimethyl-8,11-imino-3,6:16,13-dinitrilo-1,18-benzodiazacycloeicosine-5,14-dipropanolato- κ N1, κ N18, κ N23, κ N24, κ N25]-, (PB-7-11-233'2'4)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—CH₂—OMe—CH₂—OMe

RN 246252-06-2 HCAPLUS

CN Gadolinium, bis(acetato-κO) [9,10-diethyl-20,21-bis[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]-4,15-dimethyl-8,11-imino-3,6:16,13-dinitrilo-1,18-benzodiazacycloeicosine-5,14-dipropanolato-κN1,κN18,κN23,κN24,κN25] -, (PB-7-11-233'2'4) - (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—CH₂—OMe—CH₂—OMe

RN 284041-10-7 HCAPLUS

CN Tin, dichloro[rel-ethyl (18R,19S)-3,4,20,21-tetradehydro-4,9,14,19-tetraethyl-18,19-dihydro-3,8,13,18-tetramethyl-20-phorbinecarboxylato(2-)-κN23,κN24,κN25,κN26]-, (OC-6-13)- (9CI) (CA INDEX NAME)



RN 324740-00-3 HCAPLUS

CN Vitaxin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 441070-87-7 HCAPLUS



CN 1,2,3-Triazolecarboxamide (9CI) (CA INDEX NAME)

CM 1

CRN 444891-03-6


CMF C3 H8 N4 O

CCI IDS



RN 441070-88-8 HCAPLUS

CN 5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy- α -L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, monofluoro deriv., hydrochloride, (8S,10S)-(9CI) (CA INDEX NAME)




D1-F

● HCl

RN 441070-92-4 HCAPLUS

CN Androstan-17-one, bromo-3-hydroxy-, (3 α ,5 β)-(9CI) (CA INDEX NAME)



D1- Br

RN 441772-39-0 HCAPLUS
CN Isobengazole (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 441772-43-6 HCAPLUS
CN Nagrestip (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 441772-66-3 HCAPLUS
CN Vinxaltine (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 441772-81-2 HCAPLUS
CN Sulfmosine (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 441774-07-8 HCAPLUS
CN Spicamycin D (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 441774-77-2 HCAPLUS
CN Solverol (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 60529-76-2, Thymopoietin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(receptor agonists, pharmaceutical formulation further including;
incensole and furanogermacrene and compds. as antitumor and
antimicrobial agents)

RN 60529-76-2 HCAPLUS
CN Thymopoietin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 79217-60-0, Cyclosporin
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(treatment of immunodysregulation condition caused by treatment with;
incensole and furanogermacrene and compds. as antitumor and
antimicrobial agents)

RN 79217-60-0 HCAPLUS
CN Cyclosporin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 50-07-7, Mitomycin C 1397-89-3, Amphotericin B
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL


(Biological study); USES (Uses)

(treatment of immunodysregulation condition caused by treatment with;
incensole and furanogermacrene and compds. as antitumor and
antimicrobial agents)

RN 50-07-7 HCAPLUS

CN Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-8-
[[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-
, (1aS,8S,8aR,8bS) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 1397-89-3 HCAPLUS

CN Amphotericin B (8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



L23 ANSWER 7 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:354070 HCAPLUS

DOCUMENT NUMBER: 136:350550

TITLE: Methods of treating cancer and the pain associated therewith using endothelin antagonists

INVENTOR(S): Janus, Todd J.; Padley, Robert J.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 24 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002055457	A1	20020509	US 2001-923616	20010806
PRIORITY APPLN. INFO.:			US 2000-223486P	P 20000807
OTHER SOURCE(S): MARPAT 136:350550				

AB The instant invention is directed to methods for the inhibition of bone metastases, methods for the prevention of growth of new metastases, methods for the inhibition of bone turnover, and methods for the prevention of bone loss in patients, including cancer patients, using an endothelin ET-A receptor antagonist.

IT 50-23-7, Hydrocortisone 53-03-2, Prednisone

57-83-0, Progesterone, biological studies

427-51-0, Cyproterone acetate 1406-16-2, Vitamin

D 1406-16-2D, Vitamin D, analogs

13311-84-7, Flutamide 13598-36-2D, Phosphonic acid,

alkylidinebis- derivs. 53714-56-0, Leuprolide 63612-50-0

, Nilutamide 65277-42-1, Ketoconazole 65807-02-5,

Goserelin 90357-06-5, Bicalutamide 173937-91-2

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL


(Biological study); USES (Uses)

(treatment of cancer and associated pain with endothelin antagonists)

RN 50-23-7 HCAPLUS


CN Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 53-03-2 HCAPLUS
 CN Pregna-1,4-diene-3,11,20-trione, 17,21-dihydroxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 57-83-0 HCAPLUS
 CN Pregn-4-ene-3,20-dione (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 427-51-0 HCAPLUS
 CN 3'H-Cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione, 17-(acetyloxy)-6-chloro-1,2-dihydro-, (1 β ,2 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 1406-16-2 HCAPLUS
CN Vitamin D (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 1406-16-2 HCAPLUS
CN Vitamin D (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 13311-84-7 HCAPLUS
CN Propanamide, 2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 13598-36-2 HCAPLUS
CN Phosphonic acid (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 53714-56-0 HCAPLUS
CN 1-9-Luteinizing hormone-releasing factor (swine), 6-D-leucine-9-(N-ethyl-L-prolinamide)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


PAGE 1-A



PAGE 1-B




RN 63612-50-0 HCAPLUS
 CN 2,4-Imidazolidinedione, 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-
 (9CI) (CA INDEX NAME)



RN 65277-42-1 HCAPLUS

CN Piperazine, 1-acetyl-4-[4-[[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 65807-02-5 HCAPLUS


CN 1-9-Luteinizing hormone-releasing factor (swine), 6-[O-(1,1-dimethylethyl)-D-serine]-, 2-(aminocarbonyl)hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




RN 90357-06-5 HCAPLUS
 CN Propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl- (9CI) (CA INDEX NAME)



RN 173937-91-2 HCAPLUS

CN 3-Pyrrolidinecarboxylic acid, 4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)-, (2R,3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L23 ANSWER 8 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:122776 HCAPLUS

DOCUMENT NUMBER: 136:161346

TITLE: Methods of treating cancer and the pain associated therewith using endothelin antagonists

INVENTOR(S): Janus, Todd J.; Padley, Robert J.

PATENT ASSIGNEE(S): Abbott Laboratories, USA

SOURCE: PCT Int. Appl., 86 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002011713	A2	20020214	WO 2001-US24716	20010806
WO 2002011713	A3	20030717		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

AU 2001081134	A5	20020218	AU 2001-81134	20010806
EP 1347751	A2	20031001	EP 2001-959595	20010806
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004520266	T2	20040708	JP 2002-517050	20010806
NO 2003000593	A	20030206	NO 2003-593	20030206
BG 107577	A	20031031	BG 2003-107577	20030221
PRIORITY APPLN. INFO.:			US 2000-633389	A 20000807
			WO 2001-US24716	W 20010806

OTHER SOURCE(S): MARPAT 136:161346

AB The instant invention is directed to methods for the inhibition of bone metastases, methods for the prevention of growth of new metastases, methods for the inhibition of bone turnover, and methods for the prevention of bone loss in patients, including cancer patients, using an endothelin ET-A receptor antagonist.

IT 50-23-7, Hydrocortisone 53-03-2, Prednisone

57-83-0, Progesterone, biological studies

427-51-0, Cyproterone acetate 1406-16-2, Vitamin

D 1406-16-2D, Vitamin D, analogs

13311-84-7, Flutamide 13598-36-2D, Phosphonic acid,

alkylidinebis- derivs. 63612-50-0, Nilutamide 65277-42-1

, Ketoconazole 65807-02-5, Zoladex 74381-53-6, Lupron

90357-06-5, Bicalutamide 173937-91-2, ABT-627

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL


(Biological study); USES (Uses)

(methods of treating cancer and pain associated therewith using endothelin antagonists)

RN 50-23-7 HCAPLUS

CN Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 53-03-2 HCAPLUS


CN Pregna-1,4-diene-3,11,20-trione, 17,21-dihydroxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 57-83-0 HCAPLUS
 CN Pregn-4-ene-3,20-dione (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 427-51-0 HCAPLUS
 CN 3'H-Cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione, 17-(acetyloxy)-6-chloro-1,2-dihydro-, (1 β ,2 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 1406-16-2 HCAPLUS
 CN Vitamin D (8CI, 9CI) (CA INDEX NAME)


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 1406-16-2 HCAPLUS
 CN Vitamin D (8CI, 9CI) (CA INDEX NAME)


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 13311-84-7 HCAPLUS

CN Propanamide, 2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 13598-36-2 HCAPLUS
CN Phosphonic acid (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 63612-50-0 HCAPLUS
CN 2,4-Imidazolidinedione, 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 65277-42-1 HCAPLUS
CN Piperazine, 1-acetyl-4-[4-[[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 65807-02-5 HCAPLUS


CN 1-9-Luteinizing hormone-releasing factor (swine), 6-[O-(1,1-dimethylethyl)-D-serine]-, 2-(aminocarbonyl)hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 74381-53-6 HCAPLUS

CN 1-9-Luteinizing hormone-releasing factor (swine), 6-D-leucine-9-(N-ethyl-L-prolinamide)-, monoacetate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 53714-56-0


CMF C59 H84 N16 O12

Absolute stereochemistry. Rotation (-).

PAGE 1-A




PAGE 1-B



CM 2


CRN 64-19-7

CMF C2 H4 O2



RN 90357-06-5 HCAPLUS


CN Propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl- (9CI) (CA INDEX NAME)



RN 173937-91-2 HCAPLUS

CN 3-Pyrrolidinecarboxylic acid, 4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)-, (2R,3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L23 ANSWER 9 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1999:141214 HCAPLUS

DOCUMENT NUMBER: 130:163193

TITLE: A method of preventing or treating estrogen-dependent diseases and disorders with antiestrogens

INVENTOR(S): McDonnell, Donald P.; Norris, John; Connor, Caroline; Wijayarathne, Ashini

PATENT ASSIGNEE(S): Duke University, USA

SOURCE: PCT Int. Appl., 72 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9908682	A1	19990225	WO 1998-US16864	19980814
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2301032	AA	19990225	CA 1998-2301032	19980814
AU 9889063	A1	19990308	AU 1998-89063	19980814
AU 757206	B2	20030206		
EP 1019057	A1	20000719	EP 1998-940886	19980814
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9811946	A	20000822	BR 1998-11946	19980814
EE 200000077	A	20001215	EE 2000-200000077	19980814
JP 2001515038	T2	20010918	JP 2000-509421	19980814
NZ 502738	A	20020628	NZ 1998-502738	19980814
RU 2214236	C2	20031020	RU 2000-106448	19980814
NO 2000000752	A	20000215	NO 2000-752	20000215
US 2003232795	A1	20031218	US 2003-390032	20030318
PRIORITY APPLN. INFO.:			US 1997-55881P	P 19970815
			US 1998-134146	B1 19980814
			WO 1998-US16864	W 19980814


OTHER SOURCE(S): MARPAT 130:163193

AB The invention relates, in general, to the treatment of estrogen-dependent diseases and disorders and, in particular, to a method of treating

estrogen-dependent cancers, particularly breast cancer, with antiestrogens.


IT 50-28-2, Estra-1,3,5(10)-triene-3,17-diol (17 β)-, biological studies 68047-06-3, 4-Hydroxytamoxifen
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (antiestrogens for prevention or treatment of estrogen-dependent diseases and disorders)
 RN 50-28-2 HCAPLUS
 CN Estra-1,3,5(10)-triene-3,17-diol (17 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 68047-06-3 HCAPLUS
 CN Phenol, 4-[(1Z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 1406-16-2, Vitamin D 1406-16-2D, Vitamin D, metabolites 155701-61-4, GW5638 195611-82-6, GW7604
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (antiestrogens for prevention or treatment of estrogen-dependent diseases and disorders)
 RN 1406-16-2 HCAPLUS
 CN Vitamin D (8CI, 9CI) (CA INDEX NAME)


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
 RN 1406-16-2 HCAPLUS
 CN Vitamin D (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 155701-61-4 HCAPLUS

CN 2-Propenoic acid, 3-[4-[(1Z)-1,2-diphenyl-1-butenyl]phenyl]-, (2E)- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 195611-82-6 HCAPLUS

CN 2-Propenoic acid, 3-[4-[(1E)-1-(4-hydroxyphenyl)-2-phenyl-1-butenyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 57-88-5, Cholest-5-en-3-ol (3β)-, biological studies


RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(antiestrogens for prevention or treatment of estrogen-dependent diseases and disorders)

RN 57-88-5 HCAPLUS

CN Cholest-5-en-3-ol (3β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 131384-38-8, Protein farnesyltransferase 142243-02-5,
MAP kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; antiestrogens for prevention or treatment of
estrogen-dependent diseases and disorders)

RN 131384-38-8 HCAPLUS

CN Farnesyltransferase, protein (cysteine) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 142243-02-5 HCAPLUS

CN Kinase (phosphorylating), mitogen-activated protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 80295-41-6, Complement C3

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(promoter; antiestrogens for prevention or treatment of
estrogen-dependent diseases and disorders)

RN 80295-41-6 HCAPLUS

CN Complement C3 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 10540-29-1, Tamoxifen 84449-90-1, Raloxifene

116057-75-1, Idoxifene 129453-61-8, ICI 182780


RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)

(resistance to; antiestrogens for prevention or treatment of
estrogen-dependent diseases and disorders)

RN 10540-29-1 HCAPLUS


CN Ethanamine, 2-[4-[(1Z)-1,2-diphenyl-1-butenyl]phenoxy]-N,N-dimethyl- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.



RN 84449-90-1 HCAPLUS

CN Methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 116057-75-1 HCAPLUS

CN Pyrrolidine, 1-[2-[4-[(1E)-1-(4-iodophenyl)-2-phenyl-1-

butenyl]phenoxy]ethyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 129453-61-8 HCAPLUS

CN Estradiol-1,3,5(10)-triene-3,17-diol, 7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]-, (7 α ,17 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 10 OF 10 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1998:427690 HCAPLUS
 DOCUMENT NUMBER: 129:92583
 TITLE: Assays for functional nuclear receptors
 INVENTOR(S): Nargessi, Ruhangiz Dokhi
 PATENT ASSIGNEE(S): Chiron Diagnostics Corp., USA
 SOURCE: U.S., 28 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5770176	A	19980623	US 1995-569977	19951208


PRIORITY APPLN. INFO.: US 1995-569977 19951208

AB Methods and test kits for detecting, or detecting and quantitating functional nuclear receptors in cell or tissue samples are disclosed. Such methods provide highly sensitive assays requiring small sample sizes and short turnaround times. The methods are useful in developing prognoses and/or treatment programs for cancer patients, especially in determining whether therapy to interfere with the receptor's activation of gene transcription, such as, endocrine therapy, would be helpful. An estrogen receptor (ER) ELISA involved incubating assay buffer, estradiol solution, and patient cytosol or controls in ER monoclonal antibody-coated microtiter wells; washing the wells; and adding an estrogen response element octamer that had been biotinylated. After incubation and washing, the wells were reacted with streptavidin-horseradish peroxidase conjugate. TMB was the enzyme substrate used in the assay. The absorbance was measured at 450 nm. Twenty-three breast cancer cytosols were assayed.

IT **179633-63-7**
 RL: ARU (Analytical role, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (alkaline phosphatase substrate enhancer; immunoassays for functional nuclear receptors)

RN 179633-63-7 HCAPLUS


CN Phosphonium, tris(1,1-dimethylethyl)[[4-[(trioctylphosphonio)methyl]phenyl]methyl]-, dichloride (9CI) (CA INDEX NAME)





IT **330-13-2, p-Nitrophenyl phosphate 209465-46-3**
 RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (alkaline phosphatase substrate; immunoassays for functional nuclear receptors)

RN 330-13-2 HCAPLUS

CN Phosphoric acid, mono(4-nitrophenyl) ester (9CI) (CA INDEX NAME)



RN 209465-46-3 HCAPLUS

CN Phosphonic acid, [3-(3-methoxy-4-tricyclo[3.3.1.1^{3,7}]dec-1-yl-1,2-dioxetan-3-yl)phenyl]-, disodium salt (9CI) (CA INDEX NAME)

●2 Na


IT 58-85-5, Biotin 9013-20-1, Streptavidin

RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (detectable marker binding pair component; immunoassays for functional nuclear receptors)

RN 58-85-5 HCAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanoic acid, hexahydro-2-oxo-,
 (3aS,4S,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 9013-20-1 HCAPLUS

CN Streptavidin (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 56-73-5, Glucose 6-phosphate 93-35-6, Umbelliferone

521-31-3, Luminol 2321-07-5, Fluorescein

3682-14-2D, Isoluminol, derivs. 9001-37-0, Glucose

oxidase 9001-78-9, Alkaline phosphatase 9002-17-9,

Xanthine oxidase 9014-00-0, Luciferase 9025-35-8,

 α -Galactosidase 9031-11-2, β -Galactosidase


RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(detectable markers; immunoassays for functional nuclear receptors)

RN 56-73-5 HCAPLUS


CN D-Glucose, 6-(dihydrogen phosphate) (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 93-35-6 HCAPLUS

CN 2H-1-Benzopyran-2-one, 7-hydroxy- (9CI) (CA INDEX NAME)




RN 521-31-3 HCAPLUS

CN 1,4-Phthalazinedione, 5-amino-2,3-dihydro- (6CI, 8CI, 9CI) (CA INDEX NAME)




RN 2321-07-5 HCAPLUS

CN Spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one, 3',6'-dihydroxy- (9CI) (CA INDEX NAME)



RN 3682-14-2 HCAPLUS

CN 1,4-Phthalazinedione, 6-amino-2,3-dihydro- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 9001-37-0 HCAPLUS
 CN Oxidase, glucose (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 9001-78-9 HCAPLUS
 CN Phosphatase, alkaline (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 9002-17-9 HCAPLUS
 CN Oxidase, xanthine (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 9014-00-0 HCAPLUS
 CN Luciferase (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 9025-35-8 HCAPLUS
 CN Galactosidase, α - (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 9031-11-2 HCAPLUS
 CN Galactosidase, β - (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **11103-57-4**, Vitamin A
 RL: ANT (Analyte); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PROC (Process); USES (Uses)
 (hormonal receptors; immunoassays for functional nuclear receptors)
 RN 11103-57-4 HCAPLUS
 CN Vitamin A (9CI) (CA INDEX NAME)


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **34314-06-2**, Tetramethyl benzidine **172834-40-1**
 RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (horseradish peroxidase substrate; immunoassays for functional nuclear receptors)
 RN 34314-06-2 HCAPLUS
 CN [1,1'-Biphenyl]-4,4'-diamine, tetramethyl- (9CI) (CA INDEX NAME)



4 (D1-Me)

RN 172834-40-1 HCAPLUS

CN 9-Acridinecarboxylic acid, 9,10-dihydro-3-methoxy-10-methyl-,
2,3,6-trifluorophenyl ester (9CI) (CA INDEX NAME)

IT 9003-99-0, Peroxidase

RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(horseradish, detectable markers; immunoassays for functional nuclear receptors)

RN 9003-99-0 HCAPLUS

CN Peroxidase (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 9003-99-0D, Peroxidase, conjugates with streptavidin

RL: ARG (Analytical reagent use); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PROC (Process); USES (Uses)
(horseradish; immunoassays for functional nuclear receptors)

RN 9003-99-0 HCAPLUS

CN Peroxidase (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 209619-55-6DP, biotinylated

RL: ARG (Analytical reagent use); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(immunoassays for functional nuclear receptors)

RN 209619-55-6 HCAPLUS

CN DNA (38 bp estrogen response element consensus segment tandem octamer plasmid Z16.0121 cDNA) (9CI) (CA INDEX NAME)


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 9013-20-1D, Streptavidin, conjugates with horseradish peroxidase
 RL: ARG (Analytical reagent use); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PROC (Process); USES (Uses)
 (immunoassays for functional nuclear receptors)
 RN 9013-20-1 HCAPLUS
 CN Streptavidin (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


IT 72040-63-2
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (immunoassays for functional nuclear receptors)
 RN 72040-63-2 HCAPLUS
 CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[(2,5-dioxo-1-pyrrolidinyl)oxy]-6-oxohexyl]hexahydro-2-oxo-, (3aS,4S,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 50-28-2, Estradiol, biological studies
 RL: ARG (Analytical reagent use); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PROC (Process); USES (Uses)
 (ligand for estrogen receptors; immunoassays for functional nuclear receptors)
 RN 50-28-2 HCAPLUS
 CN Estra-1,3,5(10)-triene-3,17-diol (17 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 209534-69-0

RL: ARG (Analytical reagent use); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); RCT (Reactant); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PROC (Process); RACT (Reactant or reagent); USES (Uses)
(nucleotide sequence, estrogen response element segment consensus sequence; immunoassays for functional nuclear receptors)

RN 209534-69-0 HCAPLUS

CN DNA, d(G-G-T-C-A-C-T-C-T-G-A-C-C), double-stranded complementary (9CI)
(CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 209534-71-4

RL: ARG (Analytical reagent use); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); RCT (Reactant); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PROC (Process); RACT (Reactant or reagent); USES (Uses)
(nucleotide sequence, estrogen response element segment for human c-fos gene; immunoassays for functional nuclear receptors)

RN 209534-71-4 HCAPLUS

CN DNA, d(C-G-G-C-A-G-C-G-T-G-A-C-C), double-stranded complementary (9CI)
(CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 209534-70-3

RL: ARG (Analytical reagent use); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); RCT (Reactant); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PROC (Process); RACT (Reactant or reagent); USES (Uses)
(nucleotide sequence, estrogen response element segment for human oxytocin gene; immunoassays for functional nuclear receptors)

RN 209534-70-3 HCAPLUS

CN DNA, d(G-G-T-C-A-A-G-G-T-C-A-C-C), double-stranded complementary (9CI)
(CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 209534-72-5

RL: ARG (Analytical reagent use); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); RCT (Reactant); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PROC (Process); RACT (Reactant or reagent); USES (Uses)
(nucleotide sequence, estrogen response element segment for human prolactin gene; immunoassays for functional nuclear receptors)

RN 209534-72-5 HCAPLUS

CN DNA, d(G-G-C-C-A-A-G-G-T-G-A-C-A), double-stranded complementary (9CI)
(CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 209619-55-6P

RL: ARG (Analytical reagent use); BPN (Biosynthetic preparation); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); RCT (Reactant); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses)
(nucleotide sequence, estrogen response element segment; immunoassays for functional nuclear receptors)

RN 209619-55-6 HCAPLUS

CN DNA (38 bp estrogen response element consensus segment tandem octamer plasmid Z16.0121 cDNA) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 177022-07-0 177022-07-0D, dimers or trimers or tetramers
206335-59-3, GenBank I72386
RL: ARG (Analytical reagent use); BPR (Biological process); BSU
(Biological study, unclassified); PRP (Properties); RCT (Reactant); THU
(Therapeutic use); ANST (Analytical study); BIOL (Biological study); PROC
(Process); RACT (Reactant or reagent); USES (Uses)
(nucleotide sequence, estrogen response element segment; immunoassays
for functional nuclear receptors)

RN 177022-07-0 HCAPLUS
CN DNA, d(C-C-A-G-G-T-C-A-G-A-G-T-G-A-C-C-T-G-A-G-C-T-A-A-A-A-T-A-A-C-A-C-A-T-
T-C-A-G), double-stranded complementary (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 177022-07-0 HCAPLUS
CN DNA, d(C-C-A-G-G-T-C-A-G-A-G-T-G-A-C-C-T-G-A-G-C-T-A-A-A-A-T-A-A-C-A-C-A-T-
T-C-A-G), double-stranded complementary (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 206335-59-3 HCAPLUS
CN DNA, d(G-G-T-C-A-C-A-G-T-G-A-C-C) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 206335-61-7, GenBank I72388
RL: ARG (Analytical reagent use); BPR (Biological process); BSU
(Biological study, unclassified); PRP (Properties); RCT (Reactant); THU
(Therapeutic use); ANST (Analytical study); BIOL (Biological study); PROC
(Process); RACT (Reactant or reagent); USES (Uses)
(nucleotide sequence, thyroid T3 response element segment; immunoassays
for functional nuclear receptors)

RN 206335-61-7 HCAPLUS
CN DNA, d(A-G-G-T-A-A-G-A-T-C-A-G-G-G-A-C-G-T) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d que stat l28

L3 1 SEA FILE=REGISTRY ABB=ON "PROGESTERONE 17A-HYDROPEROXIDE
"/CN
L4 1 SEA FILE=REGISTRY ABB=ON PROGESTERONE/CN
L6 1 SEA FILE=REGISTRY ABB=ON 19-NORTESTOSTERONE/CN
L11 2 SEA FILE=REGISTRY ABB=ON "1,25-DIHYDROXYVITAMIN D3"/CN
L13 1 SEA FILE=REGISTRY ABB=ON "VITAMIN D"/CN
L24 1193867 SEA (PROGESTERON? OR PREGNAN? OR ESTRAN? OR GONAN? OR L3 OR L4
OR L6)
L25 108329 SEA VITAMIN? (W) (D OR D3) OR L11 OR L13
L26 4320 SEA L24 AND L25
L27 21 SEA L26 AND (?OVAR? OR ?REPROD?) (W) (?CANCER? OR ?CARCIN? OR
?NEOPLASM? OR ?TUMOR? OR ?TUMOUR?)
L28 17 DUP REMOV L27 (4 DUPLICATES REMOVED)

=> => d ibib abs l28 1-17

L28 ANSWER 1 OF 17 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN

ACCESSION NUMBER: 2004301080 EMBASE
TITLE: Hormone replacement therapy in postmenopausal women.
AUTHOR: Staren E.D.; Omer S.
CORPORATE SOURCE: Dr. E.D. Staren, Department of Surgery, Medical College of
Ohio, 3065 Arlington Ave., Toledo, OH 43614-5807, United
States. estaren@mco.edu
SOURCE: American Journal of Surgery, (2004) 188/2 (136-149).
Refs: 136
ISSN: 0002-9610 CODEN: AJSUAB
PUBLISHER IDENT.: S 0002-9610(04)00129-1
COUNTRY: United States
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 010 Obstetrics and Gynecology
016 Cancer
018 Cardiovascular Diseases and Cardiovascular Surgery
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English

AB Background For many years, hormone replacement therapy (HRT) was
considered an effective method of restoring the relative protection from
coronary artery disease enjoyed by premenopausal women compared with men
of similar age. This view has been supported by a substantial number of
basic science and observational studies. Data sources Results of recent
randomized controlled trials have seriously challenged the concept of the
protective value of HRT by showing that rather than decreasing the risk of
coronary artery disease, HRT actually appears to increase it. In addition,
it increases the risk for breast cancer, stroke, venous thromboembolism,
and cholecystitis. Results Despite some benefits such as increased bone
mineral density and decreased risk of fracture and colorectal cancer,
these data suggest that the risks of HRT outweigh the benefits.
Conclusions HRT is no longer routinely recommended for prevention of
chronic disease. We present the current scientific data, benefits, risks,
and consequent clinical recommendations regarding HRT use in
postmenopausal women. .COPYRGT. 2004 Excerpta Medica, Inc. All rights
reserved.

L28 ANSWER 2 OF 17 MEDLINE on STN DUPLICATE 1
ACCESSION NUMBER: 2003419370 MEDLINE
DOCUMENT NUMBER: PubMed ID: 12959189
TITLE: New insights regarding pharmacologic approaches for

ovarian cancer prevention.
AUTHOR: Rodriguez Gustavo
CORPORATE SOURCE: Division of Gynecologic Oncology, Evanston Northwestern
Healthcare, Evanston, IL, USA.. grodriguez@enh.org
SOURCE: Hematology/oncology clinics of North America, (2003 Aug) 17
(4) 1007-20, x. Ref: 82
Journal code: 8709473. ISSN: 0889-8588.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200403
ENTRY DATE: Entered STN: 20030909
Last Updated on STN: 20040303
Entered Medline: 20040302

AB The pathogenesis of epithelial **ovarian cancer** is not completely understood, but it commonly is believed that the process of recurrent ovulation (incessant ovulation) causes genetic damage in ovarian epithelial cells and that sufficient genetic damage can lead to **ovarian cancer** in susceptible individuals. Under this model, it has been suggested that reproductive and hormonal factors, such as **pregnancy** and oral contraceptive use, decrease **ovarian cancer** risk mainly via their inhibitory effects on ovulation. There is mounting evidence that the ovarian epithelium is a hormonally responsive target organ whose biology can be impacted strongly by the local hormonal environment. Progestin-mediated apoptotic effects may be a major mechanism underlying the **ovarian cancer** protective effects of **pregnancy** (a high progestin state) and oral contraceptive pill use. Similarly, retinoids, **vitamin D**, and non-steroidal anti-inflammatory drugs may have biologic effects on the ovarian epithelium that are cancer preventive, whereas androgens may have stimulatory effects on the ovarian epithelium, leading to an increased **ovarian cancer** risk.

L28 ANSWER 3 OF 17 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN

ACCESSION NUMBER: 2003425234 EMBASE
TITLE: Present and future pharmacotherapy for osteoporosis.
AUTHOR: Doggrell S.A.
CORPORATE SOURCE: S.A. Doggrell, Dept. of Physiology and Pharmacology, School
of Biomedical Sciences, University of Queensland, Brisbane,
QLD 4072, Australia. s-doggrell@yahoo.com
SOURCE: Drugs of Today, (2003) 39/8 (633-657).
Refs: 155
ISSN: 0025-7656 CODEN: MDACAP
COUNTRY: Spain
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 003 Endocrinology
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English

AB Although neither calcium nor **vitamin D** has been shown to prevent osteoporosis in postmenopausal women alone, the combination does. Both calcium and **vitamin D** are commonly used in the treatment of osteoporosis. The estrogens and raloxifene both prevent bone loss in postmenopausal women, and the estrogens probably also

decrease the risk of first fracture. There is good evidence that raloxifene prevents further fractures in postmenopausal women who have already had fractures and some evidence that estrogen does as well. Calcitonin increases bone mineral density in early postmenopausal women and men with idiopathic osteoporosis, and also reduces the risk of new fractures in osteoporotic women. The bisphosphonate alendronate prevents bone loss and reduces fractures in healthy and osteoporotic postmenopausal women, and in osteoporotic men. Risedronate is more potent and has fewer upper gastrointestinal side effects than alendronate, and reduces the incidence of fractures in osteoporotic women. Intermittent use of the potent bisphosphonate zoledronate also increases bone mineral density and may become an alternative in the prevention and treatment of osteoporosis. All of the agents discussed above prevent bone resorption, whereas teriparatide increases bone formation and is effective in the treatment of osteoporotic women and men. In the treatment of secondary osteoporosis associated with the use of glucocorticoids to treat inflammation or prevent rejection after transplantation, the bisphosphonates are effective. The agents that have undergone some clinical trialing as new or alternative drugs for the treatment of osteoporosis include tibolone, new SERMs, androgens, growth hormone, insulin-like growth factor-1 and stontium ranelate. The targets/drugs that are being developed to inhibit bone resorption include the OPG/RANKL/RANK system, cathepsin K inhibitors, vitronectin receptor antagonists, estren, the interleukin-6 and gp130 system, cytokines and growth factors. New drugs/targets to promote bone formation include the commonly used lipid-lowering statins and the calcilytic release of PTH. .COPYRG. 2003 Prous Science. All rights reserved.

L28 ANSWER 4 OF 17 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN

ACCESSION NUMBER: 2003134676 EMBASE
TITLE: Hormone replacement therapy and endometrial, ovarian and colorectal cancer.

AUTHOR: Gambacciani M.; Monteleone P.; Sacco A.; Genazzani A.R.
CORPORATE SOURCE: Prof. Dr. M. Gambacciani, Dept. of Obstetrics and

Gynecology, University of Pisa, Via Roma 67, 56100 Pisa, Italy. margamba@tin.it

SOURCE: Bailliere's Best Practice and Research in Clinical
Endocrinology and Metabolism, (2003) 17/1 (139-147).

Refs: 52

ISSN: 1521-690X CODEN: BBPMFY

COUNTRY: United Kingdom

DOCUMENT TYPE: Journal; General Review

FILE SEGMENT: 003 Endocrinology
016 Cancer
038 Adverse Reactions Titles
037 Drug Literature Index
030 Pharmacology
010 Obstetrics and Gynecology
048 Gastroenterology

LANGUAGE: English

SUMMARY LANGUAGE: English

AB Sex-steroid-related tumours in women are represented by breast cancer and endometrial cancer, but a possible relationship may exist between sex steroids and both ovarian and colon cancer. Unopposed oestrogen therapy is known to increase the risk of endometrial cancer and is appropriate only for hysterectomized women. In women with an intact uterus, an appropriate combination of oestrogen and progestin does not appear to increase-and may even decrease- the risk of endometrial cancer. Current users of HRT seem to benefit from a reduced risk for colon cancer. As for epithelial

ovarian cancer, the present data are very conflicting. The association between replacement hormones and this malignancy seems to be stronger for unopposed oestrogen than for oestrogen-progestin treatment. Data available at the moment do not allow discriminating for dose, routes of administration, bioavailability and tissue effects of different compounds so that it is inappropriate to consider all forms of HRT jointly. The future of HRT in post-menopausal women lies in the individualization of the therapy based upon personal risk factors and characteristics.

L28 ANSWER 5 OF 17 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN

ACCESSION NUMBER: 2003397887 EMBASE

TITLE: **Ovarian cancer** and high-risk women -
Implications for prevention, screening, and early
detection.

AUTHOR: Modugno F.; Boyd J.; Baum A.; Bigbee W.L.; Cramer D.;
Ferrell R.; Gallion H.H.; Greene M.H.; Goldman P.; Johnson
K.A.; Junker B.; Kuller L.; Kurman R.J.; Maihle N.; Narod
S.; Ness R.B.; Risch H.; Rodriguez G.; Sadetzki S.; Skates
S.; Stein M.; Weissfeld J.L.

CORPORATE SOURCE: Dr. F. Modugno, Department of Epidemiology, Graduate School
of Public Health, University of Pittsburgh, Pittsburgh, PA
15261, United States. modugno+pitt.edu

SOURCE: Gynecologic Oncology, (1 Oct 2003) 91/1 (15-31).
Refs: 261

ISSN: 0090-8258 CODEN: GYNOA3

COUNTRY: United States

DOCUMENT TYPE: Journal; General Review

FILE SEGMENT: 010 Obstetrics and Gynecology
016 Cancer
037 Drug Literature Index

LANGUAGE: English

SUMMARY LANGUAGE: English

AB Objectives. The aim of this study was to understand the strengths and limitations of current prevention, detection, and screening methods for **ovarian cancer** and to identify research areas to improve prevention, screening, and detection of the disease for all women as well as for women carrying a mutation in the BRCA1/2 genes. Methods. We convened an **ovarian cancer** symposium at the University of Pittsburgh in May 2002. Nineteen leading scientists representing disciplines such as epidemiology, molecular biology, pathology, genetics, bioinformatics, and psychology presented the latest data on **ovarian cancer** prevention, screening, and early detection. Results. **Ovarian cancer** is the most common cause of death from a gynecologic malignancy in the United States. Because survival depends on stage of diagnosis, early detection is critical in improving clinical outcome. However, existing screening techniques (CA125, transvaginal ultrasound) have not been shown to reduce morbidity or mortality. Moreover, with the exception of oral contraceptives, there are no available chemopreventive agents. Bilateral salpingo-oophorectomy also has been shown to reduce incidence, but this procedure has several drawbacks in terms of a woman's reproductive, cardiovascular, skeletal, and mental health. Conclusion. Better methods to prevent, detect, and screen for **ovarian cancer** in all women, but particularly in high-risk women carrying mutations in BRCA1/2, are urgently needed. This article reviews the current state of knowledge in the etiology, prevention, and early detection of **ovarian cancer** and suggests several areas for future clinical, epidemiologic, and laboratory-based research. .COPYRG. 2003 Elsevier Inc.

All rights reserved.

L28 ANSWER 6 OF 17 MEDLINE on STN DUPLICATE 2
 ACCESSION NUMBER: 2002420741 MEDLINE
 DOCUMENT NUMBER: PubMed ID: 12174912
 TITLE: Immunohistochemical analysis of 1,25-dihydroxyvitamin-D3-receptors, estrogen and **progesterone** receptors and Ki-67 in **ovarian carcinoma**.
 AUTHOR: Villena-Heinsen Carlos; Meyberg Roland; Axt-Fliehn Roland; Reitnauer Karin; Reichrath Jorg; Friedrich Michael
 CORPORATE SOURCE: Department of Gynecology, University of Saarland, Homburg, Germany.
 SOURCE: Anticancer research, (2002 Jul-Aug) 22 (4) 2261-7.
 Journal code: 8102988. ISSN: 0250-7005.
 PUB. COUNTRY: Greece
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 200209
 ENTRY DATE: Entered STN: 20020815
 Last Updated on STN: 20021002
 Entered Medline: 20020913

AB BACKGROUND: The aim of this study was to analyze immunohistochemically the expression of VDR in normal and carcinomatous ovarian tissue to evaluate whether ovarian tissue may be a new potential target for biologically active **vitamin D** analogues. MATERIALS AND METHODS: The expression of 1,25-dihydroxyvitamin-D3-receptors (VDR) was immunohistochemically investigated in **ovarian carcinomas** (n=40). VDR immunoreactivity (mAb 9A7gamma) was compared with the staining pattern of the proliferation marker Ki-67, of the estrogen receptors (ER) and of the **progesterone** receptors (PR). The percentage of positive tumour cells (PP), the intensity of staining (SI) and a resulting immunoreactivity score (IRS) were determined for the semiquantitative evaluation of VDR-, ER- and PR-expression. RESULTS: A total of 16.7% of the normal surface ovarian epithelium was VDR-negative, while the remaining 83.3% revealed weak to moderate VDR immunoreactivity. Moderate to strong nuclear immunoreactivity for VDR was detected in almost all **ovarian carcinomas** analyzed. Both the intensity of VDR immunostaining and the number of VDR-positive cells were significantly increased in **ovarian carcinomas** as compared to normal ovarian tissue. Analyzing coexpression of VDR with the proliferation marker Ki-67 or with the estrogen and **progesterone** receptors, no significant correlation was found. CONCLUSION: Our findings indicate that: (I) VDR expression is increased in **ovarian carcinomas** as compared to normal ovarian tissue. (II) Up-regulation of VDR in **ovarian carcinomas** is not exclusively induced by an increase of proliferation, but by different unknown mechanisms. (III) Expression of VDR in **ovarian carcinomas** is independently regulated from the expression of ER and PR. (IV) Ovarian tissue may be a new target organ for therapeutically applied **vitamin D** analogues exerting fewer calcemic side-effects. New **vitamin D** analogues may be promising drugs for the treatment of advanced **ovarian carcinomas**.

L28 ANSWER 7 OF 17 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
 ACCESSION NUMBER: 2002:630074 BIOSIS
 DOCUMENT NUMBER: PREV200200630074
 TITLE: Evaluation of **ovarian cancer** preventive

agents in the chicken.

AUTHOR(S): Rodriguez, Gustavo C. [Reprint author]; Barnes, John; Anderson, Ken; Petite, Jim; Windham, Jennifer; Lancaster, Johnathan; Wenham, Robert; Berchuck, Andrew; Kopelovich, Levy; Carver, Donna

CORPORATE SOURCE: Evanston Northwestern Healthcare, Northwestern University, Evanston, IL, USA

SOURCE: Cancer Epidemiology Biomarkers and Prevention, (October, 2002) Vol. 11, No. 10 Part 2, pp. 1193s. print.
Meeting Info.: Proceedings of the American Association for Cancer Research Conference on Frontiers in Cancer Prevention Research. Boston, MA, USA. October 14-18, 2002. American Society of Preventive Oncology.
ISSN: 1055-9965.

DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)

LANGUAGE: English

ENTRY DATE: Entered STN: 12 Dec 2002
Last Updated on STN: 12 Dec 2002

L28 ANSWER 8 OF 17 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN

ACCESSION NUMBER: 2002:630035 BIOSIS

DOCUMENT NUMBER: PREV200200630035

TITLE: A case-control study of candidate **ovarian cancer** susceptibility polymorphisms.

AUTHOR(S): Schildkraut, Joellen M. [Reprint author]; Wenham, Robert [Reprint author]; Lancaster, Johnathan [Reprint author]; Calingaert, Brian [Reprint author]; McLean, Kia [Reprint author]; Halabi, Susan [Reprint author]; Marks, Jeffrey [Reprint author]; Berchuck, Andrew [Reprint author]

CORPORATE SOURCE: Duke University Medical Center, Durham, NC, USA

SOURCE: Cancer Epidemiology Biomarkers and Prevention, (October, 2002) Vol. 11, No. 10 Part 2, pp. 1165s. print.
Meeting Info.: Proceedings of the American Association for Cancer Research Conference on Frontiers in Cancer Prevention Research. Boston, MA, USA. October 14-18, 2002. American Society of Preventive Oncology.
ISSN: 1055-9965.

DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
Conference; (Meeting Poster)

LANGUAGE: English

ENTRY DATE: Entered STN: 12 Dec 2002
Last Updated on STN: 12 Dec 2002

L28 ANSWER 9 OF 17 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

ACCESSION NUMBER: 2002041948 EMBASE

TITLE: Hormone replacement therapy and cancer. International Menopause Society Expert Workshop.

AUTHOR: Genazzani A.R.; Gadducci A.; Gambacciani M.

CORPORATE SOURCE: Prof. A.R. Genazzani, Department of Gynecology, University of Pisa, Via Roma 35 56126, Italy

SOURCE: Gynecological Endocrinology, (2001) 15/6 (453-465).
Refs: 82
ISSN: 0951-3590 CODEN: GYENER

COUNTRY: United Kingdom

DOCUMENT TYPE: Journal; Conference Article

FILE SEGMENT: 010 Obstetrics and Gynecology

016 Cancer
037 Drug Literature Index

LANGUAGE: English
SUMMARY LANGUAGE: English

AB Sex steroids are not known to damage DNA directly. They can stimulate or inhibit cell proliferation, and thus can modulate tumor developmental progression. Sex steroid-related tumors in women are represented by breast cancer and endometrial cancer, and possible relationship exists between sex steroids and both ovarian and colon cancer. Among current ERT users or those who stopped use 1-4 years previously, the relative risk of having breast cancer diagnosed increases by a factor of 1.023 for each year of hormone use. This increase is comparable with the effect on breast cancer of delaying menopause, and seems to be largely limited to lean women. The breast cancers diagnosed during ERT are more likely to contain ER and are less aggressive. Some reports indicate no increase in breast cancer mortality in HRT users. Recent data suggest that an estrogen-progestin regimen may increase breast cancer risk beyond that associated with estrogen alone. However, the effect of progestogens on the breast awaits further clarification. ERT/HRT is generally considered to be contraindicated in breast cancer patients, as no firm data are yet available from randomized clinical trials. Despite the potential risks, ERT/HRT could be considered for breast cancer patients suffering from menopausal symptoms resistant to alternative treatments, after completely informed consent is given, particularly in women with ER- (hormone-resistant) cancers. Unopposed estrogen therapy is known to increase endometrial cancer risk, and is appropriate only for hysterectomized women. To negate the excess risk of endometrial hyperstimulation, an adequate progestin dose must be given in a continuous combined regimen or for an appropriate number of days in sequential regimens (10 days or more for some progestogens or 12 days or more for other progestogens). An appropriate combination of estrogen and progestin does not appear to increase, and may even decrease, the risk of endometrial cancer. HRT is generally considered to be contraindicated in endometrial cancer patients. Despite the potential risks, HRT could be considered for patients suffering from menopausal symptoms resistant to alternative treatments, after completely informed consent is given. Available data suggest a reduced risk of colorectal adenoma and colon cancer in current users of HRT, but definitive studies are still needed. There is no contraindication to HRT prescription in colon cancer survivors. Consistent epidemiological data describe a decreased incidence of **ovarian cancer** with oral contraceptive use during the reproductive years. Studies on HRT and risk of epithelial **ovarian cancer** have produced conflicting results but most data seem to exclude a strong association. While no data contraindicate HRT use in epithelial **ovarian cancer** survivors, current studies do not allow us to exclude the possibility that estrogens alone could stimulate **ovarian cancer** growth in a small fraction of patients. Additional studies are required. It is important to consider that not all estrogens and progestins are used with the same dosage, route of administration (oral, transdermal and for estradiol intranasal) and, mostly, different estrogens do not show the same bioavailability and tissue effects. The available data do not allow to discriminate for all these variables and therefore it is inappropriate to consider jointly all forms of hormonal therapy. This issue is considered as an important area for future evaluation and research. The International Menopause Society is in the process of drawing up specific recommendations for further research in the field of HRT and cancer.

L28 ANSWER 10 OF 17 MEDLINE on STN
ACCESSION NUMBER: 2001557397 MEDLINE

DOCUMENT NUMBER: PubMed ID: 11603218
 TITLE: Expression of calretinin in human ovary, testis, and ovarian sex cord-stromal tumors.
 AUTHOR: Cao Q J; Jones J G; Li M
 CORPORATE SOURCE: Department of Pathology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, USA.
 SOURCE: International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists, (2001 Oct) 20 (4) 346-52.
 Journal code: 8214845. ISSN: 0277-1691.
 PUB. COUNTRY: United States
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 200202
 ENTRY DATE: Entered STN: 20011018
 Last Updated on STN: 20020222
 Entered Medline: 20020221

AB Calretinin, a calcium-binding protein, is primarily expressed in certain subtypes of neurons. It has also been found to be present in mesothelial cells and mesotheliomas but not in many types of carcinomas. Using a polyclonal anti-calretinin antibody, we investigated the expression of calretinin immunohistochemically in nonneoplastic human ovaries and testes and ovarian sex cord-stromal tumors (SCSTs). In ovaries, calretinin was expressed in theca interna cells, hilus cells, and scattered individual stromal cells. Oocytes, granulosa cells, theca externa cells, rete ovarii, and most stromal cells were negative. Expression of calretinin was also seen in the ovarian surface epithelium and in collapsed and flat epithelial inclusion glands (EIGs), but not in round, columnar, and ciliated EIGs. In some glands, a transition from calretinin-positive to calretinin-negative epithelium was observed. In postpubertal testes, calretinin was expressed in Leydig cells, but not in germ cells or most rete testes and Sertoli cells. In ovarian SCSTs, strong calretinin staining was seen in all hilus cell tumors (4/4) and the Leydig cell component of Sertoli-Leydig cell tumors (10/10). The Sertoli cell component showed focal weak positivity in 5/10. Fibrothecomas were completely negative (0/8). In granulosa cell tumors, the tumor cells were either completely negative (8/14) or weakly positive at the periphery of the tumor (6/14) while scattered stromal cell staining was seen in 9/14 cases. The expression of calretinin in normal Leydig cells, theca interna cells, the Leydig cell component of Sertoli-Leydig cell tumors, and hilus cell tumors suggests its functional relationship with androgen production. Its pattern of expression in ovarian SCSTs is useful in the differential diagnosis of these tumors. The presence of a transition from calretinin-positive, flat, nonciliated epithelium to calretinin-negative, columnar, ciliated epithelium in the same glands provides strong evidence for mullerian metaplasia.

L28 ANSWER 11 OF 17 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
 on STN

ACCESSION NUMBER: 2001411197 EMBASE
 TITLE: Controversial issues in climacteric medicine II: Hormone replacement therapy and cancer.
 AUTHOR: Genazzani A.R.; Gadducci A.; Gambacciani M.
 CORPORATE SOURCE: A.R. Genazzani, Department of Reproductive Medicine, Division of Gynecology, University of Pisa, Via Roma 35, 56126 Pisa, Italy. a.genazzani@obgyn.med.unipi.it
 SOURCE: Maturitas, (30 Nov 2001) 40/2 (117-130).
 ISSN: 0378-5122 CODEN: MATUDK
 PUBLISHER IDENT.: S 0378-5122(01)00282-1

COUNTRY: Ireland
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 010 Obstetrics and Gynecology
013 Dermatology and Venereology
016 Cancer
037 Drug Literature Index
048 Gastroenterology

LANGUAGE: English

SUMMARY LANGUAGE: English

AB Sex steroids are not known to damage DNA directly. They can stimulate or inhibit cell proliferation, and thus can modulate tumor developmental progression. Sex steroid-related tumors in women are represented by breast cancer and endometrial cancer, and a possible relationship exists between sex steroids and both ovarian and colon cancer. Among current ERT users or those who stopped use 1-4 years previously, the relative risk of having breast cancer diagnosed increases by a factor of 1.023 for each year of hormone use. This increase is comparable with the effect on breast cancer of delaying menopause, and seems to be largely limited to lean women. The breast cancers diagnosed during ERT are more likely to contain ER and are less aggressive. Some reports indicate no increase in breast cancer mortality in HRT users. Recent data suggest that an estrogen-progestin regimen may increase breast cancer risk beyond that associated with estrogen alone. However, the effect of progestogens on the breast awaits further clarification. ERT/HRT is generally considered to be contraindicated in breast cancer patients, as no firm data are yet available from randomized clinical trials. Despite the potential risks. ERT/HRT could be considered for breast cancer patients suffering from menopausal symptoms resistant to alternative treatments, after completely informed consent is given, particularly in women with ER-negative (hormone-resistant) cancers. Unopposed estrogen therapy is known to increase endometrial cancer risk, and is appropriate only for hysterectomized women. To negate the excess risk of endometrial hyperstimulation, an adequate progestin dose must be given in a continuous combined regimen or for an appropriate number of days in sequential regimens (10 days or more for some progestogens or 12 days or more for other progestogens). An appropriate combination of estrogen and progestin does not appear to increase, and may even decrease, the risk of endometrial cancer. HRT is generally considered to be contraindicated in endometrial cancer patients. Despite the potential risks, HRT could be considered for patients suffering from menopausal symptoms resistant to alternative treatments, after completely informed consent is given. Available data suggest a reduced risk of colorectal adenoma and colon cancer in current users of HRT, but definitive studies are still needed. There is no contraindication to HRT prescription in colon cancer survivors. Consistent epidemiological data describe a decreased incidence of **ovarian cancer** with oral contraceptive use during the reproductive years. Studies on HRT and risk of epithelial **ovarian cancer** have produced conflicting results but most data seems to exclude a strong association. While no data contraindicate HRT use in epithelial **ovarian cancer** survivors, current studies do not allow us to exclude the possibility that estrogens alone could stimulate **ovarian cancer** growth in a small fraction of patients. Additional studies are required. It is important to consider that not all estrogens and progestins are used with the same dosage, route of administration (oral, transdermal and for estradiol intranasal) and, mostly, different estrogens do not show the same bioavailability and tissue effects. The available data do not allow to discriminate for all these variables and, therefore, it is inappropriate to consider jointly all forms of hormonal therapy. This issue is considered as an important area for future evaluation and research. The International Menopause

Society is in the process of drawing up specific recommendations for further research in the field of HRT and cancer.

L28 ANSWER 12 OF 17 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN

ACCESSION NUMBER: 1999196834 EMBASE
TITLE: Novel class of non-steroidal **progesterone**
receptor antagonists.
AUTHOR: Zhi L.; Marschke K.B.
CORPORATE SOURCE: L. Zhi, Ligand Pharmaceuticals Inc., 10275 Science Center
Drive, San Diego, CA 92121, United States. lzhi@ligand.com
SOURCE: Expert Opinion on Therapeutic Patents, (1999) 9/6
(695-700).
Refs: 19
ISSN: 1354-3776 CODEN: EOTPEG
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 030 Pharmacology
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English

AB Development of antiprogestins as a new class of therapeutic agents has been of great interest to the pharmaceutical industry for decades. Currently, all clinically available antiprogestins are compounds with a steroidal skeleton. The new generation of non-steroidal antiprogestins is very promising but still in its infancy. This review summaries the recent progress in the area of non-steroidal **progesterone** receptor antagonists. These antiprogestitional compounds, derived from cyclocymopols, dihydroquinolines, pyridazines, linear tricyclic sesquiterpenes and **vitamin D** derivatives, have been proposed to be used as contraceptive agents, abortifacients and for use in hormone replacement therapy, as well as for use in the treatment of endometriosis, osteoporosis and **progesterone** responsive cancers of the ovary, breast and prostate.

L28 ANSWER 13 OF 17 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
STN

ACCESSION NUMBER: 1999:394496 BIOSIS
DOCUMENT NUMBER: PREV199900394496
TITLE: Expression of 1,25-dihydroxyvitamin-D3-receptors (VDR),
estro-gen and **progesterone** receptors and Ki-67 in
ovarian carcinoma.
AUTHOR(S): Villena-Heinsen, C. [Reprint author]; Reitnauer, K.;
Woll-Hermann, A. [Reprint author]; Tilgen, W.; Schmidt, W.
[Reprint author]; Reichrath, J.; Friedrich, M. [Reprint
author]
CORPORATE SOURCE: Department of Gynecology, University of the Saarland,
D-66421, Homburg, Germany
SOURCE: European Journal of Clinical Investigation, (April, 1999)
Vol. 29, No. SUPPL. 1, pp. 25. print.
Meeting Info.: 33rd Meeting of the European Society for
Clinical Investigation. Milan, Italy. April 8-10, 1999.
European Society for Clinical Investigation.
CODEN: EJCIB8. ISSN: 0014-2972.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 28 Sep 1999
Last Updated on STN: 6 Dec 1999

L28 ANSWER 14 OF 17 JICST-EPlus COPYRIGHT 2004 JST on STN

ACCESSION NUMBER: 970473620 JICST-EPlus
 TITLE: Immunohistochemical Localization of Estrogen Receptor,
Progesterone Receptor and Vitamin
D Receptor in Ovarian Cancer.
 AUTHOR: HIRATA MASATO; YABUSHITA HIROMITSU; FURUYA HIROSHI;
 NARUMIYA HISAO; TSUKADA HIDEFUMI; YAMADA HIDEFUMI;
 SAWAGUCHI KEIZO; NOGUCHI MASAYOSHI; NAKANISHI MASAMI
 CORPORATE SOURCE: Aichi Med. Univ.
 SOURCE: Tokai Sanka Fujinka Gakkai Zasshi (Tokai Journal of
 Obstetrics and Gynecology), (1996) vol. 33, pp. 91-96.
 Journal Code: L2634A (Fig. 8)
 ISSN: 0915-7204
 PUB. COUNTRY: Japan
 DOCUMENT TYPE: Journal; Article
 LANGUAGE: Japanese
 STATUS: New

L28 ANSWER 15 OF 17 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
 on STN

ACCESSION NUMBER: 95360805 EMBASE
 DOCUMENT NUMBER: 1995360805
 TITLE: Biological and clinical aspects of plasminogen activator
 inhibitor type 2.
 AUTHOR: Kruithof E.K.O.; Baker M.S.; Bunn C.L.
 CORPORATE SOURCE: Div. Angiologie d'Hemostase, Hop. Cantonal Universitaire
 Geneve, CH-1211 Geneva, Switzerland
 SOURCE: Blood, (1995) 86/11 (4007-4024).
 ISSN: 0006-4971 CODEN: BLOOAW
 COUNTRY: United States
 DOCUMENT TYPE: Journal; General Review
 FILE SEGMENT: 016 Cancer
 025 Hematology
 029 Clinical Biochemistry
 031 Arthritis and Rheumatism
 037 Drug Literature Index
 LANGUAGE: English

L28 ANSWER 16 OF 17 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
 on STN

ACCESSION NUMBER: 93314365 EMBASE
 DOCUMENT NUMBER: 1993314365
 TITLE: Menopause.
 AUTHOR: Dawood M.Y.; Tidey G.F.
 CORPORATE SOURCE: Div. of Reproductive Endocrinology, Department of
 Reproductive Sciences, University of Texas Medical
 School, Houston, TX, United States
 SOURCE: Current Problems in Obstetrics, Gynecology and Fertility,
 (1993) 16/5 (172-207).
 ISSN: 8756-0410 CODEN: CPOIEN
 COUNTRY: United States
 DOCUMENT TYPE: Journal; (Short Survey)
 FILE SEGMENT: 010 Obstetrics and Gynecology
 016 Cancer
 037 Drug Literature Index
 038 Adverse Reactions Titles
 LANGUAGE: English
 SUMMARY LANGUAGE: English
 AB Menopause is best viewed as an endocrinopathy characterized by ovarian
 hypofunction, which results in a deficiency of estrogen and

progesterone. Other syndromes of endocrine hypofunction, such as hypothyroidism or hypoadrenalism, result in acute clinical syndromes necessitating urgent physiologic replacement of the deficient hormone; however, the focus of hormone replacement therapy after the menopause is primarily health maintenance and prevention of chronic disease. Accordingly, protection against cardiovascular disease is now the primary indication for estrogen replacement, because this leading cause of mortality in women can be reduced by half in estrogen users. Although smaller in magnitude, a substantial reduction in osteoporosis-related morbidity and mortality is also enjoyed by menopausal women who receive estrogen. Given these considerable benefits, an increasingly important mission of the primary care physician over the next decade is to ensure that appropriate hormone replacement therapy is given to most women who suffer from this endocrinopathy. Like many other interventions for health maintenance and disease prevention, hormone replacement has received a lukewarm response from many patients and some physicians. This is in part because of the unwanted and sometimes unexpected side effect of persistent bleeding as well as a fear of increased risk of cancer, which has received excessive media coverage but is largely unjustified. We therefore review both basic and clinical studies that support the overwhelming benefits of estrogen replacement in menopausal women. More important, however, we discuss new hormone replacement regimens that minimize the incidence of unwanted vaginal bleeding, and we review the controversial literature on breast cancer risk in estrogen users. Finally, alternatives to standard hormone replacement regimens for women with contraindications to estrogen therapy are discussed.

L28 ANSWER 17 OF 17 MEDLINE on STN
ACCESSION NUMBER: 68281712 MEDLINE
DOCUMENT NUMBER: PubMed ID: 4871924
TITLE: Treatment of miscellaneous disorders of growth.
AUTHOR: Kaufman S L
SOURCE: Modern treatment, (1968 Jan) 5 (1) 218-40. Ref: 20
Journal code: 7511504. ISSN: 0026-8526.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 196808
ENTRY DATE: Entered STN: 19900101
Last Updated on STN: 19900101
Entered Medline: 19680806